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Nowadays, the mean age of the population and life expectancy are rapidly increasing. 
The percentage of people aged ≥65 years old is expected to rise from 15% in 2000 to 
24% in 2030 in European countries1. This trend results in a growing burden of chronic 
diseases in many countries. A recent study showed for example, that in the Netherlands, 
34% of general practice patients had at least 1 chronic disease while 13% was diagnosed 
with ≥2 chronic diseases2. Among the elderly aged ≥75 years this prevalence was even 
higher, with 84% having at least 1 and 59% having ≥2 chronic diseases2. Both cancer and 
diabetes belong to the most common chronic diseases, and in 2008 they accounted for 
7.6 million and 1.3 million deaths worldwide, respectively3.
Cancer is characterized by abnormal cell growth and division. Instead of dying, cancer 
cells grow out of control, and form new abnormal cells. These cancer cells have the 
potential to invade nearby normal tissue and metastasize to other body parts after 
the cancer cells get into the bloodstream. The most common ways to treat cancer are 
surgery, chemotherapy, and radiation therapy. Cancer can present itself in over 100 
subtypes named after their anatomical origin. In 2014, a total of 104.000 people were 
diagnosed with cancer, this was an increase of 2% as compared to the year before4. The 
cancer types with the highest incidence include skin cancer, colorectal cancer, breast 
cancer, lung cancer, and prostate cancer with 15.339, 15.003, 14.631, 11.910, and 9.926 
incident cases in 2014, respectively4. In this thesis, the main focus will be on colorectal 
cancer and breast cancer.
Diabetes mellitus, further referred to as diabetes, is a chronic metabolic disorder. 
Diabetes that is undertreated or untreated is characterized by chronic hyperglycemia 
(i.e. elevated blood glucose levels)5. Hyperglycemia is usually accompanied by symptoms 
of polyuria, polydipsia, and blurred vision, and can cause more severe complications on 
the long-term, including loss of vision, renal failure, neuropathy, sexual dysfunction, and 
cardiovascular disease5. Two types of diabetes can be distinguished, type 1 is the least 
common and accounts for 5-10% of all cases while type 2 diabetes is prevalent in >90% 
of all cases. Type 1 diabetes generally develops during childhood or adolescence, and 
is characterized by the damage and destruction of the beta cells as result of an auto-
immune response. This leads to absolute insulin deficiency. In type 2 diabetes, there is a 
relative insulin deficiency as a result of both insulin resistance of bodily tissues and insulin 
deficiency resulting from beta-cell dysfunction. This type of diabetes often develops 
at older age, and mainly results from poor lifestyle habits (i.e. overweight/obesity and 
lack of physical activity)5. In the Netherlands, after diabetes is diagnosed, patients are 
firstly encouraged to improve the quality of their diet, lose weight, and engage more in 
physical activity. If lifestyle education does not result in improved blood glucose levels, 
treatment with oral glucose lowering drugs (GLDs) is initiated. Since 2006, metformin 
is used as a first line treatment, however, if blood glucose levels are poorly controlled 
metformin is substituted or other agents, such as sulphonylurea derivatives, other GLDs, 
and eventually insulin, are added6.
The burden of cancer and diabetes
The number of cancer survivors is increasing due to aging of the population and 
declining mortality rates as a result of earlier cancer detection and better treatment. In 
the Netherlands, the 10-year prevalence of cancer patients or survivors (i.e. all people 
diagnosed with cancer in the past 10 years and still alive at index date) is expected to 
increase drastically from 420.000 men and women in 2009 to 660.000 men and women 
in 20207. Similarly, the number of diabetes patients in the Netherlands is expected to 
nearly double from 740.000 in 2007 to 1.3 million in 20258.
Due to the increased prevalence of both cancer and diabetes, these diseases often 
occur together. Additionally, recent meta-analyses reported that some cancers develop 
more often among diabetes patients. Diabetes has been strongly associated with a 
higher risk of developing liver9, pancreatic10, and endometrial cancer11 with hazard ratios 
ranging between 1.82 and 2.50. Similarly, although less strong, associations between 
diabetes and a 20-40% increased risk of breast12, colorectal13, bladder14, non-Hodgkin’s 
lymphoma15, and kidney cancer16 have been observed. In contrast, prostate cancer risk 
has been reported to be 15% lower in men with diabetes17. As diabetes is associated 
with increased cancer risk, the number of patients living with both cancer and diabetes 
is bound to increase. In a report published by the Dutch Cancer Society, the number of 
cancer patients with diabetes at diagnosis was expected to double from 5.500 patients 
in 2000 to 10.000 patients in 201518. Other research shows that comorbidity, including 
the prevalence of diabetes, increases with age, but remains stable or decreases after 
the age of 80 years19. Data from the Netherlands Cancer Registry shows that on January 
1, 2015 already 20% of colorectal and breast cancer patients aged between 75 and 85 
years had diabetes at cancer diagnosis (Figure 1).
Proposed mechanisms on the association between cancer and 
diabetes
Although the exact mechanisms underlying the associations between cancer and 
diabetes are largely unknown, several mechanisms were proposed in literature. Cancer 
and diabetes share several risk factors that might be common denominators, and thus 
(partly) explain the association between both diseases. Besides non-modifiable risk 
factors such as older age and race/ethnicity, cancer and diabetes share several modifiable 
risk factors including obesity, smoking, physical inactivity, excessive alcohol use, and 
poor dietary habits20. The combination of both these non-modifiable and modifiable 
risk factors increases the likelihood for an individual with diabetes to develop cancer and 
vice versa. Also, several biological mechanisms for the association between diabetes and 
cancer risk have been proposed20,21. The leading hypothesis is that hyperinsulinemia (i.e. 




elevated blood insulin levels) promotes tumor cell growth through direct and indirect 
pathways. In an early stage of diabetes, the pancreas increases the secretion of insulin 
to compensate for the decreased insulin sensitivity in the body tissue, which results in 
hyperinsulinemia. The majority of tumor cells express insulin and insulin-like growth factor 
1 (IGF-1) receptors on their surface. Insulin can bind to insulin receptors on the tumor 
cells which may result in direct cell growth promotion22. In addition, hyperinsulinemia 
can indirectly promote cell growth as insulin reduces the hepatic production of IGF 
binding proteins, and thereby increasing active IGF-1 levels23. Subsequently, IGF-1 could 
act, after binding to the IGF-1 receptor, as a growth stimulus for the tumor cells and 
increase tumor growth, invasion, and metastasis24.
Figure 1 The prevalence of diabetes among colorectal cancer patients and breast cancer 
patients at January 1, 2015, stratified by age categories.
Datasource: South region of the Netherlands Cancer Registry
The dual impact of cancer and diabetes on patient reported 
outcomes
Previous research regarding the association between cancer and diabetes mainly focused 
on the impact of diabetes on cancer incidence and mortality, while less attention has 
been paid to the impact of having both diseases on Patient Reported Outcomes (PROs). 
These patient perspectives have become important outcome measures to evaluate the 
impact of a disease and its treatment on a patient’s life, and are increasingly incorporated 
in guidelines for research and policy25,26. PROs is used as an umbrella term and include a 
wide range of measures, for example Health-Related Quality of Life (HRQoL), symptoms, 
and satisfaction with health-care.
Up to now, studies that have investigated the dual impact of cancer and diabetes on PROs 
mainly focused on HRQoL27-31. HRQoL is a multidimensional construct, which reflects 
patient’s perceptions of their physical, emotional, social and cognitive function, and 
disease and treatment-related symptoms. All previous studies27-30, but one longitudinal 
study31, suggest that having both cancer and diabetes results in poorer HRQoL. However, 
due to the limited evidence, the different study populations (which are mainly confined 
to prostate cancer patients), the predominantly cross-sectional study designs, and the 
different HRQoL measurements used, no strong conclusions can be drawn. Moreover, 
other important outcomes which are highly prevalent among people with both cancer 
and diabetes, such as neuropathic symptoms32,33 and sexual dysfunction34-36, need further 
attention.
Both cancer and diabetes independently negatively affect PROs, however, it is unclear 
whether having both diseases results in even worse outcomes than the sum of their 
individual effects (i.e. 1+1=3). When we know which factors explain the possible worse 
outcomes among patients with both diseases, this might enhance further research 
in developing interventions to improve outcomes. Moreover, it might aid clinicians 
in their decisions regarding treatment types to prevent side-effects, symptoms, and 
complications that have a significant impact on a person’s daily life. Thus, more research 
is needed to determine the effects of having both cancer and diabetes on PROs. This was 
recently underlined in a review that described the current evidence on the association 
between cancer and diabetes37. The authors identified gaps in literature and stated that 
future studies should address the hypothesis that cancer patients with diabetes have 
reduced HRQoL, and additionally, the influence of lifestyle and PROs on this association 
need to be elucidated37.
The dual impact of cancer and diabetes on mortality
A meta-analysis that included 23 studies showed that cancer patients with diabetes 
at diagnosis have about a 40% higher mortality risk as compared with cancer patients 




without diabetes38. A higher mortality was mainly found among patients with diabetes 
and endometrial (HR=1.76; 95%CI:1.34-2.31), breast (HR=1.61; 95%CI: 1.46-1.78) or 
colorectal (HR=1.32; 95%CI:1.24-1.41) cancer as compared to those without diabetes38. 
The exact mechanism underlying this increased mortality is unknown. However, a review 
published in 2011 identified several methodological key points that should be taken into 
account regarding the association between diabetes and mortality in cancer patients39. 
Research, particularly among breast cancer patients, shows that patients with diabetes 
present with more advanced cancer stage at diagnosis40. This might be a consequence 
of lower screening uptake in cancer patients with versus without diabetes41. Another 
possible explanation for the higher mortality among cancer patients with diabetes lies 
within the received cancer treatment. A study conducted in the Netherlands showed that 
esophageal, colon, breast, and ovary cancer patients with diabetes at cancer diagnosis 
were treated less aggressively as compared to those without diabetes42.
Besides clinical factors, modifiable lifestyle factors also might play a role in the higher 
mortality rates observed among patients with both diseases. Physical inactivity, 
underweight or obesity, smoking, and excessive alcohol use have all been associated 
with increased mortality among both cancer and diabetes patients43-50. However, in a 
meta-analysis that assessed the association between preexisting diabetes and mortality 
among colorectal cancer patients only 12 of the 21 included studies adjusted for lifestyle 
behaviors51. Therefore, as cancer patients with diabetes might have an even worse lifestyle 
than cancer patients without diabetes, the influence of lifestyle on the increased mortality 
in patients with both diseases needs to be studied further.
Glucose lowering drugs and mortality among cancer patients
Research regarding the link between cancer and diabetes was initiated at least 100 
years ago52 but at that time the topic did not reach mainstream interest. However, major 
interest for the link between cancer and diabetes was raised in 2005 after a study was 
published that showed that treatment with metformin, used as primary treatment in 
diabetes, was associated with lower cancer incidence53. Moreover, the simultaneous 
publication of four studies in a prominent scientific journal raised the question of a 
possible association between use of insulin glargine, a long-acting insulin analogue, 
and increased cancer risk54-57. These results led to major focus on the potential effects 
of GLDs, mainly metformin, on cancer incidence as well as on mortality. Several of the 
studies that followed presented exceptionally strong protective effects of metformin on 
mortality among cancer patients58-61. However, these observational studies had several 
methodological limitations. Studies that assessed the association between GLD use and 
mortality among cancer patients, often classified patients as GLD user at time of cancer 
diagnosis and not from the actual drug initiation onwards. This classification may have 
induced immortal time bias as patients cannot die in the period prior to drug initiation, 
introducing a period of immortal time62. In addition, several studies mainly focused on 
metformin use versus non-use, whereas diabetes patients often switch between different 
GLDs or use a combination of GLDs. Finally, earlier studies often did not assess dose-
response associations. Thus to gain insight in the association between GLD use, including 
metformin, and mortality among cancer patients there is a need for well-designed large 
observational studies that account for immortal time bias and test for dose-response 
associations.
Aims and outline of the thesis
Thus, following the results of previous studies, the association between cancer and 
diabetes is complex, and several knowledge gaps were identified. Even though 1 in 
5 cancer patients presents with diabetes at cancer diagnosis, there is a considerable 
gap in our knowledge on the impact of both cancer and its treatment, and diabetes on 
PROs. Moreover, it is still unclear which factors underlie the increased mortality found 
among cancer patients with as compared to cancer patients without diabetes. Therefore, 
this thesis aimed to assess the dual impact of cancer and diabetes on PROs (Part I) and 
mortality (Part II). The main objectives of this thesis were:
 - To assess the impact of comorbidity, with a main focus on cancer and diabetes, on 
PROs, including HRQoL and symptoms (Part I)
 - To assess the impact of cancer and diabetes, and the role of lifestyle factors, on 
mortality (Part II)
 - To assess the effect of glucose lowering drug use on mortality among breast cancer 
patients (Part II)
Based on the current literature, we hypothesize that cancer patients with diabetes have 
poorer outcomes, both regarding PROs and mortality.
 
The current literature on the effect of cancer and diabetes on PROs is limited, and 
therefore, in Part I we first systematically reviewed the scientific literature regarding the 
dual impact of cancer and diabetes on PROs (Chapter 2). In this chapter, we additionally 
identified gaps in current literature and proposed a research agenda for further research. 
In Chapter 3-7, PROs were studied among cancer patients. For these studies, clinical data 
was retrieved from the Netherlands Cancer Registry (NCR) and linked to longitudinal 
data on PROs collected by the web-based Patient Reported Outcomes Following 
Initial treatment and Long-term Evaluation of Survivorship (PROFILES) registry63. First, 
we described the variance in HRQoL explained by comorbidity in comparison with 
sociodemographic and clinical characteristics among thyroid, colorectal cancer and 
(non)-Hodgkin’s lymphoma patients in Chapter 3. Moreover, we assessed the effect 
of individual comorbidities on HRQoL. Subsequently we studied the individual and 
combined effect of cancer and diabetes on HRQoL (Chapter 4). For this study a sample 
including colorectal cancer patients with and without diabetes, and a normative sample 
with and without diabetes was used. As the prevalence of neuropathic symptoms among 
cancer as well as diabetes patients is high and little is known about the prevalence 
of these symptoms among patients with both diseases, we assessed the difference in 
neuropathic symptoms between colorectal cancer patients with and without diabetes in 




Chapter 5. As previous studies reported that cancer patients with versus without diabetes 
might be less aggressively treated, we additionally assessed whether the type of received 
cancer treatment differed between both groups. Finally, we studied the difference in 
HRQoL between colorectal cancer patients with and without diabetes prospectively in 
Chapter 6. Moreover, as cancer and diabetes share several lifestyle-related risk factors 
which are independently associated with worse HRQoL, we additionally assessed the 
role of lifestyle on HRQoL among both groups.
In Part II we assessed the dual impact of cancer and diabetes on mortality. Literature 
shows that mortality among cancer patients with versus without diabetes is about 40% 
higher but often lifestyle factors are not taken into account. As lifestyle factors are 
independently associated with mortality, we aimed to assess whether lifestyle factors 
could explain the increased mortality found among colorectal cancer patients with versus 
without diabetes (Chapter 7). In the following two chapters of this thesis we focused 
on the effect of GLDs on the prognosis of breast cancer patients in response to recent 
literature on the promising protective effect of metformin on mortality among cancer 
patients. We conducted complex time-varying analyses to account for methodological 
restrictions in previous studies, and assessed the effect of GLD use on mortality among 
breast cancer patients with type 2 diabetes using data from the United Kingdom (UK) 
in Chapter 8. As we had no (complete) data regarding breast cancer stage and receptor 
status in the UK sample, we conducted similar analyses in a Dutch sample where this 
information was available (Chapter 9). For this study, clinical data from the NCR was 
linked to the PHARMO database network which contains data on drug dispensions from 
out-patient pharmacies in the Netherlands64. Finally, a summary of the main findings, 
methodological considerations, and implications of the results presentend in this thesis 
were described in the general discussion (Chapter 10).
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This systematic review aims to summarize the current literature regarding potential 
effects of having both cancer and diabetes on Patient Reported Outcomes (PROs) and 
to provide directions for future research.
Methods 
MEDLINE, The Cochrane Library, CINAHL and PsycINFO were searched from inception to 
January 2015. All English, peer-reviewed studies that included patients with both cancer 
and diabetes and assessed PROs, were included. All included studies were independently 
assessed on methodological quality by two investigators.
Results 
Of the 3,553 identified studies, 10 studies were included and all were considered of high 
(40%) or adequate (60%) methodological quality. Eight of the 10 studies focused on 
Health-Related Quality of Life (HRQoL), functioning or symptoms and 2 studies assessed 
diabetes self-management. Overall, HRQoL and functioning was lower, and symptoms 
were higher among patients with both cancer and diabetes as compared to having cancer 
or diabetes alone. Furthermore, one study reported that diabetes self-management was 
impaired after chemotherapy.
Conclusions
Having both cancer and diabetes resulted in worse PROs compared to having either 
one of the diseases, however, the considerable heterogeneity of the included studies 
hampered strong conclusions. Future studies are needed as this research area is largely 
neglected. As the majority of the included studies focused on HRQoL, future research 
should address the impact of both diseases on other PROs such as depression, patient 
empowerment and self-management.
Introduction
Due to the increased aging of the population, early detection, and better treatment 
of diseases, the number of cancer survivors is increasing1. As a result, more and more 
cancer survivors live with other chronic diseases of which diabetes is one of the most 
prevalent2. The prevalence of concurrent diabetes among cancer patients depends on 
cancer type, gender, and age at diagnosis, and varies from 8% among prostate cancer 
patients to approximately 26% among pancreas cancer patients aged 65 years or older2. 
This high prevalence of diabetes among cancer patients results in worse outcomes and 
increases the burden on health systems worldwide. 
The link between cancer and diabetes is extensively studied in recent literature and is 
mainly focused on the impact of diabetes on cancer incidence and mortality. Recent meta-
analyses show that diabetes is strongly associated with the development of pancreatic 
(OR=1.82, 95%CI:1.66-1.89)3, liver (OR=2.50, 95%CI:1.80-3.50)4, and endometrial cancer 
(RR=2.10, 95%CI:1.75-2.53)5. Moderate, positive associations have been reported for 
diabetes and breast (RR=1.20, 95%CI:1.12-1.28)6, colorectal (RR=1.26, 95%CI:1.05-1.50)7 
and bladder (RR=1.24, 95%CI:1.08-1.42)8 cancer incidence, while diabetes has been 
associated with a decreased incidence of prostate cancer (RR=0.84, 95%CI:0.76-0.93)9. 
Furthermore, previous research shows that having diabetes is associated with a 30-40% 
increased mortality risk among cancer patients, which was mainly apparent among 
breast, endometrial, and colorectal cancer patients10,11. 
As the group of patients with both cancer and diabetes is growing, patients’ experience 
of living with both diseases is becoming more important. However, this research area is 
largely neglected. Patient Reported Outcome (PRO) assessments such as Health-Related 
Quality of Life (HRQoL), functioning and symptoms are needed as it is plausible that 
patients with multiple chronic diseases experience more problems. This knowledge is 
essential to improve clinical practice and care for this growing group of patients. 
A significant number of cancer survivors consistently report lower physical functioning, 
sexual functioning, and more symptoms of distress and fatigue12,13. Similarly, diabetes 
patients are more likely to suffer from depression14, report a lower quality of life15 and 
lower sexual functioning16. As both cancer and diabetes patients report deteriorated 
PROs compared to people without the disease, we hypothesize that having both chronic 
diseases will result in even more deteriorated PROs. The aim of this systematic literature 
review is to summarize the current knowledge on the impact of having both cancer 
and diabetes on PROs. In addition, as we expect that this research area will be largely 
neglected, we also aim to provide directions for future research. 
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LF conducted the systematic literature search on August 2013 and updated the search on 
January 2015. The following databases were included: MEDLINE, The Cochrane Library, 
CINAHL and PsycINFO. Subject headings and free text terms for diabetes (i.e. diabet* OR 
diabetes mellitus) were combined with search terms for cancer (i.e. cancer* OR neoplasm* 
OR oncolog*). As PROs cover a wide range of different aspects, we did not include any 
search terms for PROs to avoid missing relevant papers. The full search strategy is shown 
in Appendix A (page 40). After the search was conducted the cited references of the 
selected studies were searched using Web of Science and their references lists checked; 
in addition, PubMed Related Articles were used for the two most recent included studies 
to identify studies that were not found with the initial literature search.
Selection criteria
All retrieved studies (including abstracts of unpublished studies) were screened and 
studies that met the following four selection criteria were included: (1) the study is 
focused on patients with both cancer and diabetes, (2) PRO is primary or secondary 
outcome measure of the study, (3) is published in a peer-reviewed journal, and (4) is 
published in English. Studies that assessed the effects of several chronic or comorbid 
diseases, including diabetes, among cancer patients on PROs were not included as the 
studies should have a primary focus on both cancer and diabetes. Similarly, studies 
that aimed to address comorbid or chronic diseases, including cancer, among diabetes 
patients were excluded. 
Quality assessment
Each selected study was independently scored on methodological quality by 2 reviewers 
(PV and MT) based on a set of 14 quality criteria (Table 1). These quality criteria were 
based on established criteria lists used in previous studies17,18. Disagreements between 
the reviewers on the quality criteria were resolved during a consensus meeting. All 
studies received 1 point for each of the 14 quality criteria that was met. If a criterion was 
not met or described insufficiently, 0 point was assigned. Thus, each study can obtain a 
maximum score of 14 points. Studies that scored 75% or more of the maximum attainable 
score (i.e. ≥11 points) were considered as ‘high quality study’, studies scoring between 
50-75% (i.e. 7-10 points) were considered of ‘adequate quality’, while those scoring <50% 
(i.e. ≤6 points) were considered of ‘low quality’. These criteria were arbitrarily chosen 
and based on previous research17.
Positive if with respect to Number of studies 
that scored positive
Patient Reported Outcomes N (%)
1. Examining PROs was a primary objective of the study 10 (100)
2. A validated questionnaire to measure PROs was used 10 (100)
Study population
3. The patient sampling process is described 10 (100)
4. A (healthy) normative sample is included for comparison 3 (30)
5. Patients with both cancer and diabetes are compared to either patients with 
only cancer or only diabetes on at least two sociodemographic variables
8 (80)
6. A description is included of at least two clinical variables regarding cancer 
diagnosis (e.g. cancer stage, treatment, time since cancer diagnosis)
8 (80)
7. A description is included of at least two clinical variables regarding diabetes 
diagnosis or severity (e.g. HbA1c levels, treatment, time since diabetes 
diagnosis)
3 (30)
8. Inclusion and/or exclusion criteria are described 9 (90)
9. Participation rates for patient groups are described and these are >75% 4 (40)
10. Information is given regarding differences in demographic and/or clinical 
characteristics of respondents versus non-respondents
3 (30)
Study design
11. The study sample includes at least 75 patients (arbitrarily chosen) 8 (80)
12. The process of data collection is described 8 (80)
13. The difference in the outcome variable between cancer patients with 
diabetes and patients with only cancer and/or only diabetes is assessed 
in multivariable models, including at least 2 covariates
8 (80)
Results
14. Mean, median, standard deviations or percentages are reported and 
compared between cancer patients with diabetes and patients with only 
cancer and/or only diabetes for the most important outcome measures
8 (80)
Table 1 List of criteria for assessing the methodological quality of studies on patient reported 
outcomes among patients with cancer and diabetes
Results
Description of the included studies
The initial broad search strategy on cancer and diabetes, that did not include a term 
for ‘PROs’, yielded 3,553 hits, and after the removal of duplicates and the application of 
selection criteria a total of 10 studies were included in this study, of which 2 were based 
on the same data19,20 (Figure 1). Eight of the included studies had a sample size of at 
least 590 participants while 2 studies, based on the same data, included 43 patients19,20 
(Table 2). The number of patients with both cancer and diabetes was rather low; 5 studies 
included less than 100 patients with both diseases19 -23. Moreover, only 4, of which 3 
unique, studies had a longitudinal design19,20,24,25, while the other 6 studies addressed 
the associations between cancer and diabetes and PROs cross-sectionally21-23,26-28. Most 
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studies focused on patients with specific cancer types including patients with diabetes 
and prostate 22-25, colorectal 27,28, or breast cancer23. Five studies included cancer patients 
with diabetes (CA+DM+) and made a comparison with cancer patients without diabetes 
(CA+DM-)21,22,24,25,28, one study compared CA+DM+ patients with patients with diabetes 
only (CA-DM+)23 and two studies included CA+DM-, CA-DM+ and patients without 
both diseases (CA-DM-) for comparison26,27. Two studies, based on the same data, only 
included CA+DM+, and did not include a comparison group19,20. Of the 10 included 
studies, 8 focused on HRQoL, self-perceived health status, functioning or symptoms, 
while 2 studies assessed the impact of cancer and its treatment on diabetes self-
management. Most studies used a validated questionnaire. The Short Form (SF)-36 
was used most frequently to assess HRQoL or self-perceived health status21,22,25, other 
studies used the Health Utility Index Mark 3 (HUI3)26, the EuroQoL Group’s EQ-5D23, the 
Audit of Diabetes Dependent Quality of Life (ADDQoL)23, the European Organization for 
Research and Treatment of Cancer core Quality of Life Questionnaire (EORTC QLQ-C30)27, 
or the University of California, Los Angeles, Prostate Cancer Index (UCLA-PCI)22,24,25. The 
EORTC QLQ-Chemotherapy-Induced Peripheral Neuropathy (CIPN)-20 was used to assess 
neuropathic symptoms28. Eight out of 10 studies conducted multivariate analyses and 
mainly adjusted for socio-demographic19,21,22,24-28 and cancer-related covariates19,21,22,25,27,28, 
while diabetes-related covariates19 and lifestyle factors24,26-28 were less often adjusted for.
Study quality
The 10 included studies scored a mean quality score of 10 out of 14, and scores ranged 
between 7 and 13. Four studies (40%) were classified as being of high quality and 6 
(60%) of adequate quality according to our quality criteria. No studies were considered 
of low quality. The criteria that were least often met are (#4) the inclusion of a (healthy) 
normative sample for comparison, (#7) a description of at least two clinical variables 
regarding diabetes diagnosis, and (#10) information is given regarding differences in 
demographic and/or clinical characteristics of respondents versus non-respondents (all 
met by 3 studies) (Table 1).
HRQoL, functioning and symptoms
All included studies reported worse PROs among CA+DM+ compared to CA+DM-, 
CA-DM+ or CA-DM- on at least 1 studied item or subscale, except for 1 longitudinal 
study25. Nine out of the 10 included studies assessed more than 1 PRO, while 1 study 
only included a general measure of HRQoL26.
General HRQoL
A large cross-sectional study conducted in Canada reported lowest average HRQoL scores 
for CA+DM+ (n=940) followed by CA+DM- (n=1,692), CA-DM+ (n=4,394) and CA-DM- 
(n=107,295) patients with average HUI3 scores ranging between 0.67 and 0.89 (i.e. where 
-0.36=worst possible health, 0=death, and 1=perfect health)26. The HUI3 indirectly 
measures HRQoL using 8 attributes (vision, hearing, speech, ambulation, dexterity, 
emotion, cognition, and pain) and a mean difference of 0.03 was considered as clinically 
important. Multivariable regression analyses showed similar results with a lower HRQoL 
for CA+DM+, CA+DM- and CA-DM+ patients as compared to CA-DM- patients with 
beta’s of -0.10, -0.04 and -0.04, respectively, which was regarded clinically relevant26. 
Similarly, lower general health was reported in a cross-sectional study among 65 prostate 
cancer patients with versus 525 without diabetes with average SF36 scores of 51.9 versus 
62.5, which remained significant in multivariable analyses (beta=-0.13)22. A longitudinal 
study among prostate cancer patients did observe differences between CA+DM+ and 
CA+DM- in general health at baseline, but after adjustments for age, marital status, 
educational level, income, employment status, baseline HRQoL, cancer stage, primary 
treatment, baseline PSA and baseline Gleason score this difference did not remain 
significant25. Other studies did not report a worse general health among those with 
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Figure 1 Flow chart of the selection process of the systematic literature search
*Selection criteria include: the study (1) includes patients with both cancer and diabetes, (2) PRO is primary or 
secondary outcome measure of the study, (3) is published in a peer-reviewed journal, and (4) is published in English
**Article of our own research group was accepted for publication on the 13th of January 2015 and published 
online on 3 February 2015
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Physical functioning or mobility
Five studies included a measure of physical functioning or mobility. In a study with 76 
CA+DM+ and 585 CA+DM, CA+DM+ scored on average 12 points lower on the physical 
functioning subscale of the SF-36 as compared to CA+DM-21, as this difference was larger 
than 0.5 times the standard deviation it can be considered to be clinically relevant29. 
Similarly, a cross-sectional study found more problems with mobility and usual activities 
among men with prostate CA+DM+ as compared to CA-DM+, but this difference was 
not found among women with breast cancer23. Colorectal CA+DM+ reported a worse 
physical functioning as compared to CA+DM- (beta=-3.8)27. Two studies did not report 
lower physical functioning among CA+DM+22,25, however, one study did report lower 
vitality among prostate CA+DM+ as compared to CA+DM- (beta=-0.12), which was 
considered a clinically relevant difference22. 
Sexual functioning
Sexual functioning was assessed in one study among colorectal CA+DM+27 and in two 
studies with prostate CA+DM+24,25. Colorectal CA+DM+ reported more male sexual 
problems compared to colorectal CA+DM- (beta=9.4) in a cross-sectional study from 
the Netherlands27. Among prostate cancer patients, two longitudinal studies did not 
observe a significant association between comorbid diabetes and sexual functioning24,25.
Urinary and bowel functioning
Three studies among prostate cancer CA+DM+ and CA+DM- patients also focused 
on prostate cancer specific symptoms, including urinary functioning and/or bowel 
functioning22,24,25. One study reported lower urinary function during follow-up among 
prostate CA+DM+ as compared to CA+DM- (mean score 72±24 vs 77±22)24, but the 
other studies did not report differences in urinary or bowel functioning22,25.
Neuropathic symptoms
A cross-sectional study by our research group among 218 colorectal CA+DM+ and an age- 
and sex-matched sample of 975 CA+DM- patients assessed differences in neuropathic 
symptoms28. CA+DM+ patients reported more neuropathic symptoms regardless of 
cancer treatment as compared with CA+DM- patients regarding tingling fingers or hands 
(OR=1.40; 95%CI:1.00-1.94), tingling toes or feet (OR=1.47 95%CI:1.04-2.07), numbness 
in toes or feet (OR=1.83; 95%CI:1.28-2.62) and erection problems among men (OR=1.83; 
95%CI:1.11-3.03). However, the majority of reported symptoms were of mild severity.
Mental Health
CA+DM+ patients did not report worse mental health or emotional functioning compared 
to CA+DM- or CA-DM+ in 3 cross-sectional21,22,27 and one longitudinal study25. One study 
included a measure of problems with anxiety, but no significant differences were found 
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Diabetes self-management
Two studies, using the same longitudinal data, addressed problems with diabetes self-
management among 43 patients with a solid tumor and type 1 or 2 diabetes19,20. One 
study showed that patients reported higher scores on symptom burden and lower 
scores on diabetes self-management after 8 weeks on chemotherapy as compared to 
baseline (mean 32.57±4.49 vs 25.43±3.81 and 45.86±2.65 vs 50.84±2.47, respectively)20. 
In addition, a moderate impact of cancer on diabetes self-management was observed, 
which mainly affected the ability to exercise, blood sugar monitoring, and ability to eat 
and drink. Moreover, in qualitative assessments many individuals indicated that they 
prioritized cancer care instead of diabetes care20. The other study mainly focused on 
predictors of diabetes self-management19. This study showed that living arrangements, 
years with DM, the total number of medications, baseline DM self-management, DM 
self-efficacy and baseline and 8-week symptom severity were significant predictors 
of diabetes self-management, while diabetes complications, cancer type, stage and 
treatment, outcome expectancies, and anxiety and depression were not19.
Discussion
The majority of the included studies in this systematic review (i.e. 8 out of 10 studies) 
addressed HRQoL, self-perceived health, functioning or symptoms, and two studies, 
based on the same data, assessed diabetes self-management. In all included studies, 
CA+DM+ patients reported worse outcomes, but in 1 longitudinal study among prostate 
cancer patients, differences disappeared after adjustments25. CA+DM+ patients mainly 
scored lower on general HRQoL22,26, physical functioning21,23,27 and sexual functioning27. 
In addition, prostate CA+DM+ patients reported lower urinary functioning24 and lower 
vitality22, while colorectal CA+DM+ versus CA+DM- patients reported more neuropathic 
symptoms in a cross-sectional study28. Finally, among diabetes patients that also had 
concurrent cancer, symptom severity increased and diabetes self-management, mainly 
exercise, blood sugar monitoring, and the ability to eat and drink, was impaired after 8 
weeks on chemotherapy20.
Similar to the results found in our systematic review, literature shows that comorbidity 
has a significant impact on HRQoL. Several other studies that were not included in this 
review but included diabetes as one of the studied comorbid conditions showed that 
cancer patients with comorbidity reported lower HRQoL or functioning30-33. A few of 
those studies reported the impact of diabetes separately and found a poorer general 
health30, lower physical functioning30,33, more symptoms of nausea31 and more erections 
problems among CA+DM+ men32. In line with these results, the number of comorbidities, 
including cancer, among patients with diabetes has also been shown to result in poorer 
HRQoL34. These studies were excluded from the present review as CA+DM+ patients 
were not the main sample, and as a result the number of included patients with both 
diseases was often low.
Although the included studies were of adequate to high quality, they differed substantially in 
design, population, and methodology. Different instruments were used to measure HRQoL 
which hampers comparison of the results. Moreover, different cancer types were studied 
and sample sizes in subgroups were generally low, particularly for CA+DM+ patients. 
The majority of studies included CA+DM+ and CA+DM- patients, although some studies 
additionally included a normative sample or CA-DM+ patients for comparison. As a 
result, information regarding diabetes characteristics was scarce with only 3 out of 10 
studies including clinical data regarding diabetes. However, it is important to take the 
duration and severity of diabetes into account as this may influence the outcomes. Only 
4 prospective studies were included, of which 2 were based on the same data, and these 
studies were conducted mainly among prostate cancer patients.
Despite the heterogeneity in patient samples and PROs studied, this systematic review 
also has several strengths. It is the first to summarize the literature on PROs among 
CA+DM+ patients. In addition, a broad search strategy was used and thereby a complete 
overview of the previous literature is presented. Finally, the quality of all included studies 
was assessed by two independent investigators with a 14-item checklist.
Directions for future research
Although previous studies suggest that having both cancer and diabetes results in worse 
outcomes, the evidence is scarce and many relevant topics have not been studied yet. 
This systematic review shows that the majority of studies focused on general HRQoL 
and physical function, however, only little attention has been paid to mental health. 
Mental health was assessed in 5 of the 10 included studies but did not appear to be 
deteriorated in CA+DM+ patients as compared with CA+DM- and CA-DM+ patients. 
However, this might be a result of the used instrument, as all studies used a subscale of 
a HRQoL instrument, which might not be sensitive to more specific symptoms of anxiety 
or depression. Depression is a common problem in both cancer and diabetes patients. 
Previous research shows that depression is highly prevalent, in about a third of all cancer 
as well as diabetes patients and is associated with worse prognostic outcomes35-38. 
Therefore, it is possible that CA+DM+ patients might encounter more mental health 
issues, which were not picked up in the limited studies in this review. Thus, future studies 
should focus on mental health issues, including depression among CA+DM+ patients.
Previous studies show that among both cancer and diabetes patients BMI, physical 
activity, and smoking are significant predictors of HRQoL39-43. However, only 4 of the 
studies included in this review adjusted for lifestyle factors of which 3 only included 
BMI24,27,28 and 1 study additionally adjusted for physical activity and smoking26. These 
studies showed that CA+DM+ patients have a higher BMI24,26-28 and are less physically 
active26 at baseline than those without diabetes. Although, these studies did observe 
lower HRQoL among CA+DM+ versus CA+DM- patients independent of the adjustment 
for lifestyle factors, more research is needed. It is important to assess whether the poorer 
lifestyle, rather than clinical factors, of CA+DM+ patients is responsible for the lower 
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HRQoL in this group. Moreover, future research should focus on the effect of changes 
in lifestyle factors and their impact on HRQoL; with that knowledge interventions can 
be developed to improve HRQoL on the long term. 
Elderly often live with several chronic illnesses such as cancer and diabetes, which poses 
a burden on patients. Due to the improved survival, self-management of these chronic 
diseases is becoming more important. This review included two studies on diabetes 
self-management which showed that cancer patients performed fewer diabetes self-
management behaviors, such as monitoring of the blood glucose levels and exercising, 
after 8 weeks on chemotherapy20. Moreover, qualitative research showed that diabetes 
patients who develop cancer prioritize their cancer care over their diabetes care20. 
Among diabetes patients, self-management is widely studied and a previous literature 
review and meta-analysis shows that self-management interventions can improve blood 
glucose levels, increase knowledge and self-efficacy, and eventually might reduce costs of 
healthcare utilization44. It is important that both patients as well as specialists recognize 
the importance of self-management of multiple chronic illnesses. It is important that 
patients are able to utilize their resources and feel that they are in control of life and 
solve problems when necessary. Therefore, we believe that empowerment of patients and 
improving self-management behavior are important topics to address in future studies 
among patients with multiple chronic diseases.
Conclusion
In conclusion, this systematic review indicates that having both cancer and diabetes 
results in worse PROs. However, a relatively low number of studies was included and 
no definitive conclusions can be drawn because of the heterogeneity of the included 
studies. The included studies were of reasonable quality but a main issue was that clinical 
information regarding diabetes was missing. More prospective studies with sufficient 
sample sizes are needed to establish these findings. As this research area is largely 
neglected and the majority of studies focused on HRQoL and physical function, future 
research should focus on other PROs that are highly prevalent among both cancer 
and diabetes patients such as mental health, including depression. In addition, as the 
occurrence of multiple chronic diseases poses important constraints on a person’s life 
and their health care, topics such as self-care and patient empowerment should receive 
more attention in future research.
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Appendix A Search strategy for all databases which were searched on August 28, 2013 
and updated on January 27, 2015
MEDLINE (Ovid and Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations)
1.  exp *Diabetes Mellitus/ 
2.  diabet$.ti. 
3.  1 or 2
4.  exp *Neoplasms/
5.  (cancer$ or neoplasm$ or oncolog$).ti.
6.  4 or 5
7.  3 and 6
8.  randomized controlled trial.pt.
9.  controlled clinical trial.pt.
10.  randomized.ab.
11.  placebo.ab.





17.  (animals not (humans and animals)).sh.
18.  16 not 17
19.  7 and 18
20.  exp Epidemiologic Studies/
21.  cohort$.tw.
22.  (case$ and control$).tw.
23.  (case$ and series).tw.
24.  case reports.pt.
25.  (case$ adj2 report$).tw.





31.  (animals not (humans and animals)).sh.
32.  30 not 31
33.  7 and 32
34.  19 or 33
35.  limit 34 to english language
The Cochrane Library
#1 MeSH descriptor: [Diabetes Mellitus] explode all trees
#2 diabet*:ti 
#3 #1 or #2 
#4 MeSH descriptor: [Neoplasms] explode all trees
#5 (cancer* or neoplasm* or oncolog*):ti 
#6 #4 or #5 
#7 #3 and #6 
CINAHL (EBSCOhost)
S1 (MM “Diabetes Mellitus+”)
S2 TI diabet*
S3 S1 OR S2
S4 (MM “Neoplasms+”)
S5 TI ( cancer* or neoplasm* or oncolog*)
S6 S4 OR S5




3. 1 or 2
4. exp neoplasms/
5. (cancer$ or neoplasm$ or oncolog$).ti.
6. 4 or 5
7. 3 and 6
C H A P T E R  3
P a u l i n e  A . J .  V i s s e r s 
M e l i s s a  S . Y .  T h o n g
F r a n s  P o u w e r
M a r j o l e i n  M . J .  Z a n d e r s
J a n - W i l l e m  W .  C o e b e r g h
L o n n e k e  V .  v a n  d e  P o l l - F r a n s e
 
J o u r n a l  o f  C a n c e r  S u r v i v o r s h i p ,  2 0 1 3 ;  7 ( 4 ) : 6 0 2 - 6 1 3
T H E  I M P A C T  O F  C O M O R B I D I T Y  O N  H E A L T H -
R E L A T E D  Q U A L I T Y  O F  L I F E  A M O N G  C A N C E R 
S U R V I V O R S :  A N A L Y S E S  O F  D A T A  F R O M  T H E 
P R O F I L E S  R E G I S T R Y
3




The aim of this study was to assess the difference in explained variance of Health-Related 
Quality of Life (HRQoL) between comorbidity, sociodemographic characteristics and 
cancer characteristics. This association was assessed among thyroid cancer, colorectal 
cancer, and (non-)Hodgkin’s lymphoma patients.
Methods 
Data from three large population-based surveys on survivors of thyroid cancer, colorectal 
cancer, and (non-)Hodgkin’s lymphoma were used. Cancer-specific HRQoL was assessed 
with the European Organization for Research and Treatment of Cancer (EORTC) Quality 
of Life Questionnaire Core 30 (QLQ-C30) of which physical function, emotional function, 
fatigue, and pain were included in the analyses. Comorbidity was assessed using the Self-
reported Comorbidity Questionnaire. The association between comorbidity and HRQoL 
was assessed with multivariate linear regression models. Semi-partial R2 was reported to 
assess the amount of variance in HRQoL explained by comorbidity in comparison with 
sociodemographic and cancer characteristics.
Results
In total, 3,792 cancer survivors were included in this analysis. The variance in HRQoL 
subscales explained by comorbidity was higher compared with sociodemographic and 
cancer characteristics for physical function (11-17 vs. 2-4 and 1-2 %, respectively) and 
emotional function (7-17 vs. 1-3 and 1-3 %, respectively), regardless of cancer type. In 
addition, comorbidity explained 7-20 and 11-13 % of the variance in pain and fatigue, 
respectively, compared to 0-4 % for both sociodemographic and cancer characteristics. 
Osteoarthritis and back pain were strongly associated with physical function and pain, 
while depression was strongly associated with emotional function. Depression and back 
pain were strongly associated with fatigue.
Conclusions
This study showed that comorbidity explained more variance in physical and emotional 
function, pain, and fatigue in comparison with sociodemographic and cancer 
characteristics in cancer survivors, regardless of cancer type. Our findings emphasize 
the importance of adjusting for the presence of comorbid diseases when assessing 
HRQoL in cancer survivors.
Introduction
Comorbidity is a complex issue in cancer research. Worldwide, there is a trend of aging 
of the population1. At the same time the number of cancer survivors is rapidly increasing 
due to earlier diagnosis and more effective treatments2. Together, these two trends 
increase the number of patients who survive cancer and have coexisting disease(s), 
comorbidity. In the Netherlands, around 60% of elderly cancer patients aged 65 years or 
older suffer from at least one other serious condition with the highest prevalence being 
previous cancer, heart disease, hypertension, chronic obstructive pulmonary disease 
(COPD), and diabetes mellitus3.
Recently, in cancer research, more attention is being paid to health-related quality of 
life (HRQoL) of cancer survivors4, where previously the focus was more on objective 
outcome measures such as treatment effects and mortality. Comorbid diseases generally 
affect patients’ HRQoL negatively, with somatic comorbid conditions affecting mainly 
physical HRQoL and psychiatric disorders affecting mainly psychosocial aspects of 
HRQoL5,6. A study among head and neck cancer patients showed that having two or 
more comorbid conditions was strongly associated with decreased HRQoL subscales7,8. 
Another previous study among 158 prostate cancer survivors showed that the Charlson 
combined comorbidity index impacted on global health and physical function domains 
of HRQoL9. Furthermore, severe comorbidity among lung cancer patients resulted in 
poorer HRQoL compared to lung cancer patients with no severe comorbidity10. Our 
previous research showed that comorbidity is a strong independent predictor of 
HRQoL in colon and rectal cancer survivors11,12. Furthermore, disease characteristics 
were less important in predicting HRQoL in cancer survivors, compared with social and 
demographic characteristics13,14. Previous studies mainly focused on head and neck 
cancer, lung cancer and prostate cancer patients and all studies found an association 
between comorbidity and a lower HRQoL. This implies that comorbidity might impact 
on HRQoL generalizable to a wider range of cancer types. 
Furthermore, not much attention has been paid to the relative impact of comorbidity 
on HRQoL. Most studies do not investigate the variance in HRQoL explained by 
comorbidity, while this effect size can address the relative importance of comorbidity 
in comparison with sociodemographic characteristics and cancer characteristics. One 
study conducted among inpatients showed that comorbidity explained 20-60 % of 
the total variance of the model predicting HRQoL subscales15. One previous study 
among breast cancer patients found that comorbidities explained most variance 
on nearly all subscales of HRQoL in comparison with demographics and clinical 
variables16 Furthermore, comorbidity was found to be an independent prognostic 
indicator among cancer survivors3. While the number of comorbidities increases with 
age17, the elderly are often less aggressively treated compared to younger cancer 
patients3. Therefore, we will also conduct a subanalysis among elderly cancer survivors. 
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The aim of this study was to assess the difference in explained variance of HRQoL 
between comorbidity, sociodemographic characteristics and cancer characteristics. This 
association was assessed among thyroid cancer, colorectal cancer, and (non-)Hodgkin’s 
lymphoma patients. We hypothesized that (1) comorbidity explains a similar or higher 
amount of variance in HRQoL measures compared with sociodemographic and cancer 
characteristics, (2) comorbidity has an impact on HRQoL regardless of cancer type and 
(3) there is a higher prevalence of comorbidity and a higher impact of comorbidity on 
HRQoL among the elderly cancer patients. The results of this study could highlight 
the importance of including and correcting for a measure of comorbidity in studies 
addressing HRQoL among cancer survivors.
Methods
Subjects
For this study, data from three large population-based surveys on survivors of thyroid 
cancer, colorectal cancer, and non-Hodgkin’s and Hodgkin’s lymphoma conducted 
between 2008 and 2010 were used. The aim of these surveys was to assess late treatment 
effects, physical, and mental HRQoL along with other patient-reported outcomes among 
cancer survivors. Data from these studies will become available online for noncommercial 
scientific research, subject to study question, privacy and confidentiality restrictions, and 
registration from our patient-reported outcomes registry, PROFILES (www.profilesregistry.
nl)18.
The Eindhoven Cancer Registry (ECR), maintained by the Comprehensive Cancer Center 
South, records data on all newly diagnosed cancer patients in the southern region of 
The Netherlands covering an area with 2.3 million inhabitants and ten hospitals19. All 
thyroid cancer patients diagnosed between 1990 and 2008, all colorectal cancer patients 
diagnosed between 2000 and 2009, and all lymphoma patients diagnosed between 1999 
and 2008 were eligible for participation in the surveys. All cancer patients were surveyed 
at least 6 months after their cancer diagnosis, in order to ensure that cancer treatment 
was completed at the time of the survey, and at most 10 years (colorectal cancer and 
(non-)Hodgkin’s lymphoma) to 20 years (thyroid cancer) after cancer diagnosis. Detailed 
flow charts of the patient samplings have been reported elsewhere20-22. Patients who 
died prior to the study start were identified through the Central Bureau of Genealogy, 
which collects information on all deceased Dutch citizens via the civil municipal registries 
and hospital records. After excluding the deceased patients, the treating physicians 
verified the status of each eligible patient before the patient was approached for study 
participation (e.g., patients with serious cognitive impairment or who were in transition 
to terminal care were excluded). All eligible patients received an invitation letter with 
a login account and password to complete the survey online. If patients did not have 
access to internet or preferred to take the survey on paper, they could return a postcard, 
and they received the paper questionnaire within 1 week. After 2 months, reminders 
were sent to patients who did not respond to the survey. More detailed information on 
the method of data collection is described elsewhere18. After completion of the data 
collection, data from each patient were linked to their clinical characteristics registered 
in the ECR. All surveys were approved by a medical ethics committee.
Clinical and sociodemographic characteristics
Information on clinical characteristics was available from the ECR, where date of cancer 
diagnosis, primary treatment, and cancer stage are routinely collected from medical 
records by trained registrars. Since the ECR only collects data on the primary tumor 
and treatment, it cannot be ascertained that patients were disease-free at the time of 
the survey. Sociodemographic characteristics, including age, gender, and educational 
level, were assessed in the questionnaire. In this study, education level was categorized 
as high (pre-university education, high vocational training or university) compared with 
medium or low.
Health-Related Quality of Life
All cancer survivors completed the European Organization for Research and Treatment of 
Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) (version 3.0) to assess 
cancer-specific quality of life. The QLQ-C30 is a 30-item self-report questionnaire which 
covers five function scales, a measure of global health or quality of life, and nine scales 
on symptoms and side effects23. Since the EORTC QLQ-C30 does not include an overall 
score of all scales, and in order to prevent multiple testing and avoid an associated type 
1 error, the four most important or distinctive scales were selected. Physical function 
was included; this scale is hypothesized to be most distinctive for the somatic health of 
different subgroups of cancer survivors11,21. Furthermore, the emotional function scale 
was included to investigate the impact of comorbidity on mental health as well. Finally, 
the symptoms pain and fatigue were included since these symptoms are highly prevalent 
among different groups of cancer survivors24-26. All items were scored on a scale from 1 
(not at all) to 4 (very much) and then linearly transformed to a 1 to 100 scale; a higher 
score on function domains represents better function and quality of life, while a higher 
score on symptom scales represents more symptoms27.
Comorbidity
Comorbidity was assessed using a modified version of the Self-Administered 
Comorbidity Questionnaire15. The questionnaire addressed the prevalence, hindrance 
in daily activity, and treatment of 14 comorbidities including heart disease, stroke, high 
blood pressure, COPD/asthma, diabetes, stomach disease, kidney disease, liver disease, 
anemia, depression, thyroid disease, osteoarthritis, back pain, and rheumatoid arthritis. 
Since measuring hindrance in daily activities could be intertwined with measures of 
HRQoL, this could pose a confounding effect in our planned analyses. Therefore, we only 
addressed the number of prevalent comorbidities, and not treatment, and hindrance in 
daily activities, resulting in a score ranging between 0 and 14. 
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In addition, the effect of individual comorbidities on HRQoL was studied among the two 
largest cancer patient samples including colorectal cancer and non-Hodgkin’s lymphoma 
patients. Among thyroid cancer and Hodgkin’s lymphoma patients, the prevalence 
of specific comorbidities was not high enough, with 10 out of 14 and 14 out of 14 
comorbidities being prevalent in less than 50 patients, respectively. Stroke, stomach, 
kidney, and liver diseases were prevalent in less than 5 % of the colorectal cancer and 
non-Hodgkin’s lymphoma patients and were therefore excluded from further analysis 
as well.
Statistical analyses
Differences in baseline characteristics of the study population were analyzed using 
analysis of variance or chi-square, where appropriate. Unadjusted associations between 
the number of prevalent comorbidities (0, 1 or ≥2) and HRQoL subscales were studied 
and presented graphically.
Multivariate linear regression models were constructed to assess the variance in 
HRQoL subscales explained by the number of comorbidities, which was entered as a 
continuous variable into the model. Explained variance was reported as the semi-partial 
correlation coefficient in percentages in order to assess the unique contribution of each 
independent variable. The semi-partial correlation coefficients (R2) of age, gender, and 
education were summed and further referred to as sociodemographic characteristics. 
Similarly, the coefficients of years after cancer diagnosis, primary cancer treatment, 
and, where appropriate, cancer stage, are further referred to as cancer characteristics. 
Thereafter, all comorbidities, with an arbitrarily chosen prevalence of 5% or higher, were 
included separately into the model to study the effect of each individual comorbid 
disease on HRQoL domains. Since anemia (3-8 %) has previously been reported as being 
an important long-term effect of cancer treatment in non-Hodgkin’s and Hodgkin’s 
lymphoma patients, this disease was included in further analyses28.
A subanalysis among the elderly aged 70 years or older was conducted to investigate 
whether the association between comorbidity and HRQoL domains was different from 
the total study population by using a comparable method as for the main analyses. We 
defined elderly oncology patients as those ≥70 years old, according to the European 
Society for Medical Oncology29. Hodgkin’s patients were excluded from this analysis since 
only 13 Hodgkin’s patients were 70 years or older. Due to the large number of statistical 
tests conducted in this study and to avoid type 1 errors, all differences with a P-value 
<0.01 were indicated as statistically significant. All statistical analyses were performed 
using SAS statistics (version 9.2 for Windows, SAS institute Inc., Cary, NC).
Results
Characteristics of the study population
Seventy-one percent of the 5,317 invited cancer survivors returned a completed 
questionnaire; 892 invited patients actively refused or did not complete the survey for 
other reasons; and the address of 633 patients could not be verified (Figure 1). Response 
rates were 54, 73, and 67% among thyroid cancer, colorectal cancer, and (non-)Hodgkin’s 
lymphoma patients, respectively. Respondents were on average 2 years younger and 
6% more often male and surveyed closer to their cancer diagnosis compared with 
non-respondents. In addition, respondents were 4% more often treated with surgery 
and 6% more often treated with chemotherapy or surgery and radiotherapy. Detailed 
information of the study populations is described elsewhere20,21,30. In total, 3,792 patients 
were included in the present study (Table 1). Hodgkin’s lymphoma patients were the 
youngest and most highly educated compared to the other cancer patients included. 
In total, 5317 patients were eligible for participation 
(i.e. after excluding deceased patients, terminally 
ill/demented patients, patients in hospitals which were 
not willing to participate) 
 
Colorectal cancer patients 
Diagnosed between 2000-2009 
N=3585 
 
Thyroid cancer patients 
Diagnosed between 1998-2008 
N=568 
 
Hodgkin Lymphoma patients 
Diagnosed between 1998-2008 
N=223 
 
Non-Hodgkin Lymphoma patients 
Diagnosed between 1998-2008 
N=1064 
 
In total, 3972 cancer patients completed the 
questionnaire, including: 
Thyroid cancer patients     N=306   (54%)  
Colorectal cancer patients     N=2620 (73%)  
Hodgkin lymphoma patients     N=150   (67%)  
Non-Hodgkin’s lymphoma patients N=716   (67%)  
 
 
The  addresses of 633 patients 
could not be verified 
 
892 patients actively refused or 
did not complete the 
questionnaire for other reasons 
 
 
Figure 1 Flowchart of the study process
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Age 56 ±15 69 ±10 47 ±15 64 ±12 <0.0001
Gender
Male 76 (25) 1446 (55) 81 (54) 439 (61) <0.0001
Female 230 (75) 1174 (45) 69 (46) 277 (39)
Educational level
Medium or low 225 (74) 2083 (80) 101 (68) 532 (77) <0.0001
High 80 (26) 508 (20) 48 (32) 163 (23)
Cancer characteristics
Years after diagnosis 10 ±5 5 ±3 5 ±3 5 ±3 <0.0001
Tumor stage
1 172 (58) 778 (30) NA 100 (33) <0.00011
2 59 (20) 945 (37) NA 77 (25)
3 48 (16) 723 (28) NA 54 (18)
4 20 (7) 114 (4) NA 76 (25)
Treatment
Surgery and iodine ablation 212 (70) <0.0001
Surgery only 83 (27) 1256 (48) 11 (2)
Surgery and radiotherapy 9 (3) 588 (23) 6 (1)
Surgery and chemotherapy 545 (21) 9 (11)
Surgery, radio- and chemotherapy 203 (8) 10 (11)
Chemotherapy only 14 (1) 55 (37) 303 (44)
Radiotherapy only 2 (0) 4 (3) 62 (9)
Watchful waiting 1 (1) 187 (27)
Radio- and chemotherapy 90 (60) 85 (12)
Stemcell transplantation 1 (0)
Stemcell transplantation and chemotherapy 22 (3)
HRQoL (QLQ-C30)
Physical functioning 83 ±20 80 ±21 87 ±16 80 ±20 0.0002
Emotional functioning 84 ±20 86 ±19 83 ±23 84 ±21 0.04
Pain2 17 ±25 16 ±24 13 ±22 16 ±25 0.27
Fatigue2 28 ±25 22 ±24 28 ±27 28 ±25 <0.0001
Table 1 Characteristics of the study population in means ± standard deviation or n(%)
1Excluding Hodgkin’s lymphoma patients
2Pain and fatigue are scored in opposite direction with higher scores indicating more symptoms
NA = Not applicable
Thyroid cancer patients were surveyed furthest from their diagnosis (10±5 years) 
compared with other cancer patients included (5±3 years). Primary cancer treatment 
and cancer stage differed significantly between the four different cancer types. Hodgkin’s 
lymphoma patients scored highest on physical function compared to the other cancer 
patients. Emotional function was highest, while fatigue symptoms were lowest among 
colorectal cancer survivors.
Comorbidity
Colorectal and thyroid cancer patients suffered from most comorbid diseases with 46 
and 44% suffering from two or more comorbid conditions, respectively (Table 2). Heart 
disease was most prevalent among colorectal cancer and non-Hodgkin’s lymphoma 
patients with an approximate prevalence of 20%. High blood pressure (35%) and 
diabetes (15%) were most prevalent among colorectal cancer survivors. Anemia was 
highest among non-Hodgkin’s lymphoma patients (8%), while thyroid disease was most 
prevalent among thyroid cancer patients (30%) and Hodgkin’s lymphoma patients (12%).
















Number of comorbidities (n(%))
None 75 (25) 613 (25) 64 (46) 189 (29) <0.0001
1 92 (31) 708 (29) 43 (31) 205 (31)
≥2 133 (44) 1126 (46) 32 (23) 266 (40)
Types of comorbid diseases (n(%))
Heart disease 33 (11) 462 (19) 13 (9) 130 (20) 0.0002
Stroke 4 (1) 66 (3) 2 (1) 13 (2) 0.33
Hypertension 79 (26) 862 (35) 15 (11) 141 (21) <0.0001
Asthma/COPD 30 (10) 266 (11) 17 (12) 75 (11) 0.89
Diabetes 22 (7) 356 (15) 6 (4) 49 (7) <0.0001
Stomach disease 5 (2) 41 (2) 1 (1) 13 (2) 0.78
Kidney disease 8 (3) 100 (4) 1 (1) 13 (2) 0.01
Liver disease 1 (0) 78 (3) 1 (1) 6 (1) 0.0002
Anemia 13 (4) 117 (5) 4 (3) 55 (8) 0.001
Thyroid disease 89 (30) 117 (5) 16 (12) 31 (5) <0.0001
Depression 21 (7) 170 (7) 14 (10) 52 (8) 0.49
Osteoarthritis 76 (25) 635 (26) 21 (15) 264 (25) 0.04
Back pain 98 (33) 664 (27) 23 (17) 160 (24) 0.002
Rheumatoid arthritis 26 (9) 164 (7) 4 (3) 46 (7) 0.16
3
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Figure 2a-d Means of four domains of the QLQ-C30 questionnaire according to the number 
of comorbidities among thyroid- (a), colorectal cancer (b), Hodgkin’s lymphoma (c) Hodgkin’s 
lymphoma (d.) Non-Hodgkin’s lymphoma
†Significantly different from participants with no comorbidity (P-value<0.01)
‡Significantly different from participants with no comorbidity and those with one comorbidity (P-value<0.01)
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Number of comorbidities and HRQoL
Among all cancer survivors, except for thyroid cancer patients, having one and/or two 
or more comorbidities was significantly associated with lower physical and emotional 
function and higher levels of pain and fatigue (Figure 2a-d). Among thyroid cancer 
patients, no significant difference in emotional function between no, one, or two or 
more comorbidities was observed. Similarly, physical function was lower, while levels 
of pain and fatigue were higher among thyroid cancer patients having one and/or 
two comorbidities compared with those who had no comorbidity. Multivariate linear 
regression models showed that the number of comorbidities was strongly related to 
the studied subscales of the QLQ-C30, with a P-value <0.01 among all cancer survivors. 
All standardized betas were in the expected direction with more comorbidities resulting 
in lower physical and emotional function (standardized betas; −0.3 to −0.5). Similarly, 
having more comorbidities was associated with higher levels of pain and fatigue, with 
all standardized betas ranging between 0.3 and 0.5.
These models also showed that the variance explained by the number of comorbidities 
was higher compared with sociodemographic and cancer characteristics for all cancer 
survivors (Figure 3a-d). The number of comorbidities explained 11-17% of the variance 
in physical function compared with 2-4 and 1-2% for sociodemographic and cancer 
characteristics, respectively. A 7-17% of the variance in emotional function was explained 
by the number of comorbidities compared with 1-3% for both sociodemographic and 
cancer characteristics. Finally, the number of comorbidities explained 7-20 and 11-
13% of the variance in pain and fatigue, respectively, compared with 0-4% for both 
sociodemographic and cancer characteristics. When including the overlap between the 
studied predictors of HRQoL as well, the total explained variance (R2) of the models 
ranged between 9 and 27% (Figure 3a-d).
Individual comorbidities and HRQoL
Including the selected comorbidities separately in the model resulted in higher 
proportions of explained variance (2-11%) for all studied subscales compared to including 
the number of comorbidities (Table 3 and Figure 3). Variance in physical function was 
explained most by heart disease and back pain with 2-4% among colorectal and non-
Hodgkin’s lymphoma patients (Table 3). Depression explained most variance in emotional 
function with 12 and 8% among colorectal and non-Hodgkin’s lymphoma patients, 
respectively. Variance in pain was explained most by back pain with around 7%, and 
variance in fatigue was mainly explained by depression and back pain with 2-3%. Again, 
all significant standardized betas were in the expected direction ranging between −0.1 
and −0.2 for physical function, between −0.1 and −0.4 for emotional function, between 
0.1 and 0.3 for pain, and between 0.1 and 0.2 for fatigue. The total explained variance 
(R2) in HRQoL ranged between 20 and 30% across the different models.
3
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Figure 3a-d Variance (semi-partial R²(%)) explained by sociodemographic- (age, gender and 
educational level), cancer characteristics (primary treatment, stage, and years after diagnosis), 
and the number of comorbidities among thyroid- (a), colorectal cancer (b), Hodgkin’s lymphoma 
























































Contribution of overlap between cancer characteristics, sociodemographic variables and/or number of comorbidities
Elderly
Comorbidity among thyroid cancer, colorectal cancer, and non-Hodgkin’s lymphoma 
patients was significantly higher among the elderly. Fifty-two percent of those aged ≥70 
years suffered from two or more comorbid conditions compared with 38% of survivors 
younger than 70 years old. Compared to patients aged <70 years old, the prevalence 
of heart disease (28 vs 11%), stroke (4 vs 1%), hypertension (38 vs 27%), diabetes (16 vs 
10%), anemia (7 vs 4%), and osteoarthritis (31 vs 21%) was significantly (P-value<0.01) 
higher among elderly aged ≥70 years. Thyroid disease and depression were less prevalent 
among the elderly aged ≥70-years compared to the younger patients with 5 vs 8% and 6 
vs 8%, respectively. When studying the association between the number of comorbidities 
and HRQoL outcomes in multivariate regression models, similar results as for the total 
study population were found for elderly colorectal cancer patients (Figure 4b). Among 
elderly thyroid cancer patients, the number of comorbidity explains more of the variance 
in emotional function, pain, and fatigue compared to the total sample (Figure 4a). Among 
elderly non-Hodgkin’s patients, the number of comorbidities explained less while cancer 
characteristics explained more variance in all studied subscales compared with the total 
population (Figure 4c). When including the overlap between the studied predictors of 
HRQoL, the total explained variance (R2) of the models ranged between 9 and 46%.
Colorectal cancer Non-Hodgkin’s lymphoma
PF  EF  PA  FA  PF  EF  PA  FA  
Heart disease 1.9 ‡ 0.7 ‡ 0.4 † 1.9 ‡ 3.6 ‡ 1.3 † 0.3  1.8 †
Hypertension 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1
Asthma/COPD 1.8 ‡ 0.3 † 0.5 † 1.2 ‡ 0.1 0.1 0.0 0.3
Diabetes 0.4 † 0.0 0.0 0.1 0.8 † 0.0 0.2 0.1
Anemia 1.1 ‡ 0.0 0.7 ‡ 0.7 ‡ 0.2 0.0 0.2 0.1
Thyroid disease 0.1 0.2 0.2 0.0 0.0 0.1 0.1 0.0
Depression 1.0 ‡ 12.0 ‡ 0.6 ‡ 3.2 ‡ 1.2 † 7.9 ‡ 0.9 † 2.6 ‡
Osteoarthritis 0.4 † 0.0 1.6 ‡ 0.2 1.6 † 0.2 3.3 ‡ 0.7
Back pain 1.6 ‡ 1.2 ‡ 6.5 ‡ 2.0 ‡ 2.5 ‡ 3.8 ‡ 7.2 ‡ 2.9 ‡
Rheumatoid Arthritis 0.2 0.2 † 0.9 ‡ 0.1 1.6 † 0.3 2.4 ‡ 2.0 †
Sociodemographic 
characteristics1 4.5 ‡ 1.0 ‡ 0.8 † 0.4 † 3.3 † 0.6 0.5 0.5
Cancer characteristics2 2.0 ‡ 1.6 † 0.9 † 1.6 † 1.4 2.7 0.9 4.2 †
Total R² 23.6  20.7  21.3  17.3  29.8  20.1  26.2  20.5  
Adjusted R² 22.9  20.0  20.6  16.6  27.1  17.1  23.4  17.4  
†P-value <0.01, ‡P-value <0.0001
PF: physical function, EF: emotional function, PA: pain, FA: fatigue
1Sociodemographic characteristics include age, gender and educational level, variable is regarded as statistically 
significant if at least 1 of the cancer characteristics has a P-value<0.01 (†) or P-value<0.0001 (‡) 
2Cancer characteristics include time since cancer diagnosis, primary treatment and stage where applicable, 
variable is regarded as statistically significant if at least 1 of the cancer characteristics has a P-value<0.01 (†) or 
P-value<0.0001 (‡)
Table 3 Variance (R²(%)) in health related quality of life measures explained by most frequent 
comorbidities, age and cancer characteristics. Thyroid and Hodgkin’s lymphoma patients were
not included due to the low prevalence (N<50) of most comorbidities
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Figure 4a-c Variance (semi-partial R²(%)) explained by sociodemographic- (age, gender and 
educational level), cancer characteristics (primary treatment, stage, and years after diagnosis), 
and the number of comorbidities among elderly (≥70 years) thyroid- (a), colorectal cancer (b), 




Contribution of overlap between cancer characteristics, sociodemographic variables and/or number of comorbidities
Discussion
In this study, we showed that in comparison with sociodemographic and cancer 
characteristics, comorbidity explained more variance in physical function, emotional 
function, pain, and fatigue. This was found regardless of cancer type. Similar patterns 
were seen for thyroid cancer, colorectal cancer, and (non-)Hodgkin’s lymphoma patients. 
Among the elderly (≥70 years) thyroid cancer patients, comorbidity seemed to become 
more important, while in elderly (≥70 years) non-Hodgkin’s lymphoma patients, cancer 
characteristics seemed to have greater impact on HRQoL compared to the results for the 
total population. As hypothesized, the prevalence of comorbidity was higher among the 
elderly, but did not have a higher impact compared to sociodemographic and cancer 
characteristics among all cancer survivors.
The total explained variance found in the models predicting physical function, emotional 
function, pain, and fatigue ranged between 9 and 27%. This amount of explained variance 
is comparable to that of a previous study conducted among hospitalized patients who 
reported a total explained variance of 25, 19, and 20% for physical functioning, bodily 
pain, and vitality, respectively15. Comorbidity explained about 7-19% of the variance 
in HRQoL in our study. A previous study among breast cancer patients found that 
comorbidity explained less variance ranging between 0 and 10%, which might be the 
result of this different study population16. In general, the total explained variance in our 
study is still somewhat low, with a maximum of 27% of the variance explained. Other 
factors, which we did not take into account, could have contributed to the unexplained 
variance. Previous studies showed that personality traits such as neuroticism and coping 
strategies are also associated with HRQoL31 and might have played a role. Another 
possible predictor is social support32,33, which might contribute to the studied association. 
In addition, symptoms of pain and fatigue are found to be associated with physical 
function16 and omitting these symptoms could account for the low amount of explained 
variance in physical function that we found.
Among thyroid cancer patients, comorbidity seemed to increase in importance among 
the elderly compared with the total thyroid cancer sample. This might be a result of the 
increased prevalence of heart disease, high blood pressure, diabetes, and rheumatoid 
arthritis among the elderly. Similar results were found in a study among breast cancer 
patients, in which the impact of cancer and its treatment attenuated over time, while 
multimorbidity had greater impact on functional decline34. However, the prevalence 
of comorbidity was also higher among elderly colorectal cancer and non-Hodgkin’s 
lymphoma patients where this higher importance of comorbidity was not observed. 
Among non-Hodgkin’s lymphoma patients, the opposite was found, with comorbidity 
explaining less of the variance in HRQoL among the elderly compared to the total 
sample. Instead, cancer characteristics were more important among the elderly non-
Hodgkin’s lymphoma patients. This difference between the young and elderly non-
Hodgkin’s lymphoma patients could not be explained by differences in cancer stage, 
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primary treatment, and time since diagnosis or type of non-Hodgkin’s lymphoma 
(indolent or aggressive). Non-Hodgkin’s lymphoma patients often receive intensive 
medical treatment which can interfere with HRQoL long after their treatment35,36. But why 
elderly experience lower HRQoL as a result of cancer characteristics is unclear. Future 
studies should further assess the complex association between comorbidity and HRQoL 
among elderly cancer survivors.
This study contributes to the paucity of knowledge on the association between 
comorbidity and HRQoL in cancer survivors. It showed that comorbidity explained more 
of the variance in HRQoL compared with sociodemographic and cancer characteristics. 
Therefore, these results can contribute to further research addressing the challenging 
issue of the effect of comorbidity on HRQoL in cancer patients. In addition, clinicians 
should become more aware of the impact of comorbidity on HRQoL and provide 
necessary psychological support to assist self-management of comorbid diseases.
The self-reported nature of our comorbidity assessment could be advantageous, since 
self-report shows high agreement with physician diagnoses37, while comorbidity in 
administrative data is often underreported38. In addition, this is a large population-based 
study with a high response rate which enabled the identification of the comorbidities 
that were strongly associated with separate HRQoL subscales.
The inclusion of long-term survivors could have resulted in survivorship bias. This might 
especially be an issue among colorectal cancer and non-Hodgkin’s lymphoma patients, 
since these patients have generally a worse prognosis compared to the other cancer 
types. As such, the possible inclusion of a healthier sample could have underestimated 
the prevalence of comorbidity. Furthermore, patients who are unable to complete 
questionnaires, due to severe illness or cognitive impairments, were excluded, while these 
patients are more likely to have a high burden of comorbidities as well. This could have 
resulted in an underestimation of the found association. In addition, our inclusion of the 
cancer types in this analysis is somewhat arbitrary, which was based on the availability 
of QLQ-C30 scores for comparison. However, we expect similar results in different 
cancer types as our results are in line with other studies focusing on other cancers.
Furthermore, the cross-sectional study design makes the direction of the association 
between comorbidity and HRQoL debatable. We cannot ascertain whether the self-
reported comorbid conditions were present before the cancer diagnosis or developed 
thereafter. In addition, it is questionable whether the comorbidities measured in this 
study are independent predictors of HRQoL, since comorbid conditions can interact with 
treatments or could be caused by cancer treatment and synergistically lower HRQoL39. 
For example, anemia is common in cancer patients, and the risk of anemia increases 
when patients receive chemotherapy for a longer time28, while thyroid disease is common 
among thyroid cancer patients and among Hodgkin’s lymphoma survivors treated with 
external radiotherapy40. Furthermore, the prevalence of thyroid disease might have been 
overestimated among thyroid cancer patients as these patients might have reported 
having thyroid disease as a result of their cancer diagnosis. However, sensitivity analyses 
among thyroid cancer patients excluding thyroid disease as a comorbidity revealed 
similar findings (data not shown). In addition, some comorbid conditions might increase 
the risk of complications from cancer therapy, with, for example, diabetes increasing the 
risk of neuropathy in patients treated with paclitaxel41, and hypertension and obesity 
increasing the risk of heart failure in patients treated with trastuzumab42,43. Furthermore, 
lifestyle factors, such as eating patterns and physical activity, were out of the scope of 
this study but could have influenced the association between comorbidity and HRQoL. 
Therefore, future research should address the complex association between comorbidity 
and lifestyle factors and its association with HRQoL.
In conclusion, this study showed that comorbidity explains more variance in physical and 
emotional function, and pain and fatigue compared with sociodemographic and cancer 
characteristics in cancer survivors, regardless of cancer type. These results emphasize the 
importance of adjusting for the presence of comorbid diseases when assessing HRQoL 
in cancer survivors. Future research should focus on the prevention and treatment of 
comorbidity to improve HRQoL in cancer patients.
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This study examined the individual and combined effect of having colorectal cancer 
(CRC) and diabetes mellitus (DM) on Health-Related Quality of Life (HRQoL) and sexual 
functioning.
Methods
Data from questionnaires collected in 2010 among CRC patients and a sample of the 
general Dutch population were used. All persons older than 60 years were included in 
this study. DM prevalence among the CRC sample as well as the sample of the general 
population was self-reported. HRQoL was measured using the European Organization 
for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire version 3.0 
(QLQ-C30), and sexual functioning was assessed with four scales from the EORTC-QLQ-
CR38.
Results
In total 624 persons without CRC and DM, 78 persons with DM only, 1,731 with CRC 
only, and 328 with both CRC and DM were included. Having both CRC and DM did not 
result in lower HRQoL and sexual functioning than the sum of the individual effects of 
both diseases. CRC, irrespective of having DM, was associated with lower scores on most 
EORTC-QLQ-C30 subscales, except global health, pain, and appetite loss. CRC was also 
independently associated with more erection problems among males. DM, irrespective 
of having CRC, was associated with lower physical functioning and more symptoms of 
dyspnea.
Conclusions
Having both CRC and DM did not result in lower HRQoL and sexual functioning than 
the sum of the individual effects of both diseases. As CRC was found to be consistently 
associated with lower functioning and more symptoms, CRC and its treatment seem to 
contribute stronger to lower HRQoL and sexual functioning compared with DM.
Introduction
Due to aging of the population, the number of elderly suffering from multiple chronic 
diseases is increasing1. Both cancer and diabetes belong to the four main types of chronic 
diseases, which are among the leading causes of deaths world-wide with 7.6 million 
and 1.3 million deaths in 2008, respectively2. Colorectal cancer (CRC) is one of the most 
common cancers with over one million new cases worldwide each year3. As CRC and 
diabetes have several overlapping risk factors, including obesity, sedentary lifestyle, and 
Western diet4,5, they often co-occur. As a result, diabetes is one of the most prevalent 
chronic diseases among CRC patients with a prevalence of 14%6.
Previous studies showed a higher mortality among CRC patients with diabetes compared 
to those without and suggested that diabetes increases the risk of complications and 
recurrence among CRC patients7,8. Despite the recognition of the link between CRC and 
diabetes on prognostic outcomes in current literature, little is known on patient reported 
outcomes such as Health-Related Quality of Life (HRQoL) and sexual functioning for CRC 
patients with comorbid diabetes.
Previous studies among patients with only CRC report lower role, cognitive, and social 
functioning; more symptoms of dyspnea, constipation, and diarrhea; and more financial 
difficulties compared to a normative sample even 10 years after CRC diagnosis9. Moreover, 
CRC patients report lower sexual functioning compared to the general population10,11, 
possibly as a result of surgery12. Similarly, patients with only diabetes report lower HRQoL 
compared to the general population13. Furthermore, a link between diabetes and sexual 
dysfunction is widely recognized, with most research focusing on the high prevalence 
(up to 75%) of erectile problems among men14.
Although both CRC and diabetes individually affect HRQoL and sexual functioning, it 
remains unclear to what extent CRC and diabetes have independent negative effects 
on HRQoL and sexual functioning. Only five previously conducted studies investigated 
the combined effect of cancer and diabetes on HRQoL15-19. Of these studies, three were 
among prostate cancer patients16-18 and found a small negative effect of diabetes on 
general health and vitality17,18, and urinary function16. Two studies included patients 
with different cancer types15,19 and showed significantly lower HRQoL15 among persons 
with cancer and diabetes compared to persons without both diseases or with only 
cancer or diabetes. Furthermore, cancer patients with diabetes scored lower on physical 
functioning compared with cancer patients without diabetes19. No previous studies 
focused on sexual functioning among patients with both cancer and diabetes.
With the increasing number of cancer patients also suffering from diabetes and only a 
few studies on patient reported outcomes among individuals with both diseases, this 
study aims to assess the individual and combined effects of having CRC and diabetes on 
HRQoL and sexual functioning. As both CRC and diabetes independently affect HRQoL 
and sexual functioning and having diabetes results in more complications and cancer 
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recurrence among CRC patients7,8 we hypothesize that the combined effect of CRC and 
diabetes results in an even worse HRQoL and sexual functioning than the sum of the 
individual effects of CRC and diabetes. If the co-occurrence of CRC and diabetes results 
in a greater negative effect on HRQoL and sexual functioning, future interventions should 
aim at this patient group to address symptoms and functional problems most efficiently.
Methods
Study population
Data from a large population-based survey conducted in 2010 among CRC patients 
with Diabetes Mellitus (CRC+DM+) or without DM (CRC+DM−) diagnosed between 
2000 and 2009, were used. Details of the data collection are described elsewhere20. Data 
were collected within PROFILES (Patient Reported Outcomes Following Initial treatment 
and Long term Evaluation of Survivorship) registry21. PROFILES registry includes a large 
web-based component and is linked to clinical data from the Eindhoven Cancer Registry 
(ECR). The ECR is part of the Comprehensive Cancer Centre South (CCCS) and records 
all newly diagnosed cancer patients in the southern region of the Netherlands, covering 
an area with 2.3 million inhabitants and 10 hospitals22. Clinical characteristics including 
primary cancer treatment, stage, and time since diagnosis were retrieved from the ECR. 
Data from the PROFILES registry will be available for noncommercial scientific research, 
subject to study question, privacy and confidentiality restrictions, and registration (www.
profilesregistry.nl)21.
To compare the data on CRC patients with persons without CRC and DM (CRC−DM−) 
or with only DM (CRC−DM+), a subsample of the general Dutch population was used. 
Those who reported having cancer were excluded from the analysis. Data collection for 
this sample of the general population was conducted by CentERdata (www.centerdata.
nl) in 2010. CentERdata uses the CentERpanel for data collection which is an online 
household panel and includes over 2,000 households which are representative of the 
Dutch-speaking population in The Netherlands. The method of data collection has been 
described elsewhere23.
As the sample of the general population was significantly younger than the CRC patients 
(54±5 vs 70±10), only participants aged ≥60 years from the general population and CRC 
samples were included. Persons with DM were identified from responses to the Self-
Administered Comorbidity Questionnaire (SCQ)24. Persons were asked whether they had 
DM in the previous year or currently, and no data were available regarding DM type and 
duration or timing of DM, i.e., either before or after CRC diagnosis. Besides DM, the SCQ 
also assesses the prevalence of 13 other comorbid conditions. For this analysis, additional 
comorbidity was categorized as none, one prevalent, or ≥2 prevalent comorbidities, 
excluding DM. Data on demographic characteristics including age, gender, and education 
were also collected. Body mass index (BMI) was available for CRC patients only.
Health-related quality of life
HRQoL was assessed with the European Organization for Research and Treatment of 
Cancer (EORTC) Quality of Life Questionnaire version 3.0 (QLQ-C30)25. This self-report 
instrument has 30 items from which scores on global health status, five functional scales, 
three symptom scales, and six single items on symptoms and financial impact are derived. 
All items were scored on a scale from 1 (not at all) to 4 (very much), except for the 
global health items which were scored from 1 (very poor) to 7 (excellent). Scores were 
linearly transformed to a 1-100 scale. Higher scores on functioning and global health 
domains represent better functioning and HRQoL, while a higher score on symptom 
scales represents more symptoms.
Sexual functioning
Seven items on sexual functioning derived from the EORTC Quality of Life Group 
Item Bank23,26 were used. Items on sexual activity and interest and one item on sexual 
enjoyment were included. Furthermore, women were asked about sexual problems, 
including lubrication problems and pain during sexual intercourse. For men, assessed 
sexual problems included problems with getting or maintaining an erection and 
ejaculation problems. All scales were linearly transformed to a 1-100 scale with a higher 
score on sexual functioning and enjoyment representing better sexual functioning and a 
higher score on male and female sexual problems indicating more complaints. No score 
on male sexual problems could be calculated for the sample from the general population 
as data on ejaculation problems were not collected among this sample. Therefore, the 
individual items on male sexual problems, including erection and ejaculation problems, 
were addressed separately. The presence of erection or ejaculation problems was 
dichotomized (yes/no). Having problems was defined by response categories “quite a 
bit” or “very much,” while having no problems was defined as “not at all” and “a little,” 
as previously done10.
Statistical analysis
Differences in baseline characteristics between CRC−DM−, CRC−DM+, CRC+DM−, and 
CRC+DM+ persons were analyzed by means of analysis of variance (ANOVA), chi-square 
tests, and independent T-tests, where appropriate. Clinically relevant differences were 
assessed with the evidence-based guidelines for the interpretation of mean differences 
in EORTC-QLQ-C30 subscales27. The clinically relevant differences are defined as small 
(3-19 points), medium (7-29 points), and large (14-29 points), depending on the studied 
subscale27. For sexuality items, Norman’s threshold of half a standard deviation was 
regarded as a relevant change28.
Multivariable linear regression models with HRQoL subscales as dependent variables and 
CRC and DM as independent variables were constructed. To assess whether the combined 
effects of having CRC and DM on HRQoL and sexual functioning go beyond the sum 
of their separate effects, we tested for biological interaction. Biological interaction is 
studied as deviation from additivity29,30. We used linear regression models to test for 
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biological interaction, where the regression coefficient of the interaction term estimates 
the effect as deviation from additivity. To test for a biological interaction effect of both 
diseases, besides a separate dichotomous variable for CRC and DM, an interaction term 
(CRC×DM) was included in the regression model (model 1)30. To study which disease has a 
greater negative effect on HRQoL and/or sexual functioning, the individual effects of CRC 
and DM were studied in similar multivariable regression models without the inclusion 
of the interaction terms (model 2). Similarly, the main effect of DM on HRQoL and 
sexual functioning was assessed in CRC patients only (model 3). All multivariable linear 
regression models were adjusted for gender, age, education, and number of comorbid 
conditions excluding DM. Model 3 additionally adjusted for BMI, cancer stage, primary 
cancer treatment, and time since cancer diagnosis. The models with sexual functioning 
scales as dependent variables were stratified for gender, and only persons with a partner 
were included. For all multivariable linear regression models, unstandardized betas were 
reported. We used multivariable logistic regression models to study the individual effects 
of CRC and DM on erection problems and the effect of DM on ejaculation problems 
among CRC patients only. Odds ratios (ORs) and 99% confidence intervals (CIs) were 
reported. We did not test for a biological interaction effect on erection and ejaculation 
problems, as logistic models test interaction as deviation from multiplicativity and not 
additivity29. Due to the high number of statistical tests conducted, a P-value of <0.01 
was regarded as statistically significant. All statistical analyses were performed using 
SAS statistics (version 9.2 for Windows, SAS Institute, Inc., Cary, NC).
Results
Characteristics of the study population
In total, 944 of the 2,619 persons from the general population sample and 3,030 of the 
3,585 persons with CRC were aged ≥60 years. Of these, 819 (87%) persons from the 
general population and 2,215 (73%) CRC patients returned a complete questionnaire. 
We excluded those who did not report whether they had DM (n=157) and those from the 
general population sample who reported having been diagnosed with cancer (n=116). 
The final analysis included 624 CRC−DM−, 78 CRC −DM+, 1,731 CRC+DM−, and 328 
CRC+DM+ persons. Among the CRC patients aged >60 years, respondents differed from 
the nonrespondents and those with unverified addresses with regard to gender (55% of 
males vs 46 and 48%, respectively), mean age (72 vs 75 and 74 years, respectively), and 
cancer treatment (51% treated with surgery only vs 61 and 62%, respectively). Among the 
sample of the general population, no differences were observed between respondents 
and nonrespondents aged ≥60 years (results not shown).
A difference in gender was found with 68% of males among CRC−DM+ and 63% among 
CRC+DM+ patients as compared to 57% of males among CRC−DM− and 54% among 
CRC+DM− patients, P-value=0.003 (Table 1). CRC+ DM+ persons were oldest (73±6), 
followed by CRC+DM−(72±7), CRC−DM+(69±7), and CRC−DM−(68±7), P-value <0.0001. 
CRC−DM− and CRC−DM+ persons were highly educated compared with CRC+DM− and 
Table 1 Patient- and cancer characteristics of the study population
aDifferences in patient characteristics between CRC−DM−, CRC−DM+, CRC+DM−and CRC+DM+ were tested 
with ANOVA for continuous outcomes and Chi-square tests for categorical outcomes. Differences in cancer 
characteristics between CRC+DM− and CRC+DM+ were tested with independent T-tests for continuous outcomes 
and Chi-square tests for categorical outcomes
bEducation levels included low = no/primary school; medium = lower general secondary education/vocational 
training; or high =pre-university education/high vocational training/university.
General population sample Colorectal cancer sample
CRC−DM− CRC−DM+ CRC+ DM− CRC+DM+ P-valuea
 n=624 n=78  n=1,731 n=328
Patient characteristics
Gender (n(%))
Male 347 (57) 53 (68) 937 (54) 207 (63) 0.003
Female 260 (43) 25 (32) 794 (46) 121 (37)
Age (mean ± SD) 68±7 69±7 72±7 73±6 <0.0001
Education (n(%))b
Low 38 (6) 5 (6) 348 (20) 94 (29) <0.0001
Medium 355 (57) 46 (59) 1,039 (61) 184 (57)
High 229 (37) 27 (35) 327 (19) 47 (14)
Number of comorbidities (n(%))
0 179 (29) 12 (15) 462 (27) 42 (13) <0.0001
1 209 (33) 25 (32) 550 (32) 93 (28)
≥2 236 (38) 41 (53) 719 (42) 193 (59)
Partner (n(%))
No 136 (22) 18 (23) 399 (23) 97 (30) 0.04
Yes 488 (78) 60 (77) 1,317 (77) 228 (70)
BMI (mean ± SD) 26±4 29±4 <0.0001
Cancer characteristics
Stage (n(%))
1 517 (31) 100 (31) 0.83
2 640 (38) 128 (40)
3 466 (28) 81 (25)
4 66 (4) 12 (4)
Time since diagnosis (mean ± SD) 5±3 5±3 0.52
Treatment (n(%))
Surgery only 859 (50) 179 (55) 0.42
Surgery & radiotherapy 387 (22) 62 (19)
Surgery & chemotherapy 351 (20) 64 (20)
Surgery, radiotherapy & chemotherapy 116 (7) 19 (6)
Chemotherapy only 10 (1) 2 (1)
Radiotherapy only 1 (0) 1 (0)
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CRC+DM+ persons (P-value <0.0001). CRC−DM+ and CRC+DM+ persons had the most 
prevalent comorbidities with 53 and 59% having ≥2 comorbid diseases, respectively. 
CRC+DM+ persons had a higher BMI but did not differ in cancer characteristics compared 
with CRC+DM− persons.
Differences in HRQoL and sexual functioning
Unadjusted means showed that CRC+DM+ reported lowest scores on global health 
(73±21) followed by CRC−DM+ (76 ±14), CRC+DM− (78±19), and CRC−DM− (79±15), 
P-value <0.0001 (Table 2). Physical functioning and cognitive functioning were highest 
among CRC−DM− persons and were lower among CRC−DM+, CRC+DM−, and CRC+ DM+ 
persons. A similar pattern was found for fatigue, nausea/vomiting, dyspnea, diarrhea, and 
financial problems with the least problems among CRC−DM− persons and increasing 
symptom scores among CRC−DM+, CRC+DM−, and CRC+DM+ persons, respectively. In 
general, the observed differences were of small or medium clinical relevance27.
Table 2 Unadjusted means (± standard deviation) of HRQoL subscales among CRC−DM−, 
CRC−DM+, CRC+DM− and CRC+DM+ persons
CRC−DM− persons without colorectal cancer and diabetes, CRC−DM+ persons with only diabetes, CRC+DM− 
persons with only colorectal cancer, CRC+DM+ persons with colorectal cancer and diabetes
aSmall and bmedium clinical relevant difference compared to CRC-DM- persons according to Cocks et al.27 
General population sample Colorectal cancer Sample
 CRC−DM− CRC−DM+ CRC+DM− CRC+DM+ P-value
 n=624 n=78 n=1,731 n=328  
Health-Related Quality of Life
Global health 79±15 76±14 78±19 73±21a <0.0001
Physical functioning 87±16 84±17 80±20a 72±23b <0.0001
Emotional functioning 90±15 91±15 87±18 85±20 <0.0001
Role functioning 87±21 89±17 81±27a 77±29a <0.0001
Cognitive functioning 91±15 91±14 86±19a 83±22a <0.0001
Social functioning 94±15 94±13 87±22a 87±23a <0.0001
Pain 18±23 13±18 16±24 18±26 0.16
Fatigue 16±19 19±19 20±23 26±25a <0.0001
Nausea/vomiting 2±8 3±8 3±11 5±12a 0.0003
Dyspnea 9±19 10±18 15±25a 22±30b <0.0001
Insomnia 15±24 10±17a 21±29a 20±28a <0.0001
Appetite loss 2±11 7±17a 6±17 7±18a <0.0001
Constipation 5±14 3±10 9±20 9±20 <0.0001
Diarrhea 3±12 6±18a 10±22a 12±21b <0.0001






































Figure 1 Unadjusted means of sexual functioning scales among CRC−DM−, CRC−DM+, 
CRC+DM− and CRC+DM+ patients with a partner stratified for men (a) and women (b) 
CRC−DM− persons without colorectal cancer and diabetes, CRC−DM+ persons with only 
diabetes, CRC+DM− persons with only colorectal cancer, CRC+DM+ persons with colorectal 
cancer and diabetes
aClinical relevant difference compared to CRC−DM−persons according to Norman et al.28
bThe scale on male sexual problems could not be calculated among the sample of the general population (CRC−
DM− and CRC−DM+) because only erectile problems and not ejaculation problems were assessed.
cFemale sexual problems were not included as they were not assessed among the sample of the general population 
(CRC−DM− and CRC−DM+) and only 17 CRC+DM+ women responded to these questions
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Sexual functioning was highest among CRC−DM− and lower among CRC−DM+, 
CRC+DM−, and CRC+DM+ in both men and women (both P-values of <0.0001) (Figure 
1a, b). Sexual enjoyment among men was lowest among CRC+DM− (Figure 1a). Among 
women, sexual enjoyment was lowest among CRC patients either with or without DM 
(Figure 1b). CRC+DM+ men reported more male sexual problems compared with 
CRC+DM− men, 55±38 versus 45±37, respectively (P-value=0.006). As the number of 
CRC−DM− women with a partner who responded to the questions on sexual functioning 
(n=10), sexual enjoyment (n=5), and female sexual problems (n=1) was low, no 
multivariable analyses were conducted regarding sexual functioning among women.
Individual and combined effects of CRC and DM on HRQoL and sexual functioning
No biological interaction effect of CRC and DM on any of the HRQoL and sexual 
functioning scales was found in the linear regression models (Table 3, model 1). Since 
the interaction terms were not significant, they were excluded in the models estimating 
the main effects of CRC and DM (Table 3, model 2). CRC, irrespective of having DM, 
was associated with lower functioning and worse symptom scores on most EORTC-
QLQ-C30 subscales, except global health, pain, and appetite loss. Furthermore, CRC was 
independently associated with lower sexual functioning among men. DM, irrespective 
of having CRC, was associated with lower physical functioning and more symptoms of 
dyspnea. Finally, when including only CRC patients (Table 3, model 3), CRC+DM+ persons 
reported lower physical functioning and more male sexual problems than CRC+DM− 
persons.
Male sexual problems, including erection and ejaculation problems, were studied 
separately in more detail. Erection problems were reported among 15% of CRC−DM−, 
27% of CRC−DM+, 48% of CRC+DM−, and 59% of CRC+ DM+ men (P-value <0.0001). 
Adjusted multivariable logistic regression models showed that CRC, irrespective of 
having DM, resulted in more erection problems (OR=4.3; 95%CI:2.6-7.3) while having 
DM, irrespective of having cancer, did not result in more erection problems (OR=1.5; 
95%CI:0.9- 2.4). Data on ejaculation problems were collected only among men with CRC. 
No difference in ejaculation problems was found between CRC+DM−and CRC+DM+ 
men (39 and 48%, respectively, P-value=0.04). Again, after adjustments, no main effect 
of DM on ejaculation problems among CRC males was found (OR=1.6; 95%CI:0.9-2.7).
Table 3 Adjusted multivariable linear regression models to assess differences in HRQoL and 
sexual functioning among patients with or without CRC and/or DM. Unstandardized regression 
coefficients are shown in the table
CRC−DM− persons without colorectal cancer and diabetes, CRC−DM+ persons with only diabetes, CRC+DM− 
persons with only colorectal cancer, CRC+DM+ persons with colorectal cancer and diabetes, NA not applicable [the 
male sexual problems scale could not be calculated among the sample of the general population (CRC−DM−and 
CRC−DM+) because only erectile problems and not ejaculation problems were assessed]
*P-value <0.01, 
**P-value <0.0001
aAdjusted for sex, age, education and comorbidity
bAdjusted for sex, age, education, comorbidity, BMI, cancer stage, time since cancer diagnosis and primary cancer 
treatment
cAnalyses on sexual functioning scales are only conducted among men with a partner, all models on sexual 
functioning are adjusted for age, education and comorbidity and model 3 is additionally adjusted for BMI, cancer 
stage, time since cancer diagnosis and primary cancer treatment
Dependent variables Analysis with total sample Analysis with CRC sample only
Model 1a Model 2a Model 3b
DM CRC CRC*DM DM CRC DM
HRQoL
Global health -0.7 0.2 -1.6 -2.0 -0.0 -2.6
Physical functioning -1.3 -3.8 ** -3.9 -4.3 ** -4.2 ** -3.8 *
Emotional functioning 2.1 -2.6 * -2.9 -0.3 -3.0 * -1.7
Role functioning 4.6 -4.1 * -5.4 0.4 -4.7 ** -0.8
Cognitive functioning 1.2 -3.3 * -2.8 -1.0 -3.7 ** -1.7
Social functioning 1.5 -5.9 ** -0.5 1.1 -6.0 ** 1.0
Pain -7.3 * -2.7 6.5 -2.1 -1.9 -0.8
Fatigue 1.3 2.9 * 1.7 2.7 3.1 * 3.5
Nausea/vomiting 0.9 1.3 -0.1 0.8 1.3 * 1.2
Dyspnea -0.9 3.2 * 5.4 3.4 * 3.9 * 3.1
Insomnia -6.1 4.9 * 3.1 -3.6 5.3 ** -2.5
Appetite loss 3.8 2.1 * -3.1 1.4 1.8 2.3
Constipation -2.6 3.2 * 2.2 -0.9 3.5 ** 0.4
Diarrhea 2.6 7.2 ** -1.9 1.1 7.0 ** 1.0
Financial problems -0.6 2.2 * 1.4 0.5 2.4 * 0.6
Sexual functioning among menc
Sexual functioning -1.4 -8.0 ** 1.0 -0.7 -7.9 ** -0.8
Sexual enjoyment -0.7 -3.9 6.4 3.6 -3.0 5.6
Male sexual problems NA NA NA NA NA 9.4 *
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Discussion
This cross-sectional study showed that CRC, irrespective of having DM, is significantly 
associated with poorer functioning and more symptoms, except for global health, 
pain, and appetite loss. Moreover, CRC is independently associated with lower sexual 
functioning and more erection problems among males. Having DM, irrespective of having 
CRC, is associated with lower physical functioning and more symptoms of dyspnea, but 
not with sexual functioning. Importantly, having both CRC and DM did not result in more 
negative outcomes than the sum of their individual effects.
From this study, we can conclude that CRC and its treatment seem to contribute stronger 
to a lower HRQoL compared to DM. CRC was found to be consistently associated with 
lower functioning and more symptoms. This is in line with the previous literature, 
reporting better HRQoL for patients with DM compared with patients with other chronic 
conditions like cardiac problems, arthritis, and lung problems13. It is possible that patients 
perceive cancer as a more life-threatening disease than DM, which might explain the 
stronger association of cancer with HRQoL. Indeed, it was found that the diagnosis of 
type 2 DM itself does not have a negative impact on perceived health status31.
An important finding of this study is the impact of CRC on sexual problems, especially 
among men. CRC was independently associated with a 4.3 times higher likelihood to 
report erection problems, irrespective of DM status. A previous study among another CRC 
cohort reported more male sexual problems among rectal cancer patients, compared 
with colon cancer patients10. While these differences were also apparent in our study, we 
could not test the effect of tumor type on sexual functioning in multivariable analyses. 
This was due to the low number of colon cancer patients (n=79) and rectal cancer 
patients (n=49) with DM who filled out the questions on sexual functioning. However, 
when adjusting for cancer type, i.e., rectal or colon cancer, in our analyses, results were 
similar as presented here (results not shown).
It is known that a high BMI is associated with a higher risk of developing DM and impaired 
HRQoL32. This could have influenced some of our results as BMI was not included in all 
statistical models since BMI was not available for the sample of the general population. 
BMI significantly contributed to worse physical functioning, more fatigue, more dyspnea, 
less appetite loss, fewer problems with constipation, and better emotional functioning, 
when included as a covariate in the model among persons with CRC. The effect of BMI 
and other lifestyle factors on HRQoL of cancer patients with DM will be studied in more 
detail in future longitudinal analyses of this study cohort.
This study has several limitations. First, this was a secondary analysis of previously 
collected data which resulted in the inclusion of an unbalanced number of persons per 
studied group. As a result, sexual problems could not be assessed in stratified analysis 
for rectal and colon cancer patients. Furthermore, after including only persons aged ≥60 
years, baseline characteristics still differed across groups. While we addressed this issue 
by including a range of relevant variables for adjustment in the multivariable regression 
models, this might not be sufficient, resulting in possible residual confounding. Moreover, 
the self-reported measure of DM did not discriminate between types 1 and 2 DM. 
Furthermore, no information on the time of DM diagnosis, either before or after cancer 
diagnosis was available. People who already live longer with DM might have reached a 
better metabolic control of their blood sugar levels, and this could have resulted in an 
underestimation of the main effect of DM. Also, we had no detailed clinical information 
on duration of DM, blood glucose levels, and DM treatment and complications. It has 
previously been shown that DM complications are strongly associated with HRQoL13,33 
and thus, it is possible that this has influenced our results. In addition, as we included 
cancer patients 1 to 10 years after their cancer diagnosis, our patient selection might be 
influenced by a survivorship bias, and therefore, these results might not be generalizable 
to all colorectal cancer patients. Finally, we cannot prove causality due to the cross-
sectional study design.
In conclusion, having both CRC and DM did not result in a worse HRQoL and sexual 
functioning than the sum of the individual effects of CRC and DM. As CRC was found 
to be consistently associated with lower functioning and more symptoms, CRC and 
its treatment seem to contribute stronger to a lower HRQoL and sexual functioning 
compared with DM. However, as DM was also independently associated with some of 
the studied subscales, the clinical management of comorbid diseases among cancer 
patients remains an important aspect of clinical care. This study provides an insight 
to the effect of both cancer and DM on long-term problems with HRQoL and sexual 
functioning. These patient reported outcomes are becoming more important; however, 
more research is needed to prove their relevance in treatment evaluation.
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This study assessed differences in neuropathic symptoms between colorectal cancer 
(CRC) patients with and without diabetes. Moreover, we aimed to explore whether 
neuropathic symptoms could be explained by the receipt of chemotherapy as it was 
previously shown that cancer patients with diabetes less often receive chemotherapy.
Methods
Data from a cross-sectional study among CRC patients (2-11 years after diagnosis) was 
used. Data were collected by the Patient Reported Outcomes Following Initial treatment 
and Long term Evaluation of Survivorship (PROFILES) registry which is linked to clinical 
data from the population-based Eindhoven Cancer Registry. Diabetes status was self-
reported and neuropathic symptoms were measured with the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced 
Peripheral Neuropathy 20 (EORTC QLQ-CIPN20).
Results
Two hundred eighteen CRC patients with diabetes were matched on age and sex to 
975 CRC patients without diabetes. After adjustments for cancer treatment including 
chemotherapy and other covariates, logistic regression models showed that CRC patients 
with diabetes experienced more mild to severe neuropathic symptoms, including tingling 
fingers or hands (odds ratio (OR)=1.40; 95% confidence interval (CI):1.00-1.94), tingling 
toes or feet (OR=1.47; 95%CI:1.04-2.07), numbness in toes or feet (OR=1.83; 95%CI:1.28-
2.62) and erection problems among men (OR=1.83; 95%CI:1.11-3.03) as compared to 
CRC patients without diabetes. No differences in cancer treatment were found between 
CRC patients with and without diabetes.
Conclusion
CRC patients with diabetes experienced more neuropathic symptoms, regardless of cancer 
treatment, suggesting that diabetes itself rather than treatment with chemotherapy 
results in more neuropathic symptoms among cancer patients with diabetes compared 
to those without.
Introduction
Due to the aging of the population, the number of elderly suffering from multiple 
chronic diseases is increasing1. A recent review shows that at least half of the elderly 
aged 60 years or older are living with two or more chronic diseases2. Both cancer and 
diabetes belong to the four most common chronic diseases, which are among the 
leading causes of death worldwide with 7.6 million and 1.3 million deaths in 2008, 
respectively3. Colorectal cancer (CRC) is one of the most common cancers with over one 
million new cases worldwide each year4. CRC and diabetes often co-occur, mostly as a 
result of overlapping risk factors, including obesity, a sedentary lifestyle, and a western 
diet5,6. As a result, diabetes is prevalent among 14% of CRC patients7, compared to 8% 
in the general Dutch population8. CRC patients with diabetes have about a 30% higher 
mortality risk compared to CRC patients without diabetes9,10. Having diabetes seems to 
increase the risk of complications and cancer recurrence among CRC patients10. Moreover, 
cancer patients with diabetes are less aggressively treated for their cancer9,11 are more 
often hospitalized and are more likely to suffer from chemotherapy-related toxicity11.
Among cancer patients, neuropathic symptoms are often induced by chemotherapeutic 
agents including taxanes and platinum agents, such as oxaliplatin12. The incidence of 
chemotherapy-induced peripheral neuropathy is strongly dependent on the type of agent, 
duration of administration and dosage used12. Neuropathic symptoms can be reversed, 
but a significant number of patients continue experiencing neuropathic symptoms many 
years after treatment is completed13-16. A previous study showed that around 10% of 
CRC patients (2-11 years after diagnosis) still reported mainly sensory symptoms, with a 
higher prevalence among those who were treated with oxaliplatin16. Similarly, neuropathy 
is one of the most common complications of diabetes, with a prevalence around 30%17-19. 
Neuropathy is a result of cellular damage caused by oxidative stress and inflammation 
as a consequence of hyperglycemia and dyslipidaemia in diabetes20. The most common 
presentation is distal symmetrical polyneuropathy characterized by numbness, tingling, 
pain or weakness mainly occurring in the feet20. Diabetes patients with neuropathy 
report a lower quality of life21, have an increased risk of falling21, and have a higher risk 
of ulcerations which in turn may lead to amputation of the lower extremities22,23. 
Despite the high prevalence of neuropathy among cancer and diabetes patients, little 
is known about neuropathic symptoms among patients with both cancer and diabetes. 
Therefore, the aim of this study was to assess neuropathic symptoms among CRC 
patients with and without diabetes. As it was previously shown that cancer patients with 
diabetes less often receive adjuvant chemotherapy9, we evaluated potential differences 
in treatment between cancer patients with and without diabetes. It is expected that 
oncologists are more reluctant to treat diabetes patients, who already have an elevated 
risk of developing neuropathy, with chemotherapies that may induce neuropathy. 
We therefore hypothesize that CRC patients with diabetes are less often treated with 
chemotherapy including oxaliplatin. Subsequently, the expected selective treatment 
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of diabetes patients with chemotherapy may result in less or perhaps similar levels of 
neuropathic symptoms as compared with CRC patients without diabetes.
Materials and methods
Study population
Data from the second wave of a longitudinal population-based survey among CRC 
patients was used. The survey started in 2010 and the second data wave was conducted 
in 2011 and included a self-reported measure on neuropathic symptoms. Data was 
collected within the framework of the Patient Reported Outcomes Following Initial 
treatment and Long term Evaluation of Survivorship (PROFILES) registry24. The PROFILES 
registry is linked directly to clinical data from the Eindhoven Cancer Registry (ECR) which 
records all newly diagnosed cancer patients in the south of the Netherlands covering an 
area with 2.3 million inhabitants and 10 hospitals25. 
Data collection
All CRC patients diagnosed between January 2000 and June 2009 were sampled from 
the ECR and invited for the survey in 2011 (i.e., all patients were surveyed 2-11 years 
after cancer diagnosis). Patients who died prior to the study start, patients with serious 
cognitive impairment or those who were in transition to terminal care were excluded. 
All eligible patients received an invitation letter from their (ex-)attending specialist with 
login codes to the online survey and a postcard to request a paper version whichever 
they preferred. Only those who responded in the first wave in 2010 were invited for the 
second wave and reminders were sent after 2 months. Data from the PROFILES registry 
is available for non-commercial scientific research and subject to study question, privacy 
and confidentiality restrictions, and registration (www.profilesregistry.nl)24. More details 
of the data collection are described elsewhere26.
Socio-demographic and clinical characteristics
Age and sex along with other clinical characteristics including primary cancer treatment, 
stage, and time since diagnosis were retrieved from the ECR. Additional data on marital 
status, educational level, and height and weight (used to calculate body mass index (BMI)) 
were addressed in the survey. Having diabetes was self-reported and measured with the 
Self-administered Comorbidity Questionnaire (SCQ)27. All patients reported whether they 
had diabetes at the time of questionnaire completion in 2011 or in the past 12 months. 
In addition, the year of diabetes diagnosis was self-reported in the survey. Similarly, 
comorbidities other than diabetes were assessed with the SCQ27.
Peripheral neuropathy
Peripheral neuropathy was measured using the European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral 
Neuropathy 20 (EORTC QLQ-CIPN20)28 which consists of 20 items scored on a four point 
Likert scale ranging from (1) “Not at all” to (4) “Very much.” As diabetes is also associated 
with an increased risk of peripheral neuropathy it is difficult to disentangle chemotherapy 
induced neuropathy from diabetes related neuropathy. Therefore, throughout this paper 
we will use the general term “peripheral neuropathy.”
Differences in treatment between colorectal cancer patients with and without 
diabetes
Previous studies show that colon cancer patients with diabetes were more often operated 
and had a lower hazard (albeit not statistically significant) of receiving chemotherapy 
than those without diabetes9. Therefore we assessed differences in treatment between 
CRC patients with and without diabetes among an age- and sex- matched survey sample, 
as well as among the unmatched original sample from the ECR. We also investigated this 
latter sample from the ECR to assess whether our survey sample was biased as a result 
of survivorship, i.e., that only the healthiest patients responded to our questionnaire. 
Therefore, we selected all patients diagnosed between January 2000 and June 2009 who 
were alive prior to the study start of the survey at the 1st of November 2010. As the ECR 
collects data on comorbidity at cancer diagnosis from the medical records since 1993, 
diabetes status of the unmatched original sample with CRC patients was retrieved from 
the ECR.
Statistical analyses   
To account for large differences in age distribution, patients with diabetes from the 
survey sample were matched on age group and sex to those without diabetes. For 
patients with (n=218) and without (n=1307) diabetes, six strata were formed using age 
(i.e. <60, 60-70, or ≥70 years old) and sex (male and female). Within each stratum, a 
maximum number of persons from the patients without diabetes were randomly matched 
based on the strata frequency distribution of the patients with diabetes. Differences in 
sociodemographic and clinical characteristics were assessed with independent sample 
T-tests and chi-square tests where appropriate. Differences in neuropathic symptoms 
between CRC patients with and without diabetes were assessed per individual item 
of the EORTC QLQ-CIPN20. The burden of neuropathic symptoms was dichotomized 
into two categories: mild to severe symptom burden (response categories “a little,” 
“quite a bit,” and “very much”) and no symptom burden (response category “not at all”). 
Differences in the burden of neuropathic symptoms between CRC patients with and 
without diabetes were assessed with univariate chi-square tests and with multivariable 
logistic regression models adjusted for BMI, educational level, the number of comorbid 
conditions (excluding diabetes) and cancer treatment (including a dichotomous variable 
for surgery, radiotherapy and chemotherapy).
Differences in primary cancer treatment were assessed among the matched survey 
sample and the unmatched original sample from the ECR with independent T-tests 
and chi-square tests where appropriate. For both groups, differences in the receipt of 
chemotherapy and/or radiotherapy between CRC patients with and without diabetes 
were assessed with multivariable logistic regression models adjusted for sex, age at 
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cancer diagnosis, and stage. A P-value<0.05 was regarded as statistically significant and 
all analyses were conducted using SAS statistics (version 9.3, SAS Institute Inc., Cary, NC).
Results
Study population
Of the 1981 CRC patients who were eligible for participation in 2011, 1643 (83%) 
responded and filled out the questionnaire. Of the 1643 respondents, 118 (7%) did not 
fill out whether they had diabetes or not and were excluded. Two hundred eighteen (13%) 
patients reported having diabetes and were matched on age and sex to 975 patients 
without diabetes. CRC patients with diabetes (CRC+DM+) were lower educated (21 vs 
14% with a low education, P-value=0.03), had a higher BMI (38 vs 15% with a BMI ≥30 
kg/m2, P-value<0.0001), and reported more comorbid conditions (47 vs 37% with ≥2 
comorbid conditions, P-value=0.0005) as compared with CRC patients without diabetes 
(CRC+DM-) (Table 1). No differences were found between CRC+DM- and CRC+DM+ 
patients regarding marital status, cancer stage at diagnosis, cancer type, and initial 
treatment. In addition, no differences were found regarding time since diagnosis, both 
patients with and without diabetes were surveyed on average 6 years (SD=2.8 years) 
after diagnosis. One hundred eighty-three (84%) CRC+DM+ patients reported their 
diabetes diagnosis date and were diagnosed on average 9.5±9.6 years prior to the study 
start (Table 1).
Differences in the burden of neuropathic symptoms between CRC patients with 
and without diabetes
Up to 39% of CRC+DM+ patients reported having mild to severe neuropathic symptoms 
(Table 2). In addition CRC+DM+ patients more often reported mild to severe neuropathic 
symptoms, regarding tingling fingers or hands (34 vs 25%, P-value=0.008), tingling toes 
or feet (31 vs 22%, P-value=0.0004), numbness in toes or feet (29 vs 18%, P-value=0.0002), 
aching or burning pain in toes or feet (20 vs 14%, P-value=0.02), and more trouble 
standing or walking (23 vs 15%, P-value=0.005) as compared with CRC+DM- patients. 
Moreover men from the CRC+DM+ group reported more problems with getting or 
maintaining an erection (84 vs 74%, P-value=0.01). After adjustments for BMI, the number 
of comorbid conditions, educational level and cancer treatment (including surgery, 
radiotherapy and chemotherapy) in multivariable logistic regression models, patients 
with DM were more likely to report mild to severe symptoms including tingling fingers 
or hands (odds ratio (OR)=1.40; 95% confidence interval (CI):1.00-1.94, P-value=0.05), 
tingling toes or feet (OR=1.47; 95%CI:1.04-2.07, P-value=0.03), numbness in toes or 
feet (OR=1.83; 95%CI:1.28-2.62, P-value=0.001) and erection problems among men 
(OR=1.83; 95%CI:1.11-3.03, P-value=0.02).  
Table 1 Sociodemographic and clinical characteristics of the study population
aEducation levels included low=no/primary school; medium=lower general secondary education/vocational 
training; or high=pre-university education/high vocational training/university.
bOnly patients diagnosed after 2008 were included, as oxaliplatin was completely registered from 2008 onwards
 CRC+DM+ CRC+DM-  
n=218 n=975 P-value
Patient characteristics   
Sex (n(%))
Male 146 (67) 653 (67) 1
Female 72 (33) 322 (33)
Age (mean ± SD) 71.3±8.1 70.8±8.6 0.37
Education (n(%))a
Low 45 (21) 138 (14) 0.03
Medium 128 (59) 580 (60)
High 44 (20) 248 (26)
Marital status
Married/with partner 160 (74) 781 (81) 0.07
Divorced/Single 18 (8) 76 (8)
Widowed 37 (17) 112 (12)
BMI (n(%))
< 25 kg/m2 41 (19) 346 (36) <0.0001
25 - 30 kg/m2 93 (43) 482 (50)
≥ 30 kg/m2 83 (38) 143 (15)
Comorbid conditions (n(%))
0 35 (16) 277 (28) 0.0005
1 80 (37) 335 (34)
≥2 103 (47) 363 (37)
Diabetes duration at study start (mean number of years ± SD) 9.5±9.6
Diabetes duration at study start (n(%))
< 5 years 69 (32)
5-10 years 52 (24)
≥ 10 years 62 (28)
Missing 35 (16)
Cancer characteristics 
Age at cancer diagnosis (mean ± SD) 65.5±8.2 64.9±8.9 0.34
TNM stage (n(%))
I 66 (30) 297 (30) 0.49
II 84 (39) 347 (36)
III 61 (28) 272 (28)
IV 5 (2) 33 (3)
Unknown 2 (1) 26 (3)
Cancer type (n(%))
Colon cancer 129 (59) 587 (60) 0.78
Rectal cancer 89 (41) 388 (40)
Primary treatment (n(%))
Surgery only 107 (49) 468 (48) 0.61
Surgery and radiotherapy 43 (20) 231 (24)
Surgery and chemotherapy 50 (23) 192 (20)
Surgery, radio- and chemotherapy 17 (8) 80 (8)
Chemotherapy only 1 (0) 2 (0)
Oxaliplatin (n(%))b 21 (26) 75 (20) 0.19
Time since diagnosis (mean ± SD) 5.9±2.7 6±2.8 0.75
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As most differences between CRC+DM- and CRC+DM+ patients were found on the 
sensory items of the EORTC QLQ-CIPN20 (Table 2), we additionally assessed the burden 
of the sensory symptoms according to the original response categories (Figure 1). This 
revealed that ≤3 % of both CRC+DM- and CRC+DM+ patients reported being “very 
much” affected on any of the sensory items presented in Figure 1. The response category 
“a little” was chosen more often (i.e. ranged between 2 and 4% for trouble distinguishing 
temperature of hot and cold water to up to 27 and 33% for trouble hearing for CRC+DM- 
and CRC+DM+ patients, respectively).
Treatment differences between CRC+DM- and CRC+DM+
Among the matched survey sample, no difference was found in primary cancer treatment 
between CRC+DM- and CRC+DM+ patients (Table 1). Similarly in multivariable logistic 
regression models excluding stage I CRC patients and adjusted for sex, age at cancer 
diagnosis and cancer stage, no association was found between diabetes and the receipt 
of chemotherapy (OR=1.27; 95%CI:0.79-2.04, P-value=0.33), radiotherapy (OR=0.88; 
95%CI:0.59-1.34, P-value=0.56), nor for the receipt of oxaliplatin (OR=1.58; 95%CI:0.73-
3.39, P-value=0.25). Differences in treatment were also addressed in the original, 
unmatched sample from the ECR (Table 3). A total of 5733 CRC patients were included, 
of whom 613 (11%) had diabetes, 4642 (81%) did not have diabetes, and of 478 (8%) 
patients the diabetes status was unknown at cancer diagnosis. CRC+DM+ patients were 
more often treated with surgery only (61 vs 54%, P-value=0.008), and less often treated 
with oxaliplatin (16 vs 22%, P-value=0.03, Table 3) as compared to CRC+DM- patients. 
However, multivariable regression models excluding stage I CRC patients and adjusted 
for sex, age at cancer diagnosis and cancer stage did not show an association between 
diabetes and the receipt of chemotherapy (OR =1.08; 95%CI:0.81-1.44, P-value=0.59), 
radiotherapy (OR=0.79; 95%CI:0.61-1.03, P-value=0.09), nor oxaliplatin (OR=0.78; 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































- Table 3 Differences in patient and clinical characteristics among CRC patients with and without 
diabetes from the unmatched, original selection drawn from the ECR
aOnly patients diagnosed after 2008 were included, as oxaliplatin was completely registered from 2008 onwards
Discussion
This study shows that CRC patients with diabetes reported a higher frequency of 
neuropathic symptoms compared to age- and sex-matched CRC patients without 
diabetes. Differences in neuropathic symptoms appeared not to be related to differences 
in receipt of chemotherapy. CRC patients with diabetes reported more symptoms of 
tingling fingers or hands, tingling and numbness of toes or feet, and erection problems 
among men. This study also showed that the majority of the reported symptoms were 
of mild severity. Although we hypothesized that clinicians might be reluctant with the 
treatment of chemotherapy among those with diabetes, we did not observe differences 
in cancer treatment between cancer patients with and without diabetes.
Using data pooled from three randomized controlled trials, a study of 1585 CRC patients, 
of whom 135 had diabetes, assessed whether the presence of diabetes influenced the 
incidence, severity and course of neuropathy with oxaliplatin therapy29. That study did 
not observe an influence of diabetes on the development of neuropathy in CRC patients 
receiving oxaliplatin therapy; however, neuropathy was assessed before and during 
 CRC+DM+ (ECR) CRC+DM- (ECR) P-value 
 N=613 N=4642
Sex (N(%))
Male 316 (52) 2443 (53) 0.62
Female 297 (48) 2199 (47)
Age at cancer diagnosis (mean±SD) 69.6±8.6 65.3±11.0 <0.0001
Stage (N(%))
I 165 (27) 1363 (29) 0.11
II 265 (43) 1805 (39)
III 145 (24) 1186 (26)
IV 13 (2) 142 (3)
Unknown 25 (4) 146 (3)
Treatment (N(%))
Su only 372 (61) 2492 (54) 0.008
Su + RT 103 (17) 944 (20)
Su + CT 100 (16) 824 (18)
Su + RT + CT 32 (5) 351 (8)
Other 6 (1) 31 (1)
Oxaliplatin (N(%))a
No 176 (84) 918 (78) 0.03
Yes 33 (16) 263 (22)  
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treatment, while long-term effects were not addressed29. In contrast, most previous 
studies did not assess the impact of diabetes on neuropathic symptoms among 
cancer patients as primary objective but mainly adjusted for diabetes in multivariable 
analyses. For example, one study assessed the association between neuropathy and 
breast cancer recurrence in a clinical trial among 4544 breast cancer patients, showing 
that hyperglycemia was associated with a higher likelihood of peripheral neuropathy 
(OR=1.42; 95%CI:1.13-1.78)30. In contrast, other studies that included diabetes as a 
predictor for the development of neuropathic symptoms did not find an association31-33. A 
study among 169 resected CRC patients, including 29 CRC patients with diabetes, showed 
no association between having diabetes and the presence of neuropathic symptoms in 
unadjusted analyses33. Moreover, a study among 340 multiple myeloma patients receiving 
bortezomib, of which 39 patients also had diabetes, again showed that diabetes was not 
a predictor for the development of peripheral neuropathy32. Moreover, a study among 45 
patients with different cancer types up to 6 years after the receipt of cisplatin or oxaliplatin 
did not identify diabetes as a determinant for persistent neuropathy31.  Another, relatively 
small study (n=62), showed that colon cancer patients with diabetes (n=15) did not have 
a higher prevalence of peripheral neuropathy (unadjusted OR=2.8, P-value=0.10) but 
they did develop neuropathy at a lower dose of oxaliplatin treatment (338 vs 610 mg/
m3) as compared with colon cancer patients without diabetes34. However, comparison of 
our results with the results from these previous studies is difficult as the earlier studies 
assessed the effect of diabetes on neuropathy mainly as a covariate rather than as a 
primary study objective. As the prevalence of diabetes in these studies was often low, 
most were underpowered to detect a true diabetes effect. Moreover, previous studies 
evaluated different therapeutic agents, and the study populations of these previous 
studies are very heterogeneous. Furthermore, most studies used clinical diagnoses to 
grade the severity of neuropathic symptoms32-34 and therefore mainly focused on more 
severe (e.g. ≥grade 2 from the Common Terminology Criteria for Adverse Events (CTAE)) 
neuropathic symptoms. As most symptoms are subjective in nature, we believe that it 
is important to not only neurologically test neuropathy symptoms but also assess self-
reported neuropathy. Importantly, we observed a high prevalence of symptoms, but 
apparently with a somewhat lower intensity. Using clinical diagnosis and cutoff values 
to define neuropathy as was done in previous studies might underestimate less severe, 
but highly prevalent symptoms. There should be more awareness for the less severe 
symptoms as patients who report multiple symptoms with a low severity can experience 
a significant impact on their daily life.
We observed a higher burden of neuropathic symptoms among CRC patients with 
diabetes as compared to those without diabetes, regardless of cancer treatment 
(including chemotherapy). This suggests that diabetes itself and not the treatment with 
chemotherapy might be responsible for the found effects. It could be that diabetes 
severity and duration might have influenced our results. In this study, 106 (58%) of 
the 183 CRC+DM+ patients who reported the date of their diabetes diagnosis were 
diagnosed with diabetes prior to their cancer diagnosis (mean 8.9±9.5 years prior to 
cancer diagnosis), indicating that these patients already might have had significant 
neuropathic symptoms at CRC diagnosis. If the diabetes itself and not the treatment 
with chemotherapy results in more neuropathic symptoms among cancer patients with 
diabetes, clinicians do not need to be reluctant with the treatment with chemotherapy 
among cancer patients with diabetes. However, more longitudinal studies addressing 
neuropathic symptoms at cancer diagnosis (i.e. before the start on chemotherapy) should 
be conducted to confirm our results.
No differences in cancer treatment were observed between CRC patients with and 
without diabetes. In contrast, a previous analysis by our group showed that cancer 
patients with diabetes were less likely to receive adjuvant chemotherapy, albeit this did 
not reach statistical significance9. A more recent, longitudinal analyses in our region 
revealed that differences in treatment between CRC patients with and without diabetes 
decreased over time35. Multivariable regression models showed only a difference among 
stage III colon cancer patients with those with diabetes being less likely to be treated 
with chemotherapy compared to those without diabetes (OR=0.7; 95%CI:0.5-0.9)35. As 
we included stage II, III and IV colon as well as rectal cancer patients in our current 
evaluation and numbers were too low to further stratify, this might explain why we did 
not observe differences in cancer treatments.
This study contributes to the limited data available regarding neuropathic symptoms 
among cancer patients with and without diabetes. Strengths of this study include its 
self-reported measure of neuropathic symptoms, which might be more sensitive to mild 
symptoms, the large population-based sample, and the high response rate. However, 
this study has several limitations; first, diabetes prevalence was self-reported at time 
of the questionnaire. As a result, some patients may have had unrecognized type 2 
diabetes and no distinction could be made between type 1 and type 2 diabetes; we 
did not have information regarding blood glucose levels, and other complications. In 
addition, information regarding the burden of neuropathic symptoms prior to cancer 
treatment was not available. Furthermore, we do not have any detailed information 
regarding the chemotherapeutic agents used, except for oxaliplatin which was only 
available for a subset of our sample as it was registered by the ECR from 2008 onwards. 
However, it has previously been shown that severity of neuropathic symptoms depends 
on type of chemotherapeutic agent, dose and the number of cycles administered12. As 
the occurrence of neuropathic symptoms often result in a decrease of the chemotherapy 
dosage, it is possible that those with acute neuropathic symptoms did not develop 
chronic neuropathic symptoms later on due to dose adjustments. Future research 
should study the impact of diabetes on peripheral neuropathy among cancer patients 
prospectively and assess neuropathic symptoms according to the type and dosage of 
different treatments used.
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In conclusion, this study shows that CRC patients with diabetes more frequently report a 
mild to severe neuropathic symptom burden compared to CRC patients without diabetes, 
mainly regarding tingling fingers or hands, tingling and numbness of toes or feet and 
erection problems among men. The higher neuropathic symptom burden appeared not 
to be associated with differences in chemotherapy treatment, suggesting that diabetes 
itself rather than chemotherapy results in more symptoms among cancer patients with 
diabetes compared to those without.
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To assess the longitudinal association between lifestyle factors, BMI and Health-Related 
Quality of Life (HRQoL) among colorectal cancer patients with (CRCDM+) and without 
diabetes (CRCDM-).
Methods 
Data from a longitudinal study among CRC patients diagnosed between 2000 and 
2009 were used. Clinical characteristics were retrieved from the Netherlands Cancer 
Registry and questionnaires were sent in 2010, 2011 and 2012 using the Patient 
Reported Outcomes Following Initial Treatment and Long term Evaluation of Survivorship 
(PROFILES) registry. Lifestyle (including moderate-to-vigorous physical activity (MVPA), 
smoking and alcohol use), Body Mass Index (BMI), diabetes status and HRQoL were 
assessed in the questionnaire.
Results 
1,739 (49%) patients responded to ≥2 questionnaires, of whom 126 CRCDM+ and 
789 CRCDM- patients were included. CRCDM+ patients had a higher BMI (26.4±3.7 
vs. 29.1±4.2 kg/m2), whereas the number of alcohol users was lower (50 vs 70%, 
p-value<0.0001) among CRCDM+ as compared to CRCDM- patients. Analyses adjusted 
for sociodemographic and cancer characteristics showed that CRCDM+ patients 
reported statistically significantly lower physical function (beta=-5.76; SE=1.67), global 
QoL (beta=-4.31; SE=1.48) and more symptoms of fatigue (beta=5.38; SE=1.95) than 
CRCDM- patients. However, these effects disappeared after adjustments for lifestyle 
factors and BMI which were all significant predictors of HRQoL. Additional adjustment 
for comorbidity further attenuated the main effect of DM on HRQoL.
Conclusions 
Diabetes was not independently associated with HRQoL but deteriorated HRQoL among 
CRCDM+ patients seem to be explained by an unhealthier lifestyle and other comorbid 
conditions. Moreover, residual confounding cannot be ruled out.
Introduction
Nowadays, the number of patients with several chronic diseases or comorbidity is 
increasing due to the increased life expectancy and aging of the population1. Both 
cancer and diabetes are common chronic diseases and were among the leading causes 
of death worldwide in 2008, with 7.6 and 1.3 million deaths due to cancer and diabetes, 
respectively2. Among cancer patients, diabetes is one of the most frequently observed 
comorbidities with a prevalence of 14% among colorectal cancer (CRC) patients3. Previous 
literature shows that patients with diabetes have an increased risk to develop CRC4, and 
that patients with both CRC and diabetes have about a 30% higher mortality risk5. Beside 
these poorer prognostic outcomes, studies also indicate that patients with both cancer 
and diabetes have a poorer Health-related Quality of Life (HRQoL)6-10.
Previous studies mainly reported a lower general HRQoL6,9, physical function or mobility7,10 
and vitality9 among cancer patients with diabetes, compared to cancer patients without 
diabetes. However, the majority of these studies focused on prostate cancer patients8,9,11,12 
and had a cross-sectional study design6,7,9-11. More importantly, only 3 studies adjusted 
their analyses for lifestyle factors6,8,10, of which 2 only included Body Mass Index (BMI) 
and no other lifestyle factors such as physical activity, smoking or alcohol use8,10.
Lifestyle factors have been shown to be important predictors of HRQoL among both 
CRC and diabetes patients. Several studies show that an increasing number of healthy 
lifestyle factors is associated with better HRQoL scores among CRC patients13-15 as well 
as among diabetes patients16. Regarding the independent effect of lifestyle factors two 
longitudinal studies among CRC patients showed that physically active (i.e. at least 
150 min/week) patients reported a higher general HRQoL as compared to patients 
who were insufficiently active or inactive17,18. Another cross-sectional study from the 
UK reported that CRC patients who are physically active, and have a moderate alcohol 
intake reported better functioning and lower levels of fatigue compared to those who 
did not consume alcohol13. No significant association between smoking and HRQoL 
was found13. In contrast, analyses of the Women’s Health Study showed that persistent 
smoking among women with breast, colorectal and endometrial cancer were more likely 
to report poor physical function, poor mental health, and lower role emotional function 
as compared to non-smoking patients19. Among diabetes patients, similar associations 
between lifestyle and HRQoL were found. Two cross-sectional studies showed that 
physical activity was positively associated, whereas BMI was negatively associated with 
both physical and mental health20,21. Smoking was less often studied, but a large study 
(n=16,428) from the US showed that patients who were not smoking were less likely to 
report a poor or fair health (OR=0.71; 95%CI: 0.56-0.89)16.
As CRC patients with diabetes (CRCDM+) are expected to have a poorer lifestyle than CRC 
patients without diabetes (CRCDM-), these poorer lifestyle behaviors might explain the 
poorer HRQoL found among CRCDM+ versus CRCDM- patients6-10. Moreover, prospective 
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studies on differences in HRQoL between CRCDM+ and CRCDM- patients are missing. 
Therefore, this study aims to assess differences between CRCDM+ and CRCDM- patients 
in (1) lifestyle, (2) HRQoL measured prospectively and (3) to assess whether lifestyle 
factors explain the differences in HRQoL between CRCDM+ and CRCDM- patients. As 
the main focus of this study was to assess the effect of individual lifestyle factors on 
HRQoL longitudinally, we confined the analyses to the independent lifestyle effects and 
did not include a composite lifestyle score. We hypothesize that CRCDM+ patients have 
a poorer lifestyle and lower HRQoL as compared to CRCDM- patients.
Methods
Setting and study population
Data from a large population-based study among CRC patients were used. All CRC 
patients diagnosed between January 2000 and June 2009 were sampled from the 
southern area of the Netherlands Cancer Registry (NCR). The NCR contains clinical data 
on all newly diagnosed cancer patients in the Netherlands. The southern area comprises 
2.4 million inhabitants, 10 hospitals and 2 radiotherapy institutes. After the initial patient 
selection, the Patient Reported Outcomes Following Initial Treatment and Long term 
Evaluation of Survivorship (PROFILES) registry was used for the longitudinal patient 
reported data collection22. Patients with cognitive impairments, unverifiable addresses 
and patients who died prior to the study start were excluded from the initial selection. 
The remaining CRC patients were invited to participate in 2010 (T1), 2011 (T2) and 
2012 (T3). Ethical approval for the study was obtained from a local certified Medical 
Ethics Committee of the Maxima Medical Centre Veldhoven. A complete overview of the 
selection process can be found elsewhere17. The primary objective of this longitudinal 
study was to identify the HRQoL and health-care use of long-term CRC survivors, and 
relate the outcomes to patient and cancer characteristics. For this secondary analysis we 
only included CRC patients who were less than 5 years after cancer diagnosis when they 
completed their first questionnaire. This cut-off was chosen as previous research shows 
that patients change their lifestyle shortly after cancer diagnosis23 Thus we expect to see 
most changes in lifestyle as well as in HRQoL within 5 years after diagnosis. Moreover, 
CRC patients with unknown diabetes status (n=5) or those who developed diabetes after 
completion of the first questionnaire (n=16) were excluded from this analyses. Data from 
this longitudinal study are (partly) available online for noncommercial scientific research, 
subject to study question, privacy and confidentiality restrictions, and registration from 
PROFILES (www.profilesregistry.nl).
Data collection
CRC patients were invited for participation via the PROFILES registry and a letter from 
their (ex-) attending specialist to inform them of the study. The letter included a secured 
link with login and password to the online questionnaire, or patients could request a 
paper version of the questionnaire via a reply card, whichever they preferred. After two 
months, a reminder with a paper questionnaire was sent. Patients were reassured that 
nonparticipation had no consequences for their follow-up care or treatment. 
Diabetes status, sociodemographic and clinical characteristics
Diabetes status was self-reported using the Self-administered Comorbidity Questionnaire24. 
Patients filled out whether they had diabetes in the past year or currently. Patients who 
reported having diabetes at the first questionnaire were classified as having diabetes. 
No distinction was made between type 1 and 2 diabetes. Month and year of diabetes 
diagnosis were reported only at T2. Similarly the SCQ was used to assess comorbidities 
other than diabetes, including  heart disease, high blood pressure, stroke, lung disease, 
anemia, kidney disease, stomach disease, liver disease, thyroid disease, depression, 
arthrosis, rheumatoid arthritis, and back pain. Age, gender and clinical information 
including cancer diagnosis date, primary cancer treatment and cancer stage were 
derived from the NCR. Moreover, patients reported their educational level which was 
categorized as low (no/primary school), medium (lower general secondary education/
vocational training) or high (pre-university education/high vocational training/university) 
educational level.
Lifestyle measures
Lifestyle measures were self-reported in the questionnaires and include smoking, alcohol 
use, height and weight and physical activity. Both smoking and alcohol were assessed 
as (1) never, (2) former and (3) current use. Number of cigarettes smoked per day and 
glasses of alcohol drunk per week were also reported. However, as the number of 
smokers and current alcohol users among CRCDM+ patients was low (i.e. n=13 and n=70 
of the 126 included CRCDM+ patients, respectively), no measure of moderate and heavy 
drinking or smoking was included. Self-reported body height and weight were used to 
calculate BMI. Physical activity was measured using questions derived from the validated 
European Prospective Investigation into Cancer (EPIC) physical activity questionnaire25. 
Patients filled out how much time they spent on walking, cycling, gardening, household 
activities and sports, six different sport types could be specified, during winter and 
summer. The mean scores for all activities during winter and summer were averaged. 
To assess the intensity, metabolic equivalent intensity (MET) scores based on previous 
classifications were assigned to each activity26,27. Hours per week spent on moderate 
to vigorous physical activity (MVPA) were calculated by summing all activities with a 
MET-score ≥3, and include walking (MET=3.5), cycling (MET=4), gardening (MET=5) and 
various sports with a MET-score ≥3. Household activities (MET=3.5) were not considered 
as MVPA in accordance with previous research28. To correct for outliers, all activity scores 
greater than the 95th percentile were replaced by the 95th percentile.
Health-Related Quality of Life
The validated European Organisation for Research and Treatment of Cancer – Quality of 
Life Questionnaire (EORTC-QLQ)-C30 was used to assess HRQoL29,30. As previous research 
shows that cancer patients with diabetes mainly score lower on physical function7,10,11, 
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general HRQoL6,9 and vitality9 as compared to those without diabetes, and to prevent 
type 1 errors as a result of multiple testing, only the global QoL, physical function, and 
fatigue scales were included in these analyses. All items were answered on a 4-point 
Likert scale ranging from ‘not at all’ to ‘very much’, while the questions regarding global 
QoL were scored on a 7-point scale. Item scores were linearly transformed to a 1 to 100 
scale. Higher scores on global QoL and physical function represent better functioning, 
while a higher score on fatigue symptoms correspond to more fatigue.
Statistical analyses
Differences in characteristics between respondents and non-respondents at T1, between 
patients who completed 1 versus those who completed ≥2 questionnaires, and CRCDM+ 
and CRCDM- patients of the final study sample were analyzed. Continuous variables were 
checked for normality. If variables were normally distributed the independent samples 
t-tests was used. Otherwise the non-parametric Wilcoxon-Mann-Whitney test was used 
to assess differences between the groups. The Chi-square test was used for categorical 
variables.
First, differences in BMI and MVPA between CRCDM+ and CRCDM- patients at each 
time point were assessed with independent samples t-tests. Smoking and alcohol status 
over time was recoded into 1 categorical variable with 4 categories: persistent smokers/
alcohol users, persistent former smokers/alcohol users, persistent non-smokers/alcohol 
users and patients with fluctuating smoking/alcohol status. Patients were assigned to 
the persistent categories when they reported the same category on all questionnaires, 
otherwise they were included in the fluctuating status category. Differences in smoking 
and alcohol category between CRCDM+ and CRCDM- patients were assessed with Chi-
square tests.
In order to gain insight into the differences in HRQoL between CRCDM+ and CRCDM- 
patients with different lifestyle behaviors, we reported unadjusted means of physical 
function, global QoL and fatigue stratified by diabetes status for each lifestyle factor 
measured at T1. To adjust for the dependence of observations within subjects, generalized 
linear mixed models, using an unstructured covariance structure were constructed. First 
differences in lifestyle factors between CRCDM+ and CRCDM- patients over time were 
assessed in a model that included the main effects of DM, time and the interaction 
between DM and time. When the interaction term was significant the results for CRCDM+ 
and CRCDM- patients were stratified, otherwise the interaction term was removed from 
the model in order to interpret the main effects of DM and time. Second, similar general 
linear mixed models were used to assess the main effects of DM and time on global QoL, 
physical function and fatigue. Both models that addressed differences in lifestyle and 
HRQoL were adjusted for sociodemographic (age, sex, educational level) and clinical 
characteristics (time since cancer diagnosis, cancer stage and treatment). Finally, the 
models predicting HRQoL were additionally adjusted for lifestyle factors to assess 
whether differences in HRQoL between CRCDM+ and CRCDM- could be explained by 
lifestyle. To examine the independent between and within-subject effects of BMI and 
MVPA on HRQoL, 2 terms were included in the model; a between term, represented by 
a person’s average BMI or MVPA over the two or three time points, as well as a within 
term, represented by the difference between a person’s BMI or MVPA at one time point 
and that persons average BMI or MVPA over the two or three time points. The categorical 
variables (i.e. persistent and fluctuating use) for both smoking and alcohol use were 
included in the generalized linear mixed models. The continuous variables (i.e. age and 
time since cancer diagnosis) were grand-mean centered in order to correctly interpret 
all model parameters. Moreover, as we expect that cancer patients with diabetes have 
more comorbid conditions other than diabetes and as comorbidity has previously been 
shown to impact on HRQoL among cancer patients31, we conducted a sensitivity analyses 
to see whether comorbidity other than diabetes explain the differences in HRQoL (i.e. 
beyond lifestyle factors) between CRCDM+ and CRCDM- patients. As information on the 
duration of diabetes at the study start was available for a subsample, we also assessed 
whether there were differences between CRCDM+ with a diabetes duration <6.5 years 
and ≥6.5 years versus CRCDM- patients in a sub-analysis. This cut-off was based on the 
median diabetes duration. A p-value <0.05 was regarded as statistically significant and 
all analyses were conducted using SAS statistics version 9.3 (SAS Institute, Inc., Cary, NC).
Results
Patient selection process
Of the 3,585 eligible CRC patients, 2,625 (73%) responded to the first questionnaire and 
1,739 (49%) responded to ≥2 questionnaires. After excluding patients who were ≥5 years 
after cancer diagnosis, patients with an unknown diabetes status (n=5, 1%) and those 
who developed diabetes during the study period (n=16, 2%), 126 CRCDM+ and 789 
CRCDM- patients were included (Figure 1). Full details of the studies selection process 
can be found online at http://www.profilesregistry.nl/dataarchive/study_units/view/22 
under ‘Data & Documentation’.  More details of the study process, the comparison 
of responders with non-responders and the comparison of those who completed 1 
versus ≥2 questionnaires are reported elsewhere17. In general, respondents at T1 were 
significantly younger, more often male, and more often diagnosed with stage I disease 
than non-respondents. CRC patients who completed ≥2 versus only 1 questionnaire 
were younger (68.4±9.4 vs. 71.3±9.4 years), less often female (43 vs. 49%), and less often 
diagnosed with stage IV disease (3 vs. 7%). Moreover, CRC patients who completed ≥2 
versus 1 questionnaire were more likely to consume alcohol (73 vs. 61%), were more 
physically active (12±9 vs. 9±9 hours/week spent on MVPA), and reported a higher global 
QoL (79±18 vs. 73±21), higher physical function (82±19 vs. 75±23) and lower fatigue 
levels (20±22 vs. 26±26).
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Response on T≥2: N=1,739 
(49%) 
<5 years after CRC dx: 
N=936 (54%) 
N=16 (2%) developed diabetes 
during the study 
N=5 (1%) diabetes status 
unknown 
915 CRC patients included: 
- N=789 (84%) without diabetes 
- N=126 (13%) with diabetes 
Figure 1 Flowchart of the study process
Differences in characteristics and lifestyle factors over time between CRCDM+ 
and CRCDM-
CRCDM+ patients were lower educated (24 versus 14% with a low education) and had 
more comorbid conditions other than diabetes (50% versus 35% with ≥2 comorbid 
conditions other than diabetes, Table 1). Diabetes duration was available for 95 (75%) 
CRCDM+ patients and CRCDM+ patients were diagnosed with diabetes on average 
8.3±7.2 years prior to the study start. No differences between CRCDM+ and CRCDM- 
patients were found on sex, age, cancer stage, time since cancer diagnosis and cancer 
treatment.
CRCDM+ patients had a significantly higher BMI at T1 (29.1±4.2 vs. 26.4±3.7 kg/m2), T2 
(28.6±4.3 vs. 26.5±4.4 kg/m2) and T3 (29.1±4.1 vs. 26.4±3.9 kg/m2, all P-values<0.0001, 
Figure 2a). In adjusted generalized linear mixed models, no interaction of DM*time was 
found, indicating that BMI did not differ between both groups over time. After removing 
the interaction term, a main effect for diabetes (Beta=2.44; SE=0.35, p-value<0.0001) 
but not for time (p-value=0.06) on BMI was observed. No difference between CRCDM+ 
and CRCDM- in MVPA at T1 (p-value=0.07), T2 (p-value=0.27) or T3 (p-value=0.59) 
was observed (Figure 2b). Again, no interaction between DM and time was observed, 
n(%) or mean ± SD CRCDM+ CRCDM-
 n=126 n=789 P-value
Male 80 (63) 453 (57) 0.2
Age (years) 70±8 68±10 0.06b
Educational levela
Low 30 (24) 113 (14) 0.02
Medium 73 (58) 488 (62)
High 23 (18) 184 (23)
Comorbidity other than diabetes
0 20 (16) 241 (32) 0.0006
1 42 (34) 251 (33)
≥2 61 (50) 263 (35)
Cancer stage
I 38 (30) 218 (28) 0.40
II 41 (33) 264 (33)
III 41 (33) 236 (30)
IV 5 (4) 38 (5)
Unknown 1 (1) 33 (4)
Time since diagnosis (years) 3±1 3±1 0.16b
Surgery 124 (98) 785 (99) N/A
Chemotherapy 46 (37) 258 (33) 0.40
Radiotherapy 36 (29) 262 (33) 0.3
Diabetes duration (years) 8.3±7.2
Diabetes duration – categorical
<6.5 years 47 (37) 
≥6.5 years 48 (38)
Unknown 31 (24)
Table 1 Sociodemographic and clinical characteristics (T1) of the study population
aEducation levels included the following categories: low=no/primary school; medium=lower general secondary 
education/vocational training; or high=pre-university education/high vocational training/university
bStatistical difference tested with the non-parametric Wilcoxon-Mann-Whitney test
N/A: No valid p-value could be obtained as the number of patients who did not receive surgery was too low (i.e. 
2 CRCDM+ and 4 CRCDM- patients) to conduct a valid Chi-square test
indicating that MVPA did not differ between both groups over time. No main effect of DM 
was observed while MVPA did significantly change over time (p-value=0.01). Although, 
there were slightly more CRCDM+ patients who persistently reported to be ex-smokers 
(63 vs 53%), no overall difference in smoking status between CRCDM+ and CRCDM- was 
observed (p-value=0.09). However, among CRCDM+ there were fewer patients who 
persistently reported to use alcohol (50 vs. 70%, p-value<0.0001). Both smoking and 
alcohol status were quite stable over time with 8% (n=77) and 13% (n=126) reporting 
fluctuating smoking and alcohol status during the study period, respectively.
6
Chapter 6 Lifestyle and HRQoL among colorectal cancer patients with and without diabetes 105104
6
Differences in HRQoL and the impact of lifestyle on HRQoL among CRCDM+ and 
CRCDM- patients
Physical function was lowest among CRCDM+ patients with BMI ≥30 kg/m2 (mean at 
T1: 68±23) and highest among CRC patients with BMI between 25-30 kg/m2 (at T1: both 
CRCDM- and CRCDM+: 84 ±18, Figure 3). CRCDM- patients with ≥14 hours/week MVPA 
reported highest physical function (at T1: 89±14), whereas inactive CRC patients report 
the lowest physical function (at T1, CRCDM-: 59±24 and CRCDM+ patients: 58±26). 
CRCDM- and CRCDM+ patients who never smoked reported highest physical function 
(at T1 84±16 and 76±19, respectively), while smokers reported lowest physical function 
with 78±19 and 62±32, respectively. Alcohol users reported higher physical function as 
compared to former or never users. For global QoL and fatigue similar patterns were 
observed.  In general, smokers, obese patients (BMI≥30kg/m2) and inactive patients 
reported lowest QoL and most fatigue, while alcohol drinkers reported highest global 













































































Figure 2 Differences in BMI (a.), MVPA (b.), smoking (c.) and alcohol (d.) use between CRCDM- 
(■) and CRCDM+(■)
**Significant difference between CRCDM+ and CRCDM- using independent samples T-test with P-value<0.0001
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In adjusted generalized linear mixed models, no interaction effect between DM and time 
was found on any of the HRQoL scales, meaning that HRQoL did not differ between 
CRCDM+ and CRCDM- patients over time. After removing the interaction term, CRCDM+ 
patients reported significantly lower physical function (beta=-5.76; SE=1.67), global QoL 
(beta=-4.31; SE=1.48), and more fatigue (beta=5.38; SE=1.95) than CRCDM- patients. 
However, after additional adjustments for BMI, MVPA, smoking and alcohol use the 
main effect of diabetes disappeared for all three subscales (Table 2, model 2). With 
each point increase in BMI, physical function decreased (beta=-0.71; SE 0.15), and 
symptoms of fatigue increased (beta=0.47; SE=0.18). No within-subject effect of BMI 
was found, i.e. individual changes in BMI during the study period were not associated 
with changes in HRQoL. With each hour increase in MVPA per week, physical function 
(beta=0.64; SE=0.07), and global QoL increased (beta=0.35; SE=0.07) whereas symptoms 
of fatigue decreased (beta=-0.50; SE=0.09). A within-subject effect was found for both 
physical function and fatigue indicating that when a person increased their MVPA with 
1 hour per week above their average MVPA during the study period, their physical 
function increased with 0.09 points (SE=0.04) and their fatigue score decreased with 
0.15 (SE=0.06). Persistent smoking as compared to never smoking was associated with 
lower physical function and global QoL and more fatigue. In contrast, persistent drinking 
during the study period was associated with higher physical function and global QoL 
and less fatigue.
After additionally adjusting the full model 2 for comorbidity (i.e. 1 or ≥2  versus 0 
comorbidity), the main effect of diabetes was attenuated even further for physical 
function (beta DM+ vs DM-=-0.85, SE=1.56), global quality of life (beta DM+ vs DM-
=-1.43, SE=1.48) and fatigue (beta DM+ vs DM-=1.11, SE=0.56). All lifestyle factors 
remained independently associated with HRQoL and estimates were similar to those 
presented in model 2, Table 2.
We also included diabetes duration and used a categorical variable including CRCDM-, 
CRCDM+ with <6.5 years diabetes duration, CRCDM+ with ≥6.5 years diabetes duration 
and CRCDM+ with unknown diabetes duration in the model. We found that in model 
1 CRCDM+ with short diabetes duration (i.e. <6.5 years) was associated with worse 
global QoL (beta=-5.02, SE=2.32) while longer term diabetes duration (i.e. ≥6.5 years) 
was associated with lower physical function (beta=-6.56, SE=2.56, data not shown). 
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Discussion
This study shows that CRCDM+ and CRCDM- differed regarding lifestyle behaviors; 
CRCDM+ had a higher BMI, and were less likely to consume alcohol. No differences in 
MVPA and smoking status between CRCDM+ and CRCDM- patients were observed. In 
addition, prospectively measured physical function and global QoL were lower, while 
fatigue was higher among CRCDM+ patients as compared to CRCDM- patients. However, 
these differences in HRQoL outcomes disappeared after adjusting for lifestyle factors; 
BMI, MVPA, smoking and alcohol were all significant predictors of HRQoL. Further 
adjustment for comorbidity further attenuated the main effect of diabetes. This suggests 
that diabetes is not independently associated with HRQoL but that the found lower 
HRQoL scores among CRCDM+ patients seems to be explained by an unhealthier lifestyle 
and other comorbid conditions.
A few studies assessed HRQoL among cancer patients with and without diabetes and 
adjusted for lifestyle factors; 2 studies adjusted for BMI only8,10 and 1 study adjusted 
for BMI, physical activity and smoking6. In line with our results, all 3 studies reported 
higher BMI among cancer patients with versus without DM. Moreover, a large Canadian 
cross-sectional study (n=113,587) also reported lower physical activity (14 vs. 20% being 
active), and no clear differences in the frequency of smoking (18 vs. 16%) between both 
groups6. In contrast to our results, after adjustment for BMI (and smoking), all 3 studies 
reported a lower HRQoL among cancer patients with versus without diabetes6,8,10. The 
large Canadian cross-sectional study found a lower Health Utility Index-3 score among 
cancer patients versus without DM with beta=-0.04 (95%CI:-0.05;-0.03)6. A longitudinal 
study among prostate cancer patients (n=1,248) reported a lower urinary function among 
prostate cancer patients with versus without diabetes, while no differences were found 
on other urinary and sexual function subscales8. In our previous cross-sectional study, 
we observed a lower physical function (beta=-3.8) and more male sexual problems 
(beta=9.4) among CRCDM+ versus CRCDM- patients10. The different cancer types studied, 
and the different measurements used in previous studies hamper comparison of the 
results. This study shows that besides BMI and smoking, MVPA and alcohol use were also 
independently associated with HRQoL and should be taken into account when comparing 
HRQoL between cancer patients with and without diabetes. Only adjusting for BMI might 
not be sufficient. Alcohol consumption was associated with better HRQoL which is in 
line with previous research13. We assume that the alcohol users in our study consumed 
moderate amounts which may be associated with fewer comorbid conditions such as 
cardiovascular disease. Vice versa patients with severe chronic disease might consume 
less alcohol. The results of the present study emphasize that health professionals still 
need to encourage and support cancer patients in improving their lifestyle behaviours. 
Besides, providing adequate information on behaviour change, health professionals also 
have to consider attitudes and motivations32.
In this study no information on clinical data regarding diabetes diagnosis was available. 
However, we did have information regarding self-reported diabetes duration for 75% of 
the CRCDM+ patients. One might expect that patients with a longer diabetes duration 
develop more complications which in turn lead to lower HRQoL. We showed that 
CRCDM+ with a diabetes duration <6.5 years had lower global QoL while CRCDM+ 
patients with a diabetes duration ≥6.5 years had a lower physical function as compared to 
CRCDM- patients. These differences were attenuated after adjustments for comorbidity 
and lifestyle, similar as in the main analyses. The absence of a consistent pattern might 
be due to the stratification which resulted in a low number of patients per group.
As cardiovascular diseases and kidney diseases are common among patients with 
diabetes33 and comorbidity is significantly associated with HRQoL31 we additionally 
adjusted model 2 for comorbidity in a sensitivity analysis. We initially did not adjust 
for comorbidity as adjustment for both lifestyle factors and comorbidity might lead 
to an overadjusted model. From literature we know that impaired glucose tolerance, 
insulin resistance, obesity, dyslipidemia, and hypertension co-occur more often than 
might expected by chance34. This group of risk factors is also known as the Metabolic 
syndrome34. Thus the metabolic syndrome might be part of the causal pathway for the 
development of diabetes. As we had no information on the date of diagnosis of the 
other comorbid conditions, we cannot ascertain whether these conditions developed 
after, and possibly as a result of, diabetes.
Obesity, physical inactivity, smoking and alcohol use are all risk factors for both CRC and 
diabetes35. Although these lifestyle factors might have influenced the development of 
both diabetes and cancer among patients in this study, our results show that changes 
in lifestyle habits can improve HRQoL after the diagnosis of both diseases: patients who 
increased their physical activity during the study period reported higher physical function 
and less symptoms of fatigue. Among cancer survivors, several lifestyle interventions 
focused on improving dietary habits, smoking cessation or increasing physical activity 
show promising results23. Moreover, in recent years  interventions have also focused 
on increasing physical and emotional condition prior to cancer treatment36. These 
prehabilitation studies showed promising results regarding morbidity, mortality, length 
of hospital stay and HRQoL36. However, sustainable long-term effects of these lifestyle 
and prehabilitation interventions are rarely studied. Thus, future studies should focus 
on the development of prehabilitation and lifestyle interventions that are effective on 
the long-term.
This study has several limitations. First, no information regarding lifestyle and HRQoL 
prior to cancer diagnosis were available. As data were collected 1 to 5 years after cancer 
diagnosis, patients might have adopted their lifestyle directly after diagnosis and prior to 
the data collection which could have influenced our results. In addition, no information 
regarding diet was available. Moreover, lifestyle factors were self-reported and may 
have been influenced by recall bias and social desirability. Previous research shows high 
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correlations between self-reported and objectively assessed BMI, however, elderly (>60 
years) often overreport their height and as a result BMI is underreported37. In addition, the 
patients included in these analyses are likely to be healthier as those with poorer health 
are less likely to participate in the study and to complete the follow-up questionnaires. 
As a result, absolute scores on HRQoL should be interpreted cautiously. However we 
do not expect the found association to be different as patients who did not respond or 
completed the follow-up are likely to report both poorer lifestyle behaviors and poorer 
HRQoL. Moreover, no data regarding diabetes type (i.e. type 1 or type 2), severity and 
complications were available, although we did conduct a sub-analysis including diabetes 
duration and additionally adjusted for comorbidity. Finally, diabetes was self-reported 
which could have resulted in misclassification. Despite these limitations, this population-
based study with relatively high response, is the first to prospectively address differences 
in HRQoL between CRCDM+ and CRCDM- patients and the impact of lifestyle.
In conclusion, this study showed that CRCDM+ patients reported lower prospectively 
measured HRQoL as compared to CRCDM- patients; however these differences 
disappeared after adjustments for lifestyle and other comorbidities. These results suggest 
that lifestyle factors and comorbidity might explain the difference in HRQoL between 
CRCM+ and CRCDM- patients, although residual confounding cannot be excluded. 
As BMI, MVPA, smoking and alcohol use were all associated with HRQoL, this study 
underlines the importance of improving lifestyle behaviors among CRC patients, either 
with or without diabetes.
References
1. Parekh AK, Goodman RA, Gordon C, 
Koh HK. Managing multiple chronic 
conditions: A strategic framework 
for improving health outcomes and 
quality of life. Public Health Reports. 
2011;126(4):460-471.
2. World Health Organization. Global status 
report on noncommunicable diseases 
2010. World Health Organization: Geneva 
2011.
3. Janssen-Heijnen MLG, Houterman S, 
Lemmens VEPP, Louwman MWJ, Maas 
HAAM, Coebergh JWW. Prognostic impact 
of increasing age and co-morbidity in 
cancer patients: A population-based 
approach. Critical Reviews in Oncology/
Hematology. 2005;55(3):231-240.
4. Larsson SC, Orsini N, Wolk A. Diabetes 
mellitus and risk of colorectal cancer: A 
meta-analysis. Journal of the National 
Cancer Institute. 2005;97(22):1679-1687.
5. Stein KB, Snyder CF, Barone BB, et al. 
Colorectal cancer outcomes, recurrence, 
and complications in persons with and 
without diabetes mellitus: A systematic 
review and meta-analysis. Digestive 
Diseases and Sciences. 2010;55(7):1839-
1851.
6. Bowker SL, Pohar SL, Johnson JA. A 
cross-sectional study of health-related 
quality of life deficits in individuals with 
comorbid diabetes and cancer. Health and 
quality of life outcomes. 2006;4:17.
7. Hershey DS, Given B, Given C, Von Eye A, 
You M. Diabetes and cancer: Impact on 
health-related quality of life. Oncology 
Nursing Forum. 2012;39(5):449-457.
8. Latini DM, Chan JM, Cowan JE, et al. 
Health-related quality of life for men 
with prostate cancer and diabetes: A 
longitudinal analysis from CaPSURE. 
Urology. 2006;68(6):1242-1247.
9. Mols F, Aquarius AE, Essink-Bot ML, 
Aaronson NK, Kil PJ, van de Poll-
Franse LV. Does diabetes mellitus as a 
comorbid condition affect the health-
related quality of life in prostate cancer 
survivors? Results of a population-based 
observational study. BJU International. 
2008;102(11):1594-1600.
10. Vissers PA, Thong MS, Pouwer F, den 
Oudsten BL, Nieuwenhuijzen GA, van 
de Poll-Franse LV. The individual and 
combined effect of colorectal cancer and 
diabetes on health-related quality of life 
and sexual functioning: Results from the 
PROFILES registry. Supportive Care in 
Cancer. 2014;22(11):3071-3079.
11. Onitilo AA, Donald M, Stankowski RV, 
Engel JM, Williams G, Doi SA. Breast and 
prostate cancer survivors in a diabetic 
cohort: Results from the living with 
diabetes study. Clinical Medicine & 
Research. 2013;11(4):210-218.
12. Thong MS, van de Poll-Franse LV, Hoffman 
RM, et al. Diabetes mellitus and health-
related quality of life in prostate cancer: 
5-year results from the Prostate Cancer 
Outcomes Study. BJU International. 
2011;107(8):1223-1231.
13. Grimmett C, Bridgewater J, Steptoe A, 
Wardle J. Lifestyle and quality of life in 
colorectal cancer survivors. Quality of Life 
Research. 2011;20(8):1237-1245.
14. Schlesinger S, Walter J, Hampe J, et al. 
Lifestyle factors and health-related quality 
of life in colorectal cancer survivors. 
Cancer Causes and Control. 2014;25(1):99-
110.
15. Blanchard CM, Courneya KS, Stein K, 
American Cancer Society’s SCS, II. Cancer 
survivors’ adherence to lifestyle behavior 
recommendations and associations with 
health-related quality of life: Results 
from the American Cancer Society’s 
SCS-II. Journal of Clinical Oncology. 
2008;26(13):2198-2204.
16. Li C, Ford ES, Mokdad AH, Jiles R, Giles 
WH. Clustering of multiple healthy 
lifestyle habits and health-related quality 
of life among U.S. adults with diabetes. 
Diabetes Care. 2007;30(7):1770-1776.
17. Husson O, Mols F, Ezendam NP, Schep 
G, van de Poll-Franse LV. Health-related 
quality of life is associated with physical 
activity levels among colorectal cancer 
survivors: A longitudinal, 3-year study of 
the PROFILES registry. Journal of Cancer 
Survivorship. 2015;9(3):472-480.
18. Lynch BM, Cerin E, Owen N, Hawkes AL, 
Aitken JF. Prospective relationships of 
physical activity with quality of life among 




19. Jang S, Prizment A, Haddad T, Robien 
K, Lazovich D. Smoking and quality of 
life among female survivors of breast, 
colorectal and endometrial cancers in 
a prospective cohort study. Journal of 
Cancer Survivorship. 2011;5(2):115-122.
20. Eckert K. Impact of physical activity and 
bodyweight on health-related quality 
of life in people with type 2 diabetes. 
Diabetes, Metabolic Syndrome and 
Obesity. 2012;5:303-311.
21. Green AJ, Fox KM, Grandy S. Impact of 
regular exercise and attempted weight 
loss on quality of life among adults with 
and without type 2 diabetes mellitus. 
Journal of Obesity. 2011;2011.
22. van de Poll-Franse LV, Horevoorts N, van 
Eenbergen M, et al. The Patient Reported 
Outcomes Following Initial treatment 
and Long term Evaluation of Survivorship 
registry: Scope, rationale and design of 
an infrastructure for the study of physical 
and psychosocial outcomes in cancer 
survivorship cohorts. European Journal of 
Cancer. 2011;47(14):2188-2194.
23. Demark-Wahnefried W, Aziz NM, 
Rowland JH, Pinto BM. Riding the crest 
of the teachable moment: Promoting 
long-term health after the diagnosis 
of cancer. Journal of Clinical Oncology. 
2005;23(24):5814-5830.
24. Sangha O, Stucki G, Liang MH, Fossel 
AH, Katz JN. The Self-administered 
Comorbidity Questionnaire: A new 
method to assess comorbidity for clinical 
and health services research. Arthritis 
Care and Research. 2003;49(2):156-163.
25. Pols MA, Peeters PH, Ocké MC, Slimani 
N, Bueno-de-Mesquita HB, Collette HJ. 
Estimation of reproducibility and relative 
validity of the questions included in the 
EPIC Physical Activity Questionnaire. 
International Journal of Epidemiology. 
1997;26(suppl 1):S181-S189.
26. Ainsworth BE, Haskell WL, Leon AS, et 
al. Compendium of physical activities: 
Classification of energy costs of human 
physical activities. Medicine and Science 
in Sports and Exercise. 1993;25(1):71-80.
27. Ainsworth BE, Haskell WL, Whitt MC, et 
al. Compendium of physical activities: 
An update of activity codes and MET 
intensities. Medicine and Science in Sports 
and Exercise. 2000;32(9):S498-S516.
28. Buffart LM, Thong MSY, Schep G, 
Chinapaw MJM, Brug J, van de Poll-Franse 
LV. Self-reported physical activity: Its 
correlates and relationship with health-
related quality of life in a large cohort 
of colorectal cancer survivors. PloS One. 
2012;7(5):e36164.
29. Aaronson NK, Ahmedzai S, Bergman 
B, et al. The European Organization 
for Research and Treatment of Cancer 
QLQ-C30: A quality-of-life instrument 
for use in international clinical trials in 
oncology. Journal of the National Cancer 
Institute. 1993;85(5):365-376.
30. Fayers PM, Aaronson NK, Bjordal K, 
Sullivan M. EORTC QLQ-C30 scoring 
manual. Brussels, Belgium. 1995;11:1-49.
31. Vissers PA, Thong MS, Pouwer F, Zanders 
MM, Coebergh JW, van de Poll-Franse LV. 
The impact of comorbidity on health-
related quality of life among cancer 
survivors: Analyses of data from the 
PROFILES registry. Journal of Cancer 
Survivorship. 2013;7(4):602-613.
32. Niu C, Eng L, Qiu X, et al. Lifestyle 
behaviors in elderly cancer survivors: 
A comparison with middle-age cancer 
survivors. Journal of Oncology Practice. 
2015;11(4):e450-459.
33. Deshpande AD, Harris-Hayes M, 
Schootman M. Epidemiology of diabetes 
and diabetes-related complications. 
Physical Therapy. 2008;88(11):1254-1264.
34. Eckel RH, Grundy SM, Zimmet PZ. 
The metabolic syndrome. Lancet. 
2005;365(9468):1415-1428.
35. Giovannucci E, Harlan DM, Archer MC, 
et al. Diabetes and cancer: A consensus 
report. Diabetes Care. 2010;33(7):1674-
1685.
36. Silver JK, Baima J. Cancer prehabilitation: 
An opportunity to decrease treatment-
related morbidity, increase cancer 
treatment options, and improve physical 
and psychological health outcomes. 
American Journal of Physical Medicine 
and Rehabilitation. 2013;92(8):715-727.
37. Kuczmarski MF, Kuczmarski RJ, Najjar M. 
Effects of age on validity of self-reported 
height, weight, and body mass index: 
Findings from the third national health 
and nutrition examination survey, 1988–
1994. Journal of the American Dietetic 
Association. 2001;101(1):28-34.
P A R T  I I
T H E  I M P A C T  O F  C A N C E R  A N D  D I A B E T E S 
O N  M O R T A L I T Y
C H A P T E R  7
P a u l i n e  A . J .  V i s s e r s 
M e l i s s a  S . Y .  T h o n g 
F r a n s  P o u w e r 
H a n s  F . M .  P r u i j t 
D a r e c z k a  K .  W a s o w i c z 
L o n n e k e  V .  v a n  d e  P o l l - F r a n s e
S u b m i t t e d
T H E  E F F E C T  O F  L I F E S T Y L E  C L U S T E R S  O N 
M O R T A L I T Y  A M O N G  C O L O R E C T A L  C A N C E R 
P A T I E N T S  W I T H  A N D  W I T H O U T  D I A B E T E S : 
R E S U L T S  F R O M  T H E  P R O F I L E S  R E G I S T R Y
7




This study assessed whether smoking, alcohol consumption, moderate-to-vigorous 
physical activity (MVPA) and body mass index (BMI), can explain the increased mortality 
rates among colorectal cancer patients with diabetes (CRC+DM+). We also examined 
the effect of lifestyle clusters to identify patients who need to be targeted for future 
intervention and prevention measures. 
Methods
Data regarding diabetes and lifestyle were retrieved from two population-based studies 
conducted in 2009 and 2010 among CRC patients. Clinical data were retrieved from the 
Netherlands Cancer Registry, and overall mortality from the municipal personal records 
database (with follow-up till December 2014).
Results
3,423 CRC patients were included of whom 497 (15%) reported to have diabetes. Four 
lifestyle clusters were identified; a ‘healthy’, ‘moderately healthy’, ‘overweight’ and 
‘smoking’ cluster. CRC+DM+ patients had a higher mortality (HR=1.29; 95%CI:1.04-
1.62) than patients without diabetes (CRC+DM-). The independent effect of diabetes was 
attenuated after adjustments for individual lifestyle factors, although the HR remained 
elevated (HR=1.24; 95%CI:0.98-1.56). In a separate model that included the lifestyle 
clusters, diabetes remained associated with a statistically significant increased mortality 
(HR=1.29; 95%CI:1.02-1.61). Patients in the ‘smoking’ cluster (70% current smokers with 
a low BMI and low MVPA) had the most markedly increased mortality risk as compared 
to patients with a relatively healthy lifestyle (HR=3.66; 95%CI:2.49-5.38).
Conclusions
After adjustment for lifestyle clusters, diabetes remained independently associated with 
increased mortality among CRC patients, suggesting that the excess mortality among 
CRC+DM+ versus CRC+DM- patients cannot be fully explained by lifestyle factors. 
Introduction
Colorectal cancer (CRC) and diabetes are increasingly co-occurring. Diabetes is prevalent 
among 14% of Dutch CRC patients1. The link between cancer and diabetes has been 
extensively studied and diabetes has been associated with a 30% increased CRC risk2. 
In a meta-analysis, CRC patients with diabetes (CRC+DM+) had a 32% higher overall 
mortality risk as compared to patients without diabetes (CRC+DM-)3. A more recent 
meta-analysis found a slightly lower effect (HR=1.17; 95%CI:1.09-1.25)4. The mechanisms 
explaining why having both CRC and diabetes is associated with higher mortality are still 
unclear. Although lifestyle factors may play a role, only 12 of the 21 studies included in 
the recent meta-analysis considered lifestyle factors4. Of these studies, only 3 reported a 
higher mortality among CRC+DM+ versus CRC+DM- patients5-7. Moreover, studies mainly 
adjusted for Body Mass Index (BMI) and/or smoking, often neglecting other potentially 
relevant lifestyle factors such as physical activity and alcohol consumption.
Lifestyle factors are important risk factors for both cancer and diabetes, and are 
independently associated with mortality. Among both CRC and diabetes patients, a 
U-shaped association with BMI was reported; being underweight or obese was associated 
with higher mortality while being normal or overweight was associated with lower 
mortality8-10. Moreover, meta-analyses reported that high versus low physical activity 
levels were associated with 41% and 42% lower overall mortality among both diabetes11 
and CRC12 patients, respectively. Current or former smoking as compared with never 
smoking13,14 and excessive alcohol consumption were associated with higher mortality 
while light to moderate alcohol consumption was associated with lower mortality in 
both cancer and diabetes patients15,16.
Several studies that assessed the association between lifestyle factors and mortality 
included a sum score for lifestyle17-19. However, a sum score is a rather crude measure, 
while specific unhealthy lifestyle factors often co-occur. In a large Swiss study, smokers 
were less physically active and had higher alcohol consumption than former and non-
smokers20. A German study identified five different health behavior clusters, and 75% 
of patients in the smoking cluster also reported inadequate physical activity and/or an 
unhealthy diet21. Identifying clusters of patients with a specific lifestyle pattern and poor 
outcomes might help to target patients who benefit most from future prevention and 
intervention measures.
To date, only a few studies that adjusted for lifestyle factors found an increased mortality 
risk for CRC+DM+ versus CRC+DM- patients. The aim of the current study is to assess 
whether lifestyle factors, including smoking, alcohol consumption, physical activity and 
BMI, explain the increased mortality rates among CRC+DM+ patients. Independent 
effects of lifestyle factors as well as effects of different lifestyle clusters will be identified 
and associated with mortality.
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Data from two population-based CRC studies conducted in 2009 and 2010 in South 
Netherlands were used. Data collection was completed within the Patient Reported 
Outcomes Following Initial treatment and Long term Evaluation of Survivorship 
(PROFILES) registry22. In short, PROFILES is an infrastructure for the collection of patient-
reported outcomes and is linked directly to clinical data from the Netherlands Cancer 
Registry (NCR). The 2009 cohort includes a random selection of CRC patients aged ≤85 
years and diagnosed in 1998-2007. The 2010 cohort includes all CRC patients diagnosed 
in 2000-200923. Participants in 2009 were excluded from participation in 2010. All eligible 
patients were informed by a letter from their (ex-)attending specialist which explained 
that by completing the questionnaire they agreed with the linkage to their clinical data 
from the NCR. Reminders were sent within two months. Informed consent for all patients 
were obtained. Ethical approval for the study was obtained from a local certified Medical 
Ethics Committee of the Maxima Medical Centre Veldhoven.
Exposure assessment
We assessed current diabetes status with the Self-reported Comorbidity Questionnaire24. 
Lifestyle factors included self-reported smoking, alcohol use, BMI, and physical activity. 
Smoking and alcohol use were assessed in 3 categories (i.e. (1) never (2) former and 
(3) current use). BMI was calculated with self-reported height and weight. Physical 
activity was assessed with questions derived from the validated European Prospective 
Investigation into Cancer (EPIC) Physical Activity Questionnaire25. Patients reported 
the average time spent, during winter and summer, on walking, cycling, gardening, 
household activities, and sports. Hours per week spent on moderate-to-vigorous physical 
activity (MVPA) were derived from estimated metabolic equivalent intensity (MET) values 
assigned to each activity based on previously described classifications26,27. MPVA was 
calculated by summing all activities with a MET-score ≥3, and include walking (MET=3.5), 
cycling (MET=4), gardening (MET=5), and various sports with a MET-score ≥3. Household 
activities (MET=3.5) were not considered as MVPA28. Outliers on all activity scores, greater 
than the 95th percentile, were replaced by the 95th percentile. Patients with complete data 
on diabetes status and lifestyle factors were included in the analyses.
Outcome and follow-up
Overall mortality was obtained from the NCR linkage with the municipal personal records 
database. Follow-up time was measured from cancer diagnosis until death, loss to follow-
up, or until the end of the study period at 31 December 2014, whichever occurred first. 
Patients with <1 year follow-up were excluded, as they might be in a palliative phase, 
and might therefore be less physically active and/or have lost weight prior to their death.
Covariates
Clinical data regarding cancer diagnosis were retrieved from the NCR and include date 
of cancer diagnosis, cancer stage, and primary cancer treatment. Sociodemographic 
data including age and sex were also retrieved from the NCR.
Statistical analyses
Differences in baseline characteristics and lifestyle factors between CRC+DM+ and 
CRC+DM- patients were assessed using independent samples T-Tests and Chi-Square 
tests, where appropriate. LatentGOLD 5.029 was used to determine different lifestyle 
clusters with latent class cluster models; smoking, alcohol consumption, MVPA, and 
BMI were used as cluster variables. Smoking and alcohol consumption were entered as 
nominal variables (1=never, 2=former and 3=current use). As both MVPA and BMI were 
not normally distributed, they were entered as ordinal variables using 9 (i.e. 0, >0-5, 
5-9, 9-13, 13-17, 17-21, 21-25, 25-29 and ≥29 hours/week) and 8 (i.e. <20, 20-22.5, 
22.5-25, 25-27.5, 27.5-30, 30-32.5, 32.5-35 and ≥35 kg/m2) categories, respectively. The 
optimal number of clusters was based on the model with the lowest Bayesian information 
criterion (BIC) which indicates the best fit. Patients were assigned to the cluster for which 
the posterior probability was highest. The clusters were exported and their impact on 
mortality were further analyzed in SAS. 
Cox regression models with time since cancer diagnosis as underlying time scale were 
used to assess differences in mortality between CRC+DM+ and CRC+DM- patients. 
Lifestyle factors were assessed 1-11 years after cancer diagnosis, which might induce 
survivorship bias, as patients with shorter time since cancer diagnosis might have a 
higher mortality risk as compared with those who already lived longer at the time of 
the questionnaire. To minimize survivorship bias, the model was left-truncated and the 
time of questionnaire completion was set as entry time. We assessed the impact of 
individual lifestyle factors (i.e. smoking, alcohol consumption, BMI, and MVPA) and the 
derived lifestyle clusters on the association between diabetes and mortality. A p-value 
<0.05 was regarded as statistically significant and all analyses were conducted using 
SAS statistics version 9.3 (SAS Institute, Inc., Cary, NC).
Results
Baseline characteristics
Respondents included 1,371 (75%) patients from the 2009 cohort and 2,625 (75%) 
patients from the 2010 cohort (Figure 1). Characteristics of the non-respondents are 
described elsewhere23. After excluding those with incomplete follow-up data, diabetes 
status or lifestyle factors, 3,423 CRC patients were included in the present study, of 
whom 15% (n=497) reported having diabetes. There were more male CRC+DM+ than 
CRC+DM-patients (61% versus 55%). Furthermore, CRC+DM+ patients were older at 
cancer diagnosis (67±8 versus 64±10 years) and lower educated (24% versus 10%) than 
CRC+DM- patients (Table 1). No differences were found in cancer stage, treatment or 
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follow-up time. In total, 503 patients died; 97(20%) CRC+DM+ and 406(14%) CRC+DM- 
patients.
Lifestyle
There were fewer current (8% versus 12%) and more former (63% versus 55%) smokers 
among CRC+DM+ as compared with CRC+DM- patients. Moreover, CRC+DM+ patients 
were less likely to be current drinkers (57% versus 72%), were less physically active (MVPA: 
9.3±8.5 versus 11.3±8.8 hours/week), and had a higher BMI (28.9±4.4 versus 26.4±4.1 
kg/m2) than CRC+DM- patients. Differences in BMI were mainly apparent in the obesity 
category, with 34% and 15% of CRC+DM+ and CRC+DM- patients, respectively, being 
obese.
- N=619 (17%) actively refused or did 
not return the questionnaire 








3,585 CRC patients diagnosed 
between 2000 and 2009, aged ≤85 
years were eligible for participation 
and received a questionnaire 
 
 
1,832 CRC patients diagnosed 
between 1998 and 2007, aged ≤85 
years were eligible for participation 









- N=311 (17%) actively refused or did 
not return the questionnaire 








- N=75 (5%) had no follow-up data, 
were lost to follow-up prior to the 
study or had a follow-up <1 year 
- N=107 (8%) did not report 
diabetes status 
- N=71 (5%) did not have complete 
data on lifestyle factors 
 
 
- N=120 (5%) had no follow-up 
data, were lost to follow-up prior to 
the study or had a follow-up <1 year 
- N=160 (6%) did not report 
diabetes status 
- N=40 (2%) did not have complete 
data on lifestyle factors 
 
 
1,118 (61%) CRC patients were 
included in the current study 
 
 
2,305 (64%) CRC patients were 
included in the current study 
 
 
In total 3,423 CRC patients were included: 
N=2,926 (85%) without diabetes 
N=497 (15%) with diabetes 
 
Figure 1 Flowchart of the study population
CRC patients





Sex - Male 303 (61) 1,595 (55) 0.007
Age at questionnaire 71.8±7.7 68.6±9.8 <0.0001
Age at cancer diagnosis 66.9±7.9 63.7±10.0 <0.0001
Education
Low 117 (24) 547 (19) 0.02
Medium 269 (55) 1,755 (61)
High 102 (21) 591 (20)
Cancer stage
I 150 (30) 867 (30) 0.21
II 203 (41) 1,080 (37)
III 125 (25) 823 (28)
IV 11 (2) 106 (4)
Unknown 7 (1) 50 (2)
Cancer treatment - Surgery 495 (100) 2,912 (100) 0.82
Cancer treatment - Chemotherapy 129 (26) 839 (29) 0.21
Cancer treatment - Radiotherapy 128 (26) 851 (29) 0.13
Follow-up
Time between questionnaire and cancer dx 4.9±2.7 4.8±2.8 0.63
Time between cancer dx and end follow-up 8.9±2.9 9.0±2.9 0.62
Time between questionnaire and end follow-up 4.0±1.2 4.2±1.1 0.01
Status at the end of follow-up
Alive 400 (80) 2,520 (86) 0.001
Dead 97 (20) 406 (14)
Lifestyle
Smoking
Never 144 (29) 960 (33) 0.006
Former 311 (63) 1,620 (55)
Current 42 (8) 346 (12)
Alcohol
Never 165 (33) 621 (21) <0.0001
Former 51 (10) 184 (6)
Current 281 (57) 2,121 (72)
MVPA (hours/week) 9.3±8.5 11.3±8.8 <0.0001
BMI (kg/m2) 28.9±4.4 26.4±4.1 <0.0001
BMI 
<20 kg/m2 3 (1) 85 (3) <0.0001
20-25 kg/m2 80 (16) 1,016 (35)
25-30 kg/m2 244 (49) 1,399 (48)
≥30 kg/m2 170 (34) 426 (15)
Table 1 Baseline characteristics of the study population
BMI=Body Mass Index, MVPA=Moderate-to-Vigorous Physical Activity
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Latent class analyses yielded 4 lifestyle clusters: 1. Healthy (n=905), 2. Moderately 
healthy (n=2,033), 3. Overweight (n=381), and 4. Smoking (n=104, Table 2). The healthy 
Cluster 1, was characterized by a low number of current smokers (3%), a majority of 
current alcohol consumers (67%), and highly physically active patients (MVPA 12.4±8.5 
hours/week) with a normal BMI (25.7±3.2 kg/m2). The moderately healthy Cluster 2 
was similar to cluster 1 regarding MVPA (12.2±8.8 hours/week) and BMI (26.7±3.8 kg/
m2) but only included former (87%) and current smokers (13%). Overweight cluster 
3, included mainly overweight/obese patients (BMI: 31.2±4.9 kg/m2), who were less 
physically active (MVPA: 2.7±3.0 hours/week). Cluster 4 mainly included smokers (69%) 
with low physical activity (MVPA: 4.0±4.1 hours/week) and a low BMI (20.3±2.0 kg/m2). 
‘Moderately healthy’ patients within cluster 2 were younger (64.0±9.3 years) than healthy 
cluster 1 and overweight cluster 3 (both 67.5±9.9 years) and smoking cluster 4 (66.5±10.9 
years, data not shown). No differences in cancer stage or treatment were found among 
the 4 lifestyle clusters. Diabetes prevalence was highest in overweight cluster 3 (n=109, 
















Never 881 (97) 0 (0) 202 (53) 21 (20) <0.0001
Former 0 (0) 1,775 (87) 145 (38) 11 (11)
Current 24 (3) 252 (13) 34 (9) 72 (69)
Alcohol
Never 265 (29) 160 (8) 306 (80) 55 (53) <0.0001
Former 36 (4) 157 (8) 27 (7) 15 (14)
Current 604 (67) 1,716 (84) 48 (13) 34 (33)
MVPA (hours/week) 12.4±8.5 12.2±8.8 2.7±3.0 4.0±4.1 <0.0001
BMI (kg/m2) 25.7±3.2 26.7±3.8 31.2±4.9 20.3±2.0 <0.0001
BMI 
<20 kg/m2 28 (1) 14 (2) 0 (0) 46 (44) <0.0001
20-25 kg/m2 639 (31) 382 (42) 17 (4) 58 (56)
25-30 kg/m2 1,041 (51) 444 (49) 158 (41) 0 (0)
≥30 kg/m2 325 (16) 65 (7) 206 (54) 0 (0)
Table 2 Lifestyle characteristics of the patients in different clusters constructed using latent 
class analysis
BMI=Body Mass Index, MVPA=Moderate-to-Vigorous Physical Activity
Association between diabetes, lifestyle factors and mortality
Unadjusted Cox regression analysis confirmed the higher mortality among CRC+DM+ 
versus CRC+DM- patients (HR=1.44; 95%CI:1.16-1.80) (Model 1, Table 3). This effect 
remained in model 3 which was adjusted for age, sex, cancer stage, and cancer 
treatment (HR=1.29; 95%CI:1.04-1.62). Additionally adjusting for individual lifestyle 
factors slightly attenuated the increased mortality risk to non-significance (Model 4, 
HR=1.24; 95%CI:0.98-1.56). In Model 4, former and current versus never smoking was 
associated with higher mortality (HR=1.36; 95%CI:1.09-1.71 and HR=2.13; 95%CI:1.58-
2.86, respectively). Moreover, current versus never alcohol use, higher MVPA (hours/
week), and a BMI between 25 and 30 kg/m2 versus 20-25 kg/m2 was associated with 
lower overall mortality with HR=0.71 (95%CI:0.57-0.88), HR=0.97 (95%CI:0.95-0.98) 
and HR=0.79 (95%CI:0.65-0.97), respectively. After adjustment for the lifestyle clusters 
(Model 5), diabetes remained statistically significantly associated with a higher mortality 
(HR=1.29; 95%CI:1.02-1.61). 
Table 3 The impact of diabetes on overall mortality using left-truncated Cox regression analyses
BMI=Body Mass Index, MVPA=Moderate-to-Vigorous Physical Activity
†Adjusted for age at cancer diagnosis, sex, cancer treatment and stage




DM+ versus DM- 1.44 (1.16-1.80)*
Model 2: Age, sex adjusted
DM+ versus DM- 1.25 (1.00-1.56)*
Model 3: Fully adjusted†
DM+ versus DM- 1.29 (1.04-1.62)*
Model 4: Model 3† + adjusted for independent lifestyle factors
DM+ versus DM- 1.24 (0.98-1.56)
Smoking: former vs never 1.36 (1.09-1.71)*
Smoking: current vs never 2.13 (1.58-2.86)*
Alcohol: former vs never 0.83 (0.58-1.17)
Alcohol: current vs never 0.71 (0.57-0.88)*
MVPA (hours/week): 0.97 (0.95-0.98)*
BMI‡: Underweight vs healthy weight 1.29 (0.81-2.05)
BMI‡: Overweight vs healthy weight 0.79 (0.65-0.97)*
BMI‡: Obese vs healthy weight 0.92 (0.70-1.20)
Model 5: Model 3† + adjusted for lifestyle in clusters
DM+ versus DM- 1.29 (1.02-1.61)*
Cluster 2 versus 1 1.21 (0.95-1.54)
Cluster 3 versus 1 1.57 (1.15-2.14)*
Cluster 4 versus 1 3.66 (2.49-5.38)*
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Moreover, as compared with the healthy cluster 1, both clusters 3 (overweight) and 4 
(smoking) were associated with increased mortality with HR=1.57 (95%CI:1.15-2.14) and 
HR=3.66 (95%CI:2.49-5.38), respectively.  In secondary analyses, we excluded patients 
with stage IV disease, but results remained the same (data not shown).
Discussion
This study confirmed previous research and showed that CRC+DM+ patients had a 
higher mortality risk as compared with CRC+DM- patients. Moreover, we found that this 
association could not be fully explained by BMI, physical activity, smoking, and alcohol 
consumption, or by lifestyle clusters. Furthermore, we identified four lifestyle clusters 
and found a significant increased mortality for patients in the overweight (HR=1.57) and 
the smoking (HR=3.66) clusters versus patients in the healthy cluster.
CRC+DM+ patients had a 29% higher mortality risk as compared with CRC+DM- patients, 
which is slightly higher than the 17% higher risk found in a recent meta-analysis4. This 
excess mortality was attenuated after the adjustment for independent lifestyle factors 
(HR=1.24; 95%CI:0.98-1.56), but remained after the adjustment for lifestyle clusters 
(HR=1.29; 95%CI:1.02-1.61). Thus the excess mortality among CRC+DM+ patients is 
likely to be explained by factors other than lifestyle, such as socioeconomic status 
(SES). Cancer patients with low SES more often have comorbidities than those with a 
high SES30, and CRC patients with a low SES may present with higher cancer stage at 
diagnosis31. However, we found no difference in cancer stage between CRC+DM+ and 
CRC+DM- patients. Second, our previous report shows that CRC+DM+ patients have 
more treatment-related toxicities32. This might have led to discontinuation of treatment 
or dose adjustments. Third, patients with both diseases might perform less diabetes 
self-management behaviors33. They might prioritize their cancer care over diabetes care 
which may lead to more diabetes-related complications. Finally, hyperinsulinemia or 
increased levels of insulin-like growth factors are known to have a direct effect on tumor 
cell proliferation and angiogenesis34 which may lead to higher risk of cancer recurrence 
and mortality among CRC+DM+ versus CRC+DM- patients35. Although lifestyle factors 
did not explain the increased mortality among CRC+DM+ patients, this group did have 
a poorer lifestyle than CRC+DM- patients.
In this study, we observed a U-shaped association between BMI and mortality, a higher 
mortality among current and former smokers, and negative association between physical 
activity and mortality consistent with previous research8-12,36.  Current alcohol use was 
associated with lower mortality. Further analyses (data not shown) showed that 90% 
of current drinkers consumed moderate amounts of alcohol (i.e. ≤14 glasses and ≤ 21 
glasses per week for women and men, respectively). This is in line with previous literature, 
in which moderate alcohol consumption was associated with lower mortality among 
both CRC and diabetes patients15,16.
After identifying four different lifestyle clusters, we found that CRC patients who smoke, 
have a low MPVA, and low BMI (cluster 4) and overweight/obese patients (cluster 3) 
have an increased mortality risk (HR=3.66; 95%CI:2.49-5.38 and HR=1.57; 95%CI:1.15-
2.14, respectively), than those with a healthy lifestyle (cluster 1). As expected, diabetes 
prevalence was highest among the overweight cluster (29%). However, it is possible 
that the majority of patients in the overweight cluster has undiagnosed diabetes or 
pre-diabetes, which we cannot account for. This study stresses the importance of 
assessing risk profiles, as specific combinations of lifestyle factors resulted in more 
marked associations with mortality. Future research should explore whether interventions 
targeted at combined, rather than single lifestyle factors result in better outcomes among 
CRC patients.
This study has several limitations. We had no information about lifestyle before cancer 
diagnosis. Previous studies show that ≈50% of patients stop smoking after cancer 
diagnosis, change their dietary habits, and engage more in physical activity37. These 
changes could have influenced our findings. Moreover, the self-reported lifestyle 
measures might have been influenced by social desirable responses. Although previous 
studies show a high correlation between self-reported and measured height and weight, 
older individuals (i.e. >60 years) often underreport their height and weight resulting in 
differences of up to 1 kg/m2 in BMI38. Similarly, self-reported physical activity is influenced 
by social desirability39. Therefore, absolute numbers regarding lifestyle factors should be 
interpreted cautiously. Furthermore, having diabetes was self-reported and information 
regarding the type of diabetes, blood glucose control or diabetes complications was 
lacking. Finally, no data regarding cause of death were available. Despite these limitations, 
this study had a high response rate and includes a large population-based sample.
In conclusion, CRC+DM+ patients had a 29% higher mortality risk as compared with 
CRC+DM- patients, which could not be fully explained by lifestyle differences. Moreover, 
as CRC+DM+ patients reported poorer lifestyle behaviors than CRC+DM- patients, these 
patients need to become aware of the importance of pursuing a healthy lifestyle. Also, 
this study shows that smokers often engage less in MVPA and have a low BMI. Therefore 
the effectiveness of interventions targeted at combined, rather than single lifestyle 
factors is worthy of further investigation.
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This study assessed the association between glucose lowering drug (GLD) use, including 
metformin, sulphonylurea derivatives and insulin, after breast cancer diagnosis and 
breast cancer-specific and all-cause mortality.
  
Methods
1,763 breast cancer patients, diagnosed between 1998 and 2010, with type 2 diabetes 
were included. Cancer information was retrieved from English cancer registries, 
prescription data from the UK Clinical Practice Research Datalink and mortality data 
from the Office of National Statistics (up to January 2012). Time-varying Cox regression 
models were used to calculate HRs and 95% CIs for the association between GLD use 
and breast cancer-specific and all-cause mortality.
Results
In 1,057 patients with diabetes before breast cancer, there was some evidence that 
breast cancer-specific mortality decreased with each year of metformin use (adjusted 
HR=0.88; 95%CI:0.75-1.04), with a strong association seen with over 2 years of use 
(adjusted HR=0.47; 95%CI:0.26-0.82). Sulphonylurea derivative use for less than 2 years 
was associated with increased breast cancer-specific mortality (adjusted HR=1.70; 
95%CI:1.18-2.46) but longer use was not (adjusted HR=0.94; 95%CI:0.54-1.66). In 706 
patients who developed diabetes after breast cancer, similar patterns were seen for 
metformin but sulphonylurea derivative use was strongly associated with cancer-specific 
mortality (adjusted HR=3.64; 95%CI:2.16-6.16), with similar estimates for short and long-
term users.
Conclusions 
This study provides some support for an inverse association between, mainly long-
term, metformin use and (breast cancer-specific) mortality. In addition, sulphonylurea 
derivative use was associated with increased breast cancer-specific mortality, but this 
should be interpreted cautiously, as it could reflect selective prescribing in advanced 
cancer patients.
Introduction
Diabetes occurs in around 16% of breast cancer patients1,2 and is associated with a 40% 
increased breast cancer-specific3 and a 50% increased all-cause mortality4.Metformin is 
currently used as primary treatment for Type 2 diabetes. If metformin monotherapy does 
not control hyperglycaemia sufficiently, sulphonylurea derivatives (SUs) or insulin may be 
added or switched to. Recently, metformin, has received much attention for its potential 
anti-tumour effects. Several laboratory studies show that metformin use is associated 
with cell growth suppression in breast cancer cells, possibly mediated by activation 
of 5’-adenosine monophosphate-activated protein kinase (AMPK)5,6. Observational 
studies also show that metformin use is associated with a 20-30% lower breast cancer 
incidence7-9.
Four studies have investigated the association between metformin use and breast 
cancer-specific mortality or recurrence in breast cancer patients but reported conflicting 
results10-13. A 53% decreased breast cancer-specific mortality was reported for metformin 
use versus non-use among human epidermal growth factor receptor 2 positive (HER2+) 
breast cancer patients10 whereas the other studies did not find any association11-13. These 
studies had several limitations such as small sample size10,12,13, no investigation of dose-
response10,12,13 and some were restricted to specific breast cancer subtypes (i.e. HER2+10 or 
triple negative breast cancer13). Additionally, the study that reported a favorable effect for 
metformin might have been influenced by immortal time bias14, as metformin users were 
classified as users from breast cancer diagnosis onwards, and not from the time of actual 
drug initiation10. Only one study used time dependent Cox regression analyses to avoid 
immortal time bias, but did not include lifestyle-related covariates11. Conflicting results 
were also reported among studies that investigated the effect of Glucose Lowering Drugs 
(GLDs) on all-cause mortality15,16. One study reported no effect of metformin use prior 
or in the 3 months after breast cancer diagnosis on overall mortality16, while another 
study did report a lower overall mortality among metformin users as compared to breast 
cancer patients without diabetes15. However, as these studies did not report on breast 
cancer-specific deaths, associations in these studies could reflect non-cancer deaths15,16. 
Further research is needed to establish the effect of metformin and other GLDs on the 
prognosis of breast cancer patients with type 2 diabetes.
Therefore, prompted by the promising preclinical evidence, our primary objective was 
to determine whether breast cancer patients with type 2 diabetes using metformin had 
reduced breast cancer-specific mortality and all-cause mortality. A secondary objective 
was to investigate the effect of other GLDs on breast cancer-specific and all-cause 
mortality.
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This retrospective cohort study used linked data from the Clinical Practice Research 
Datalink (CPRD), the National Cancer Data Repository (NCDR) and the Office of National 
Statistics (ONS). The CPRD contains demographical information, clinical diagnoses and 
prescription data for approximately 7% of the UK population17. The NCDR contains data 
on all cancer diagnoses in the UK cancer registries including data on diagnosis date, 
site of primary cancer, stage, and treatment. Data regarding deaths were retrieved from 
the ONS registration which included breast cancer-specific (ICD codes C50.0 to C50.9) 
and all-cause mortality. The CPRD, NCDR and ONS death data were linked (using an 
algorithm based upon NHS number, gender, date of birth and postcode) for cancer 
patients in England. A multicenter research ethics committee gave ethical approval for 
all observational research using CPRD data.
Study design
A cohort of female breast cancer patients, diagnosed between 1998 and 2009, with type 2 
diabetes was identified. Diabetes diagnosis was defined using previously validated clinical 
Read codes18 or the first prescription of a GLD defined below, whichever occurred first. 
This study includes patients with diabetes prior to breast cancer (prevalent diabetes) as 
well as patients who developed diabetes after breast cancer diagnosis (incident diabetes). 
Patients with type 1 diabetes, which was defined as having a type 1 diabetes diagnosis 
code and a prescription of insulin prior to breast cancer diagnosis for prevalent diabetes 
patients and within 6 months after diabetes diagnosis for patients with incident diabetes, 
were excluded. Cancer patients with a previous cancer diagnosis were excluded, apart 
from in situ neoplasms and non-melanoma skin cancers. The index date was defined 
as the date of breast cancer diagnosis for patients with prevalent diabetes and the date 
of diabetes diagnosis for patients with incident diabetes. Patients were excluded if the 
index date occurred before they were registered at a CPRD practice, CPRD records at their 
general practice (GP) were of research quality or if the index date occurred after death 
or censoring. Patients who received hormone therapy for more than 8 weeks prior their 
breast cancer diagnosis, or with diagnosed polycystic ovary syndrome were excluded. 
Follow-up started 6 months after the index date to remove deaths that occurred within 
this period, as it is unlikely that GLD medication use after diagnosis could influence 
such deaths. In the analysis of incident diabetes patients, the time since breast cancer 
diagnosis remained the underlying time variable and Cox regression models were left-
truncated with follow-up beginning 6 months after diabetes diagnosis. The patients were 
followed till death, the end of registration or last date of data collection of their GP or 
end of ONS follow-up (10th of January 2012), whichever occurred first.
Exposure to GLDs
Exposure to metformin, SUs, other GLDs and insulin was identified using chapter 6.1 
of the British National Formulary19. Days of exposure was calculated by dividing the 
prescribed quantity by the number of prescribed tablets/units per day. If the quantity or 
units per day was missing (<1 and <20% respectively), the most frequent quantity and 
the average daily dose per product were used. For insulin the units per day were not 
reported, so the days of exposure was set to 60 days for each prescription. Cumulative 
days of exposure to all GLDs was calculated in 30-day intervals.
Covariates
Cancer stage and treatment (surgery, radiotherapy and chemotherapy) within the 6 
months after breast cancer diagnosis were retrieved from the NCDR. Hormone treatment 
(including tamoxifen and aromatase inhibitor use) in the 6 months after breast cancer 
diagnosis was derived from GP prescription records. Smoking and Body Mass Index 
(BMI) closest to the index date were determined from the GP records; records more 
than 5 years prior to the index date were ignored. Comorbidities prior to the index 
date were identified using clinical Read codes which were previously validated with an 
adapted version of the Charlson comorbidity index18. The use of Hormone Replacement 
Therapy (HRT) and low-dose aspirin and statin prior to the index date were retrieved 
from the GP records. HbA1c measures in % according to the National Glycohemoglobin 
Standardization Program (NGSP) were retrieved for the year prior to breast cancer 
diagnosis for prevalent diabetes patients and between 6 months prior and 6 months 
after diabetes diagnosis for incident diabetes patients. The HbA1c measurement closest 
to the index date was used in the analyses.
Statistical analyses
The main analyses used time-dependent Cox regression models with time to breast 
cancer-specific deaths and all-cause mortality as the outcome, where metformin, SU, 
other GLDs and insulin use were modelled as time-varying covariates. A 6-month lag 
was used, which removes all GLD prescriptions in the 6 months prior to the end of study 
or death (i.e. as medication use in these months might reflect end-of-life treatment), as 
previously recommended20. Exposure to GLDs was modelled using time-varying ever/
never terms (i.e. patients are classified as unexposed until 6 months after first drug 
prescription and as exposed afterwards). In addition, a linear trend was fitted to assess 
per year exposure to GLDs, and time-varying terms for year of exposure to GLDs, with 
time-varying ever/never terms were included in the model as recommended21. Moreover 
short- and long-term exposure was modelled using categories (<2 years of exposure 
and ≥2 years of exposure). Hazard ratios (HR) and 95% confidence intervals (95%CIs) 
were reported.
An unadjusted model was constructed and included the use of metformin, SU, other 
GLDs and insulin. The fully adjusted model included the following covariates which 
were available for the entire cohort: age at breast cancer diagnosis, calendar year of 
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breast cancer diagnosis, diabetes duration for prevalent diabetes patients, breast cancer 
treatment within 6 months (i.e. dichotomous covariates for surgery, chemotherapy, 
radiotherapy and hormone therapy), the use of HRT prior to breast cancer diagnosis 
and comorbidities prior to the study start (including stroke, chronic pulmonary disease, 
congestive heart disease, diabetes with complications, myocardial infarction, peptic ulcer 
disease, peripheral vascular disease and renal disease).
Several sensitivity analyses based on the fully adjusted time-varying ever/never analysis 
were conducted and include additional adjustments for BMI, smoking, stage and HbA1c 
measures. A sensitivity analysis restricted to patients who had a follow-up >1 year in 
which the lag was increased to 1 year was performed. Among prevalent diabetes patients, 
a simplified Cox regression analyses was performed comparing GLD use to non-use in 
the 6 months after diagnosis, removing the need for time varying covariates. Moreover, 
among prevalent diabetes patients, a nested case-cohort analysis was performed. Cases 
who died of breast cancer were matched on age (5-year intervals) and year of cancer 
diagnosis (2-year intervals) to up to 10 controls within the cohort who lived at least 
as long after diagnosis as their matched case. The exposure period was defined as 
the period from breast cancer diagnosis till 6 months prior to death for cases and a 
period of identical duration from breast cancer diagnosis was defined for the matched 
controls. Metformin, SU, insulin and other GLD use was determined in the exposure 
period. Conditional logistic regression was used to calculate odds ratios (OR) and 95%CIs. 
All statistical analyses were performed using STATA 13 (College Station, TX).
Results
Study population
1,057 patients with prevalent diabetes at breast cancer diagnosis and 706 patients with 
incident diabetes were included (Figure 1). The mean age of prevalent diabetes patients 
was 70.6 (SD=11.3) years at breast cancer diagnosis and they were diagnosed with 
diabetes on average 6.6 (SD=6.0) years prior (Table 1). During follow-up, metformin 
was used by 65%, SUs by 50%, insulin by 21% and other GLDs by 21% of the prevalent 
diabetes patients. 189 (18%) prevalent diabetes patients used no GLDs, 332 (31%) 
used 1 GLD and 536 (51%) used a combination of ≥2 GLDs. The most frequently used 
combinations were metformin and SUs (n=205, 19%), metformin monotherapy (n=187, 
18%), and metformin, SUs and other GLDs (n=105, 10%). Patients who did not use GLDs 
or who used SUs during follow-up were leaner than other groups e.g. 29 and 16% had 
a BMI <25 kg/m2, respectively, compared with 11% among metformin and insulin users. 
Insulin users had more complications (25%) than other groups and had the highest 
HbA1c levels (mean=8.2, SD=1.8 %NGSP). Mean follow-up time from breast cancer 
diagnosis was 4.4 years (SD=2.9 years, maximum 13.8 years) and a total of 348 prevalent 
diabetes patients died (150 were breast cancer-specific deaths).
Incident diabetes patients were on average 64.4 (SD=11.4) years at breast cancer 
diagnosis and were diagnosed with diabetes on average 3.3 (SD=2.6) years after breast 
cancer diagnosis (Table 1). Metformin use was similar compared to prevalent diabetes 
patients (62% versus 65% using metformin during follow-up) but the use of SU, insulin 
and other GLDs was lower with 30, 5 and 10% versus 50, 21 and 21%, respectively. 224 
(32%) incident diabetes patients used no GLDs, 278 (39%) used 1 GLD and 204 (29%) 
used a combination of ≥2 GLDs. The most frequently used combinations were metformin 
monotherapy (n=235, 33%), metformin and SUs (n=115, 16%), and metformin, SUs 
and other GLDs (n=37, 5%). Metformin and other GLD users had the highest BMIs with 
respectively, 47 and 50% being obese as compared to 37 and 29% for SU and insulin 
users. HbA1c levels were highest among insulin users with an average of 8.2 %NGSP. 
Mean follow-up from diabetes diagnosis was 3.9 years (SD=2.7 years, and maximum 13.0 
years) and a total of 134 patients died (68 were breast cancer-specific deaths).
Figure 1 Patient selection
34,875 women were diagnosed with 
primary breast cancer between  
1998-2010 
3,086 women were diagnosed with 
breast cancer and diabetes type 2 
31,789 were not diagnosed with 
diabetes type 2 
1,763 patients with diabetes and 
breast cancer diagnosis were included 
1,323 excluded, because: 
- Index date after the end of follow-
up (n=282) 
- Index date preceded CPRD quality 
records (n=775) 
- Treatment with hormone therapy 
more than 2 months prior to breast 
cancer diagnosis (n=65) 
- Diagnosis of Polycystic Ovary 
Syndrome (n=1) 
- No death data or died within half a 
year after index date (n=200) 
706 developed diabetes after breast 
cancer diagnosis (incident diabetes) 
1,057 had diabetes at breast cancer 
diagnosis (prevalent diabetes) 
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The association between GLD use and mortality
Breast cancer patients with prevalent diabetes
Breast cancer-specific mortality rates were lower in metformin users compared with 
non-users (HR=0.64; 95%CI:0.46-0.91), although this was attenuated after adjustment for 
potential confounders (adjusted HR=0.78; 95%CI:0.55-1.12) (Table 2). The majority of this 
attenuation could be explained by adjustment for age and year of breast cancer diagnosis 
(HR adjusted for age and year of diagnosis=0.79; 95%CI:0.55-1.12). Sensitivity analyses 
showed that adjustment for stage further attenuated the effect of metformin (HR=0.96; 
95%CI:0.53-1.75) while increasing the lag to 1 year and the case-control analysis showed 
similar results (Table 4). The association was not observed per year of metformin use 
(unadjusted HR=0.88; 95%CI:0.75-1.04, adjusted HR=0.88; 95%CI:0.75-1.04) (Table 2). 
A more marked association with breast cancer-specific mortality was observed among 
individuals using metformin for ≥2 years (adjusted HR=0.47; 95%CI:0.26-0.82), rather 
than for shorter periods (adjusted HR=0.88; 95%CI:0.61-1.27). In sensitivity analyses the 
association between metformin use for ≥2 years was attenuated slightly after adjustment 
for BMI (HR=0.53; 95%CI:0.28-1.00), or after increasing the lag to 1 year (HR=0.54; 
95%CI:0.30-1.00). Adjustment for stage at diagnosis (available for 39% of cases) further 
attenuated this association (HR=0.62; 95%CI:0.25-1.55) (data not shown).
Breast cancer-specific mortality was increased in SU users compared with non-users 
(HR=1.56; 95%CI:1.11-2.19), but attenuated after adjustments (HR=1.41; 95%CI:1.00-
1.99). As before, the majority of this attenuation could be explained by adjustment for 
age and year of breast cancer diagnosis (HR adjusted for age and year of diagnosis=1.37; 
95%CI:0.97-1.93). Sensitivity analysis showed that adjustments for BMI and smoking 
further attenuated the association; HR=1.36; 95%CI:0.94-1.99 and HR=1.27; 95%CI:0.86-
1.89 respectively (data not shown). Additional adjustments for stage resulted in a slightly 
higher hazard ratio for SU use (HR=1.76; 95%CI:0.99-1.34), but the case-control analysis 
showed similar results (Table 4). No significant association was seen per year increase 
in SU use (unadjusted HR=0.96; 95%CI:0.81-1.14 and adjusted HR=0.96; 95%CI:0.81-
1.15, Table 2). Further analysis revealed that SU use for <2 years was associated with an 
increase in breast cancer-specific mortality (HR=1.70; 95%CI:1.18-2.46) whereas longer 
use (≥2 years) was not (HR=0.94; 95%CI:0.54-1.66). A similar pattern was seen for insulin 
users, although based on smaller numbers. There was little evidence of an association 
between use of other GLDs and breast cancer-specific mortality.
Table 1 Descriptives of the study population including patients with prevalent diabetes at breast 
cancer diagnosis and incident diabetes after breast cancer diagnosis 
Prevalent diabetes (n=1,057)
Total Metformin SU Insulin Other GLDs No GLD use
N(%) 1,057 (100) 688 (65) 528 (50) 220 (21) 220 (21) 189 (18)
Age at BC diagnosis (years)a 70.6 (11.3) 68.6 (11.0) 70.6 (11.2) 66.9 (10.6) 66.2 (10.5) 74.4 (11.1)
BMI (kg/m2)
< 25 kg/m2 172 (16) 77 (11) 85 (16) 25 (11) 18 (8) 54 (29)
25 - 30 kg/m2 325 (31) 219 (32) 175 (33) 66 (30) 63 (29) 52 (28)
≥30 kg/m2 456 (43) 338 (49) 216 (41) 111 (50) 124 (56) 62 (33)
Missing 104 (10) 54 (8) 52 (10) 18 (8) 15 (7) 21 (11)
Smoking status 
Never 570 (54) 373 (54) 289 (55) 119 (54) 118 (54) 103 (55)
Ever 368 (35) 247 (36) 169 (32) 78 (35) 79 (36) 66 (35)
Missing 119 (11) 68 (10) 70 (13) 23 (10) 23 (10) 20 (11)
Comorbidities 
Diabetes with complications 131 (12) 82(12) 63 (12) 56 (25) 28 (13) 13 (7)
Stroke 109 (10) 61 (9) 58 (11) 25 (11) 20 (9) 21 (11)
Chronic pulmonary disease 209 (20) 138 (20) 102 (19) 36 (16) 52 (24) 37 (20)
Heart disease 163 (15) 82 (12) 75 (14) 41 (19) 23 (10) 33 (17)
Time between diabetes and breast cancer 
diagnosis (years)a
6.6 (6.0) 6.4 (5.4) 6.9 (5.8) 10.0 (6.9) 6.7 (5.0) 5.1 (6.0)
Time between breast cancer and diabetes 
diagnosis (years)a
- - - - - -
HbA1c (%NGSP)a 7.2 (1.4) 7.4 (1.4) 7.5 (1.5) 8.2 (1.8) 7.6 (1.4) 6.1 (0.7)
GLD use after BC diagnosis 
Metformin 688 (65) 688 (100) 397 (75) 157 (71) 193 (88) -
Sulphonylurea derivatives 528 (50) 397 (58) 528 (100) 101 (46) 167 (76) -
Insulin 220 (21) 157 (23) 101 (19) 220 (100) 60 (28) -
Other GLDs 220 (21) 193 (28) 167 (32) 60 (27) 220 (100) -
No GLDs 189 (18) - - - - 189 (100)
Cancer stage
I 167 (16) 109 (16) 81 (15) 41 (19) 40 (18) 32 (17)
II 186 (18) 131 (19) 100 (19) 42 (19) 44 (20) 27 (14)
III 43 (4) 26 (4) 22 (4) 8 (4) 8 (4) 9 (5)
IV 14 (1) 6 (1) 4 (1) 2 (1) 1 (0) 5 (3)
Missing 647 (61) 416 (60) 321 (61) 127 (58) 127 (58) 116 (61)
Cancer treatment in 6 months after BC 
diagnosis
Surgery 817 (77) 561 (82) 413 (78) 172 (78) 188 (85) 139 (74)
Chemotherapy 152 (14) 118 (17) 76 (14) 39 (18) 42 (19) 14 (7)
Radiotherapy 419 (40) 305 (44) 209 (40) 97 (44) 104 (47) 58 (31)
Hormone treatment 821 (78) 520 (76) 415 (79) 166 (75) 156 (71) 155 (82)
HRT before BC diagnosis 284 (27) 205 (30) 136 (26) 84 (38) 80 (36) 43 (23)
Table 1 continues on next page
aValues reported are means and SD
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Continuation of table 1
aValues reported are means and SD
Incident diabetes (n=706)
Total Metformin SU Insulin Other GLDs No GLD use
706 (100) 437 (62) 210 (30) 35 (5) 74 (10) 224 (32)
64.4 (11.4) 62.1 (10.7) 64.6 (10.8) 61.6 (11.4) 60.9 (8.8) 67.7 (11.4)
55 (8) 26 (6) 14 (7) 4 (11) 3 (4) 26 (12)
164 (23) 84 (19) 41 (20) 8 (23) 14 (19) 67 (30)
280 (40) 204 (47) 78 (37) 10 (29) 37 (50) 66 (29)
207 (30) 123 (28) 77 (37) 13 (37) 20 (27) 65 (29)
345 (49) 200 (46) 90 (43) 14 (40) 29 (39) 126 (56)
250 (35) 164 (38) 76 (36) 16 (46) 31 (42) 71 (32)
111 (16) 73 (17) 44 (21) 5 (14) 14 (19) 27 (12)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
40 (6) 16 (4) 9 (4) 2 (6) 1 (1) 21 (9)
139 (20) 89 (20) 41 (20) 8 (23) 18 (24) 41 (18)
64 (9) 34 (8) 21 (10) 2 (6) 5 (7) 23 (10)
- - - - - -
3.3 (2.6) 3.1 (2.5) 2.7 (2.4) 2.4 (2.1) 2.6 (1.9) 3.9 (2.9)
7.2 (1.4) 7.5 (1.6) 7.9 (1.7) 8.2 (2.3) 7.9 (1.7) 6.5 (4.9)
437 (62) 437 (100) 172 (82) 28 (80) 72 (97) -
210 (30) 172 (39) 210 (100) 22 (63) 47 (64) -
35 (5) 28 (6) 22 (10) 35 (100) 13 (18) -
74 (10) 72 (16) 47 (22) 13 (37) 74 (100) -
224 (32) - - - - 224 (100)
140 (20) 89 (20) 30 (14) 2 (6) 10 (14) 46 (21)
175 (25) 120 (27) 61 (29) 15 (43) 20 (27) 41 (18)
24 (3) 10 (2) 6 (3) 3 (9) 2 (3) 12 (5)
9 (1) 4 (1) 6 (3) 0 (0) 0 (0) 2 (1)
358 (51) 214 (49) 107 (51) 15 (43) 42 (57) 123 (55)
626 (89) 399 (91) 190 (90) 34 (97) 70 (95) 190 (85)
163 (23) 119 (27) 64 (30) 15 (43) 21 (28) 32 (14)
337 (48) 225 (51) 103 (49) 14 (40) 40 (54) 97 (43)
516 (73) 302 (69) 153 (73) 23 (67) 50 (68) 175 (78)
240 (34) 153 (35) 61 (29) 17 (49) 30 (41) 75 (33)
N(%)
Age at BC diagnosis (years)a
BMI (kg/m2)
< 25 kg/m2












Time between diabetes and breast cancer 
diagnosis (years)a
Time between breast cancer and diabetes 
diagnosis (years)a
HbA1c (%NGSP)a
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Breast cancer patients with incident diabetes
No association between breast cancer-specific mortality and metformin use was seen 
among breast cancer patients with incident diabetes (unadjusted HR=0.97; 95%CI:0.58-
1.71, adjusted HR=0.99; 95%CI:0.58-1.71). However, cumulative exposure to metformin 
was associated with breast-cancer specific mortality (HR=0.73; 95%CI:0.56-0.95), and this 
effect remained after adjustments (HR=0.73; 95%CI:0.56-0.96). Although not significant, 
similar patterns to those with prevalent diabetes were observed for ≥2 years metformin 
use (Table 3).
Ever versus never use of SUs was associated with substantially higher breast cancer-
specific mortality (unadjusted HR=3.41; 95%CI:2.07-5.64 and adjusted HR=3.15; 
95%CI:1.87-5.30). Additional adjustment for stage and the use of a 1 year lag slightly 
attenuated the association but this effect remained significant (Table 4). No association 
between breast cancer-specific mortality and cumulative SU exposure per year was 
observed (adjusted HR=0.88; 95%CI:0.66-1.16) (Table 3). Both <2 years and ≥2 years SU 
use were associated with higher breast cancer-specific mortality (HR=3.51; 95%CI:2.04-
6.06 and HR=3.51; 95%CI:1.31-9.36, respectively). The low number of incident diabetes 
patients using insulin or other GLDs hampered the calculation of reliable estimates of 
mortality risk. For both prevalent and incident diabetes patients, additional adjustments 
for statin and aspirin use prior to breast cancer diagnosis did not materially affect 
observed associations between GLD use and breast cancer-specific mortality (data not 
shown). Analysis of all-cause mortality, also shown in Table 2 and 3, displayed similar 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































This study showed some evidence of lower breast cancer-specific and all-cause mortality 
rates in breast cancer patients with diabetes who were treated with metformin, especially 
among longer term users (≥2 years exposure), but these associations were attenuated 
in sensitivity analyses. In contrast, SU use was associated with substantially increased 
breast cancer-specific and all-cause mortality, however there was no dose response 
association, and these associations were most marked in short-term users, and in patients 
who developed diabetes after their breast cancer diagnosis.
Only one previous study11 has provided data relating to the potential effects of metformin, 
SUs, insulin and other GLDs on breast cancer-specific mortality, and adjusted for the use 
of other GLDs. This study, revealed no significant association between metformin use 
and mortality11. However, we observed some evidence of an association for long-term 
use of metformin on mortality. Also, Lega et al. did not find an association between SU 
use versus non-use and breast cancer-specific (HR=0.97; 95%CI:0.86-1.16) or all-cause 
mortality (HR=0.98; 95%CI:0.94-1.04), nor for SU use modelled per year of exposure11. In 
contrast, we observed increased breast cancer-specific and all-cause mortality for short-
term SU use among those with prevalent diabetes at breast cancer diagnosis. Among 
those with incident diabetes we found a more pronounced increased mortality among SU 
users in all the analyses. Lega et al. did not assess short- and long-term SU use and they 
did not include patients who developed diabetes after their breast cancer diagnosis11.
The observed reduction in cancer-specific mortality in longer term metformin users is 
consistent with findings from preclinical studies suggesting that metformin may have 
anti-tumor properties. Metformin may directly suppress breast cancer cell growth via 
activation of the AMP-activated protein kinase, resulting in downstream signaling of the 
protein kinase, MTOR, which regulates cell growth22,23. Moreover, due to the activation 
of the AMP-activated protein kinase and inhibition of MTOR, metformin might act 
synergistically with chemotherapeutic agents24 and positively influence response to 
adjuvant chemotherapy in diabetic breast cancer patients25. Metformin may also work 
through an indirect mechanism by improving insulin sensitivity, thereby reducing insulin 
levels26 and decreasing activation of IGF-1 receptors27. Deactivation of IGF-1 may inhibit 
Cyr61, and thereby suppress breast cancer growth and invasion28. On the other hand, the 
observed reduction in breast cancer-specific mortality rates in metformin users could 
also be due to residual confounding or reflect chance, particularly as the association was 
most apparent among long-term users of metformin. Further evidence will be provided 
by an ongoing randomized controlled trial of metformin versus placebo in over 3,500 
women with breast cancer, although results will not be reported until the end of 201629,30. 
Previous studies reported increased mortality rates in cancer patients using SUs but of 
less magnitude than associations seen in our study16,31. We believe that the increased 
cancer-specific mortality in SU users apparent in our data should be interpreted cautiously 
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for various reasons. First, we did not have a prior hypothesis regarding the association 
between SUs and mortality. Second, the association with SUs did not follow a dose-
response, which is counterintuitive. Third, although strong associations were seen in 
those with incident diabetes, the risk estimates were based on small numbers of deaths. 
Fourth, a proportion of the diabetes occurring after a breast cancer diagnosis might 
partly be due to treatment for advanced/recurrent disease (e.g. steroids), which is often 
a transient condition. Finally, in patients with advanced cancer it has been recommended 
that SUs are used in preference to metformin due to the gastro-intestinal side effects of 
metformin32, and consequently these drugs may be spuriously associated with increased 
cancer-specific mortality.
From a physiological point of view, it is possible that SUs detrimentally affect breast 
cancer progression/metastasis, possibly mediated through hyperinsulinemia, as SUs 
increase insulin secretion33 and preclinical studies have shown that hyperinsulinemia may 
promote breast cancer metastasis to the lung34. Moreover, observational studies have 
shown that hyperinsulinemia is associated with increased cancer-specific mortality35. 
Despite the caveats mentioned above, the associations we have seen between SU use 
and mortality in breast cancer patients are worthy of further investigation.
This study used data from a large population-based database which is of validated high 
quality17,18. Importantly, time-dependent analyses were performed to avoid immortal 
time bias14, and we accounted for cumulative exposure to GLDs and conducted sensitivity 
analyses to investigate the robustness of our findings. In addition, GLDs are not available 
‘over the counter’ in the UK, so it is likely that we captured all GLD use in our study, 
apart perhaps from use during care within hospital or a hospice. However, this study also 
has several limitations. We do not have data on patients’ compliance with prescribed 
medications. Cancer stage at diagnosis was missing in 60% of our study population, 
although stage distribution appeared similar in metformin users and non-users. 
Additional adjustments for stage attenuated observed hazard ratios, but this appeared 
to result from the restriction of the dataset to those with available stage, rather than 
an effect of adjustment for stage per se. We did not have data on disease progression, 
while GLD use may have changed following cancer recurrence, although associated 
biases should be reduced in lagged analyses. Moreover, there may have been some 
misclassification regarding the cause of death.
 
In conclusion, this study provides some support for an inverse association between 
metformin exposure and (breast cancer-specific) mortality among breast cancer patients. 
In addition, an increased breast cancer-specific mortality was observed among SU users. 
This finding should be interpreted cautiously, as it could reflect selective prescribing in 
advanced cancer patients, but merits further investigation.
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This study assesses the effect of glucose lowering drug (GLD) use, i.e. metformin, 
sulfonylurea derivatives (SUs), insulin and other GLDs, started after breast cancer 
diagnosis, on overall mortality.
Methods
All female breast cancer patients diagnosed between January 1st, 1998 and December 
31st, 2011 who started using GLDs after breast cancer diagnosis, were included. Clinical 
characteristics were derived from the Netherlands Cancer Registry, drug dispensing 
data from the PHARMO Database Network and data on overall mortality from the Dutch 
municipal personal records database. Time-dependent Cox regression analyses, with 
cumulative exposure to GLDs were conducted to assess effects on overall mortality.
Results
In total, 407 breast cancer patients were included. Most women (n=335, 82%) used 
metformin at some point during follow-up, followed by SUs (n=202, 50%), insulin (n=58, 
14%) and other GLDs (n=41, 10%). The average follow-up was 7.7 ± 3.6 years and 107 
(26%) patients died during follow-up. Adjusted analyses showed that metformin users 
had a lower overall mortality (HR=0.47; 95%CI:0.29-0.74), while insulin users had a higher 
overall mortality (HR=1.85; 95%CI:1.09-3.15) compared to non-users. However, when 
assessing dose-response effects no association was found between cumulative use of 
metformin, SU, insulin or other GLDs and mortality.
Conclusions
No association between cumulative exposure to metformin, SU, insulin and other GLDs 
and overall mortality was found. However, metformin users did have a lower, while 
insulin users had a higher overall mortality risk which is likely to be a result of different 
patient characteristics.
Introduction
Both cancer and diabetes belong to the most common chronic diseases worldwide, and 
both diseases are among the leading causes of death with 8.2 million and 1.5 million 
deaths in 2012, respectively1. Among women, breast cancer is the most common cancer 
and in 2012 there were 1.7 newly diagnosed breast cancer patients worldwide2. As both 
breast cancer and diabetes are common, they often co-occur; diabetes is prevalent in 
16% of breast cancer patients3,4. Previous studies showed higher mortality rates among 
cancer patients with diabetes compared to those without diabetes4-6, with increased 
mortality rates of up to 40% for women with postmenopausal breast cancer6.
Numerous studies observed an association between diabetes and an increased risk of 
breast cancer among postmenopausal women7-9. In part, this association might be the 
result of high serum insulin levels, which are known to have a direct mitogenic effect 
on normal mammary cells9. In addition, insulin receptors, which are overrepresented 
on breast cancer cells, have been associated with increased tumor size and grade at 
cancer diagnosis and increased mortality9. This insight resulted in major attention for 
the potential anti-mitogenic effect of the glucose lowering drug (GLD) metformin, as 
metformin improves insulin sensitivity of the peripheral tissue by increasing insulin-
stimulated glucose uptake in skeletal muscle tissue and adipocytes and lowering the 
hepatic glucose output10,11.
Most recent research focused on the protective effect of metformin on breast cancer 
incidence12, while the effects of metformin on tumor progression and mortality are 
less well understood. A few studies indicated that metformin might reduce tumor cell 
growth13,14. However, inconsistent results regarding the effect of metformin and other 
GLDs on mortality were found in observational studies15-23. The majority of studies 
included patients with diabetes at breast cancer diagnosis and found no association 
between metformin use and mortality15,17,18,20,21, but four studies did observe reduced 
mortality rates ranging between 24% and 53% among metformin users16,19,22,23. 
Furthermore, several studies assessed the effect of other GLDs on mortality, but also 
reported inconsistent results16-18,21,23. Other studies, showed that sulfonylurea derivative 
(SU)18,23 or insulin use18,21 was associated with increased mortality while one study showed 
that thiazolidinediones were associated with lower mortality16. Contrasting results were 
found in another study that reported no association between metformin, SU, insulin 
or other GLD use and mortality17. Comparison of previous results is complex as these 
studies included different disease subtypes (i.e. HER2+16, triple-receptor negative15 or 
all types of breast cancer patients17-23), used varying definitions of GLD exposure and 
applied different statistical techniques. Moreover, only one study included patients 
who developed diabetes after breast cancer and reported those results separately23. To 
accurately assess a dose-response relationship, the study sample should be restricted 
to those with incident diabetes. Moreover, as diabetes has been associated with cancer 
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incidence12, GLD use prior to cancer diagnosis might influence patients prognosis as 
patients with diabetes might present with a more advanced cancer stage at diagnosis24.
Therefore, the aim of this study is to assess the effect of GLD use after breast cancer 
diagnosis on overall mortality. Based on the results of previous studies, we hypothesize 
that (cumulative) exposure to metformin after breast cancer diagnosis will result in a 
lower, while exposure to SU and insulin will result in higher overall mortality.
Methods
Data sources
Data were collected from the Netherlands Cancer Registry (NCR) and linked to the 
PHARMO Database Network (PHARMO), covering a demographic region in the South-
East of the Netherlands of approximately one million inhabitants. The linkage between 
PHARMO and the NCR was performed for cancer patients diagnosed from 1998 onwards. 
The construct and validity of the linkage between the NCR and PHARMO is described 
in detail elsewhere25.
The NCR records all newly diagnosed cancer patients, for this study data from an area 
with 2.4 million inhabitants, 10 hospitals, 6 pathology departments and 2 radiotherapy 
institutions in the South of the Netherlands was used. Trained registrars routinely collect 
data on cancer diagnosis, stage, primary treatment, receptor status and comorbidity at 
time of cancer diagnosis. The PHARMO Database Network is a population-based network 
of healthcare databases and combines data from different healthcare settings in the 
Netherlands. These different data sources, including general practitioner, in- and out-
patient pharmacy, clinical laboratory, hospitals, pathology registry and perinatal registry, 
are linked on a patient level through validated algorithms. The Out-patient Pharmacy 
Database comprises GP or specialist prescribed healthcare products dispensed by the 
out-patient pharmacy. The dispensing records include information on type of product, 
date, strength, dosage regimen, quantity, route of administration, prescriber specialty 
and costs. In the Netherlands, studies with anonymized patient records do not fall under 
the scope of the Medical Research Involving Human Subjects Act. This study is therefore 
exempt from medical ethics review.
Study population
All female breast cancer patients diagnosed in the South of the Netherlands between 
January 1st, 1998 and December 31st, 2011 were selected from the NCR and linked to 
PHARMO. All incident users of GLDs (i.e. with Anatomical Therapeutic Chemical (ATC)-
code A10) after breast cancer diagnosis were selected. Incident users of GLDs were 
defined as patients who had at least six months of history prior to breast cancer diagnosis 
and did not use GLDs in these months.
Exposure and outcome
The ATC classification code was used for selection of metformin (A10BA02), SUs (A10BB), 
insulin (A10A) and other GLD (all other A10 codes) use26. The number of cumulative days 
of exposure to GLDs since the start of GLD use, was calculated from the dispensing data 
available from PHARMO. For insulin, the duration of use was not recorded and was set 
to 90 days for each dispensing. In periods of non-use the cumulative exposure up to the 
last prescription remained unchanged. Overall mortality was obtained from the municipal 
personal records database. Follow-up time was measured from breast cancer diagnosis 
until death, loss to follow-up, or until the end of the study period at 31 December 2012, 
whichever occurred first.
Covariates
Age at breast cancer diagnosis, primary cancer treatment (i.e. surgery, radiotherapy, 
chemotherapy and/or hormone treatment), TNM stage , hormone receptor status, and 
comorbidity at breast cancer diagnosis were retrieved from the ECR. The first date of 
statin and aspirin use after cancer diagnosis was retrieved from PHARMO and both statin 
and aspirin were modelled as time-dependent dichotomous variables. The calendar year 
of breast cancer diagnosis was included as a covariate as well.
Statistical analyses
Baseline characteristics of metformin, SU, insulin and other GLD users were presented. 
Time dependent Cox regression models were constructed, in which the time between 
breast cancer diagnosis and end of follow-up was the underlying time scale. Patients 
started using GLDs at different times after breast cancer diagnosis, which might impose 
survivorship bias (i.e. patients who die shortly after cancer diagnosis are missed in these 
analyses), therefore, the data was left truncated at the time of GLD initiation. To assess 
differences between users and non-users of GLDs a model was used that included 
time dependent ever/never terms for the use of metformin, SU, insulin and other GLDs 
(i.e. a GLD user was, and remained, classified as exposed after the first prescription 
of the respective drug). The main Cox regression analysis to study a possible dose 
response effect of GLD use, included cumulative exposure to GLDs (per year) modeled 
as time varying covariates. This model additionally included the time varying binary 
variables terms for all GLDs (ever/never use), to distinguish between the exposed and 
unexposed groups as has been previously recommended27. To further explore dose-
response associations, we modelled all GLDs in categories of short (<2 years) and long-
term (≥2 years) use. Results of unadjusted models as well as models adjusted for age at 
breast cancer diagnosis, calendar year of breast cancer diagnosis, cancer stage, cancer 
treatment (i.e. surgery, radiotherapy, chemotherapy or hormone therapy) and statin 
and aspirin use (i.e. modelled as time-dependent binary terms for ever/never use) were 
reported.
Sensitivity analyses
To assess the robustness of our findings, several sensitivity analyses were performed. As 
breast cancer patients with a positive hormone receptor status (Estrogen Receptor (ER) 
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and Progesterone Receptor (PR)) have a better prognosis, we conducted a sensitivity 
analysis among those with positive ER and/or PR status. In addition, we additionally 
adjusted for comorbidity at breast cancer diagnosis; this model did not include 
adjustments for aspirin and statin use. Moreover, the adjusted model was analyzed using 
a 6 month time lag, as has been recommended previously28. In this lagged analysis all 
GLD dispensings in the 6 months prior to the end of study or death were not taken into 
account as this possibly reflects end of life care. The last sensitivity analysis was restricted 
to patients with the first GLD prescription >6 months after breast cancer diagnosis, as 
diabetes might be a result of breast cancer treatment29. A P-value <0.05 was regarded 
as statistically significant and all analyses were performed using SAS software (version 
9.3, SAS institute, Cary, US).
Figure 1 Flowchart of the patient selection method
10,546 women diagnosed with breast cancer 
between 1998-2011 were selected from the 
Eindhoven Cancer Registry and linked to the 
PHARMO database 
 
1,114 women had 1 or more GLD dispensing 
(ATC code= A10)  
 
 
407 women were incident users of GLDs after 
breast cancer diagnosis 
 
 
392 women had less than 180 days of follow-
up at breast cancer diagnosis 
 
701 women were prevalent users of GLDs at 




9,074 women had at least 180 days of follow-
up in PHARMO at breast cancer diagnosis 
 
 7,960 had no GLDs dispensings 
 
1,080 women with breast cancer in situ  
were deleted 
 




6 women were excluded as no data on cancer 






In total, for 10,546 women with breast cancer diagnosed between 1998 and 2011 
data on drug use was available, of whom 407 were incident users of GLDs after breast 
cancer diagnosis (Figure 1). Of them 82% (n=335) used metformin, 50% (n=202) used 
SUs, 14% (n=58) used insulin and 10% (n=41) used other GLDs at some point in time 
during follow-up (Table 1). Patients were on average 64.6 years old (SD=11.4) at cancer 
diagnosis. Insulin users were slightly more often diagnosed with cancer stage II (62%) as 
compared to metformin (48%), SU (47%) and insulin users (44%). Seventy percent of the 
included patients had a positive ER status, and 54% had a positive PR status, which did 
not differ between the different GLD users. In addition to GLD use, patients also often 
used statins and aspirins. Other GLD users used statin most often at some time during 
follow-up (83%) which was slightly higher compared with metformin (72%), SU (65%), 
and insulin users (59%). Aspirin was used by 30% of the included patients at some time 
during follow-up. Patients started with GLDs on average 3.5 years (SD=2.8) after cancer 
diagnosis, the mean follow-up time (i.e. between breast cancer diagnosis and end of 
follow-up) was 7.7 years (SD=3.6) and 26% (n=107) died during the study period.
GLD use and overall mortality - ever/never use of GLDs
The ever/never analysis adjusted for age, calendar year, cancer stage, cancer treatment 
(i.e. surgery, radiotherapy, chemotherapy and hormone therapy), statin and aspirin 
use, showed that ever use of metformin and insulin was significantly associated with 
overall mortality with a HR of 0.47 (95%CI:0.29-0.74) and HR of 1.85 (95%CI:1.09-3.15), 
respectively (Figure 2). No effects of SU and other GLD use on mortality was observed 
with HR=1.09 (95%CI:0.71-1.68) and HR=0.34 (95%CI:0.11-1.10), respectively. In sensitivity 
analyses (Table 2) these results were attenuated after restricting the sample to those 
with a positive ER or PR status (HR metformin=0.59; 95%CI:0.29-0.98, HR insulin=1.53; 
95%CI:0.76-3.09) and after the analysis was lagged with 6 months (HR metformin=0.63; 
95%CI:0.35-1.14, HR insulin=1.18; 95%CI:0.57-2.46). After adjustment for comorbidity, 
or the restriction to patients with a first GLD prescription >6 months after breast cancer 
diagnosis, similar results as in the main analyses were found.
GLD use and overall mortality - cumulative exposure to GLDs
Dose-response effects of GLDs were addressed in time-dependent Cox regression 
models that included cumulative exposure, modeled per year of use (Figure 3). Fully 
adjusted models showed no associations between metformin (HR=0.98; 95%CI:0.84-
1.15), SU (HR=0.94; 95%CI:0.80-0.11), other GLD (HR=1.18; 95%CI:0.53-2.62) and insulin 
use (HR=0.83; 95%CI:0.62-1.11) and mortality. After modelling GLD use in categories 
of short and long-term use we found that short-term (<2 years) SU and insulin use was 
associated with an increased mortality with HR=3.12 (95%CI:1.98-4.91) and HR=4.00 
(95%CI:2.32-6.90), respectively, while long-term use (≥2 years) was not (results not 
shown). No effects for either short (<2 years) or long-term (≥2 years) metformin use 
were found. Similar to the ever/never analyses, results were mainly attenuated in analyses 
9
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Total Metformina SUa Insulina Other GLDsa
Mean ± SD or n(%) N=407 N=335 N=202 N=58 N=41
Patient characteristics
Age at cancer diagnosis (years) 64.6±11.4 64.5±10.7 65.3±12.0 63.0±12.5 62.2±7.9
Time between cancer diagnosis 
and start on GLDs in years (years) 3.5±2.8 3.6±2.9 2.9±2.3 2.3±2.0 2.8±2.1
Comorbidity
Lung disease 22 (6) 18 (6) 10 (5) 6 (11) 4 (11)
Cardiovascular disease 71 (19) 60 (19) 38 (20) 12 (22) 7 (19)
Liver disease 3 (1) 3 (1) 0 (0) 0 (0) 0 (0)
Renal disease 1 (0) 1 (0) 1 (1) 1 (2) 1 (3)
Stroke 10 (3) 9 (3) 2 (1) 1 (2) 0 (0)
Missing 28 (7) 24 (7) 12 (6) 4 (7) 5 (12)
Cancer characteristics
Cancer stage
I 157 (39) 129 (39) 78 (38) 14 (24) 19 (46)
II 191 (47) 161 (48) 94 (47) 36 (62) 18 (44)
III 45 (11) 35 (10) 24 (12) 7 (12) 3 (7)
IV 14 (3) 10 (3) 6 (3) 1 (2) 1 (2)
Cancer treatment
Surgery 386 (95) 319 (95) 190 (94) 56 (97) 40 (98)
Radiotherapy 273 (67) 226 (67) 135 (67) 37 (64) 29 (71)
Chemotherapy 100 (25) 80 (24) 47 (23) 19 (33) 10 (24)
Hormone therapy 205 (50) 172 (51) 94 (47) 31 (53) 16 (39)
Estrogen receptor
Negative 41 (10) 35 (10) 21 (10) 5 (9) 2 (5)
Positive 284 (70) 239 (71) 141 (70) 39 (67) 29 (71)
Missing 82 (20) 61 (18) 40 (20) 14 (24) 10 (24)
Progesterone receptor
Negative 74 (18) 64 (19) 39 (19) 6 (10) 4 (10)
Positive 220 (54) 183 (55) 109 (54) 32 (55) 22 (54)
Missing 113 (28) 88 (26) 54 (27) 20 (34) 15 (37)
GLD usea
Metformin 335 (82) 335 (100) 145 (72) 41 (71) 37 (90)
Sulfonylurea derivatives 202 (50) 145 (43) 202 (100) 34 (59) 31 (76)
Other GLDs 41 (10) 37 (11) 31 (15) 14 (24) 41 (100)
Insulin 58 (14) 41 (12) 34 (17) 58 (100) 14 (34)
Co-medicationa
Statin use 266 (65) 241 (72) 132 (65) 34 (59) 34 (83)
Aspirin use 123 (30) 104 (31) 63 (31) 13 (22) 8 (20)
Table 1 Baseline characteristics of the study population
aEver use of the respective drug during follow-up
restricted to those with positive ER or PR status and in the lagged analysis, however all 
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Discussion
This study showed that breast cancer patients who used metformin after cancer diagnosis 
have a 53% lower overall mortality compared to breast cancer patients on other GLD’s. 
However this might be a result of selection bias, as no effect of cumulative exposure 
to metformin on overall mortality was observed. This suggests that metformin users 
might have different characteristics that are associated with a better prognosis and 
that there is no true protective drug effect on mortality of metformin itself. Similarly, 
women with breast cancer who used insulin after cancer diagnosis seem to have a higher 
overall mortality as compared to other GLD users, but again no dose-response effect 
was observed. No significant association between SU or other GLD use and mortality 
was observed.
The majority of previous studies included breast cancer patients who used GLDs prior 
to breast cancer diagnosis and results regarding the effect of metformin have been 
inconsistent. Several studies reported no association between metformin use and 
mortality15,17,18,20,21, while some did observe reduced mortality rates among metformin 
users16,19,22,23. An American study among 1,983 HER2+ patients reported a 48% decrease 
in all-cause mortality for users versus non-users of metformin16. But as metformin users 
were classified as exposed from cancer diagnosis on and not from initial drug initiation16, 
immortal time bias may have confounded the observation30,31. Another study among 
1,013 breast cancer patients with and 4,621 without diabetes showed that metformin-
treated patients had the highest 5 year overall survival as compared to non-metformin 
treated diabetes patients and people without diabetes19. But as no dose-response 
effect was studied this could be due to selection bias, with metformin users having 
prognostically better characteristics. In a study among 1,058 breast cancer patients with 
diabetes at breast cancer diagnosis, metformin use was associated with a lower overall 
mortality (HR=0.74; 95%CI:0.58-0.96) but not breast cancer-specific mortality (HR=0.88; 
95%CI:0.59-1.29)22. Moreover, a dose-response effect was observed where a higher 
number of metformin prescriptions (i.e. 21-30 and ≥30 prescriptions) resulted in lower 
mortality, but results for other GLDs than metformin were not separately reported22. 
All these previous studies included breast cancer patients with diabetes prior to breast 
cancer diagnosis, and drug use was only taken into account from cancer diagnosis 
onwards, and thus dose-response relationships could not be assessed accurately.
Only one previous study, conducted by us using data from the UK, included 706 patients 
who started using GLDs after breast cancer diagnosis. In this study we applied time-
dependent Cox regression models to avoid immortal time bias, reported results for 
separate GLDs and assessed cumulative drug exposure, however, data on cancer stage 
was limited and no information regarding receptor status was available23. In that study, 
cumulative exposure to metformin (per year of exposure) was associated with a lower 
breast cancer specific mortality with a HR of 0.73 (95%CI:0.56-0.96) but, similar to our 
results, not with overall mortality23. However, in line with this study an increased mortality 
risk among short-term SU users (HR=3.51; 95%CI:2.04-6.06) was found23. This result 
is counterintuitive and it is likely that other factors that were not adjusted for might 
have confounded the findings. Possibly more patients with advanced cancer might have 
switched to SUs, as SUs are often preferred in the palliative phase instead of metformin 
due to possible gastro-intestinal side effects32.
Although we did not observe a statistically significant association between cumulative 
metformin use and mortality, several pre-clinical studies show that metformin suppresses 
breast cancer cell growth33,34. Metformin is suggested to directly inhibit cell growth due 
to activation of the AMPK protein kinase, which results in activation of the MTOR protein 
kinase and a decreased translation initiation33,34. In addition, metformin might inhibit 
breast cancer cell growth indirectly, due to reduced insulin levels and deactivation of 
IGF-1 receptors35, which is possibly associated with lower mortality36. Finally, lower IGF-1 
levels might inhibit the signaling protein Cyr61 which in turn, suppresses breast cancer 
cell growth and invasion37.
In this study we observed lower mortality among metformin users and higher mortality 
among insulin users, however, this is likely to be a result of selection bias, i.e. the different 
patient characteristics of different GLD users. The choice to prescribe a certain drug is 
depending on other factors that were not taken into account such as Body Mass Index 
(BMI), contra-indications for the drugs, HbA1c levels, diabetes complications etcetera. 
Thus more studies are needed to understand differences in characteristics of patients 
who start on the different GLDs. Before more observational studies are undertaken, it is 
important to reveal why patients are allocated to the specific drugs as these characteristics 
are likely to influence their mortality risk. 
Strong points of this study include its detailed information on cancer characteristics, 
including hormone receptor status, and drug dispensing, including duration of the 
dispensing. Furthermore, we performed time-dependent analyses to rule out time-
related biases. In addition, this study is one of the first that focused on patients who 
develop diabetes after cancer diagnosis which rules out the possible effect of diabetes, 
and its medication on the development of breast cancer. Despite the large population-
based sample of breast cancer patients, the final selected study population was relatively 
small and no information regarding cancer-specific deaths was available. In addition, we 
did not have information on BMI and diabetes characteristics, including Hba1c levels 
and the presence of complications. Moreover our follow-up period is relatively short for 
a study involving breast cancer patients, who generally have a good prognosis. Longer 
follow-up is necessary to assess the association between metformin and other GLDs and 
mortality in the long run in future studies.
9
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In conclusion, GLDs were not associated with mortality among patients who started using 
GLDs after breast cancer diagnosis. We did observe a lower mortality among those using 
metformin and higher mortality among those using insulin, however, this might be a 
result of differences in patient characteristics that we could not adjust for. Larger studies 
with longer follow-up among patients who start using GLDs after cancer diagnosis are 
needed to establish our findings. Moreover, differences in patient characteristics between 
those allocated to different GLDs should be identified to distinguish a potential true 
drug effect.
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Summary of results
This thesis aimed to assess the dual impact of having both cancer and diabetes on Patient 
Reported Outcomes (PROs) and mortality. The main objectives of this thesis were:
 - To assess the impact of comorbidity, with a main focus on cancer and diabetes, on 
PROs, including Health-Related Quality of Life (HRQoL) and symptoms (Part I)
 - To assess the impact of cancer and diabetes, and the role of lifestyle factors, on 
mortality rates (Part II)
 - To assess the effect of Glucose Lowering Drug (GLD) use on mortality rates among 
breast cancer patients (Part II)
As an introduction to Part I of this thesis, we started with a systematic literature review on 
the impact of cancer and diabetes on PROs in Chapter 2. Besides providing a systematic 
review of the literature in this largely neglected research area, we also proposed a research 
agenda to direct future research. A broad search strategy was used which identified a 
total of 3,553 eligible studies. After selection, only 10 studies were included that studied 
the impact of cancer and diabetes on PROs, of which 8 focused on HRQoL, functioning 
or symptoms, and 2 studies assessed the effects of cancer on diabetes self-management 
among patients with both cancer and diabetes. Results indicated that patients with both 
cancer and diabetes reported mainly lower general health, lower physical functioning 
and lower sexual functioning while prostate cancer patients with diabetes reported 
lower urinary function and lower vitality as compared to patients with either one or 
none of the diseases. Moreover, more problems with diabetes self-management were 
reported among patients with both diseases. However, no firm conclusions could be 
drawn, this was mainly due to the low number and heterogeneity of the included studies. 
We identified several important research topics for future research. For example, we 
suggest that more research is needed on the impact of having both diseases on mental 
health, as depression is highly prevalent among both cancer and diabetes patients. 
Moreover, as the occurrence of multiple chronic diseases poses important constraints on 
a person’s life and their health care, future research should focus on the self-management 
of both diseases. Patients need to be able to manage the treatment, symptoms, and 
psychological consequences of having both diseases.
Research shows that the presence of comorbidity is associated with decreased HRQoL 
among cancer patients. However, its relative impact on HRQoL as compared with 
sociodemographic and clinical characteristics is rarely studied. Therefore, we assessed 
the variance in HRQoL explained by comorbidity as compared with sociodemographic 
and clinical characteristics in Chapter 3. To determine whether results are similar for 
different cancer types we investigated this among colorectal cancer, thyroid cancer and 
(non-) Hodgkin’s lymphoma patients. We found that the number of comorbid conditions 
explained more of the variance in physical functioning (11-17%), emotional functioning 
(7-17%), pain (7-20%) and fatigue (11-13%) compared with both sociodemographic 
and cancer characteristics (0-4%) among all studied cancer types. Assessing the effect 
of individual comorbidities on HRQoL showed that particularly heart disease and back 
pain explained most variance in physical function (ranging between 2 and 4%), while 
depression explained most variance in emotional functioning (12 and 8%) among 
colorectal and non-Hodgkin’s lymphoma patients, respectively. 
Previous studies among cancer patients showed that these patients experience worse 
HRQoL as compared with a healthy population, and also, sexual problems are highly 
prevalent. Similar results are found among diabetes patients. Thus, both cancer and 
diabetes are independently associated with worse HRQoL and sexual dysfunctioning. 
However, we hypothesized that having both cancer and diabetes may result in even 
worse outcomes. Therefore, we assessed the individual and combined effects of 
colorectal cancer and diabetes on HRQoL and sexual functioning in Chapter 4. Data 
from a colorectal cancer population with (CRC+DM+) and without diabetes (CRC+DM-) 
and a normative population, with (CRC-DM+) and without diabetes (CRC-DM-) aged ≥60 
years were used. In general, CRC-DM- patients reported highest functioning and lowest 
symptoms followed by CRC-DM+, CRC+DM- and CRC+DM+ patients. No interaction 
between colorectal cancer and diabetes was observed, indicating that having both 
diseases did not result in worse outcomes than the sum of the individual effects of 
colorectal cancer and diabetes, contrary to our expectation. Colorectal cancer seemed 
to be stronger associated with worse outcomes, as it was independently associated with 
the majority of HRQoL subscales. However, diabetes was also independently associated 
with lower physical functioning and more symptoms of dyspnea. 
Next, to investigate whether treatment-related toxicities were more prevalent among 
cancer patients with versus without diabetes, we assessed differences in neuropathic 
symptoms between CRC+DM+ patients and age and sex-matched CRC+DM- patients, 
using cross-sectional data (Chapter 5). As results of previous research suggest that 
cancer patients with diabetes are often less aggressively treated with chemotherapy 
than those without diabetes, we additionally aimed to investigate whether there were 
differences in type of cancer treatment. CRC+DM+ patients experienced more mild to 
severe neuropathic symptoms including tingling fingers or hands (Odds Ratio (OR)=1.40; 
95% confidence interval (CI): 1.00-1.94), tingling toes or feet (OR=1.47; 95%CI: 1.04-2.07), 
numbness in toes or feet (OR=1.83; 95%CI: 1.28-2.62) and erection problems among men 
(OR=1.83; 95%CI: 1.11-3.03) as compared to CRC+DM- patients. However, no differences 
in cancer treatment were found between both groups. 
As cancer and diabetes share several lifestyle-related risk factors, including a high Body 
Mass Index (BMI), low physical activity, smoking and excessive alcohol consumption, in 
Chapter 6 we investigated whether lifestyle factors differed between cancer patients with 
and without diabetes. We also studied whether these lifestyle factors could explain the 
differences in HRQoL between CRC+DM+ and CRC+DM- patients. We used longitudinal 
data collected in 2010, 2011 and 2012 for this purpose. At baseline, CRC+DM+ patients 
had a higher BMI (29.1±4.2 vs. 26.4±3.7 kg/m2), moreover, the number of alcohol users 
10
Chapter 10 General discussion 169168
10
was lower (50 vs 70%) as compared to CRC+DM- patients. No differences in moderate-
to-vigorous physical activity (MVPA) and smoking were observed between the two 
groups. Adjusted analyses of the longitudinal data showed that CRC+DM+ patients 
reported significantly lower physical function (beta-5.76; SE=1.67), global QoL (beta-
4.31; SE=1.48) and more symptoms of fatigue (beta=5.38; SE=1.95) as compared to 
CRC+DM- patients. However, these effects disappeared after adjustments for lifestyle 
factors; BMI, MVPA, smoking and alcohol use were all significant predictors of HRQoL. 
The association between diabetes and HRQoL was further attenuated after additional 
adjustments for comorbidity.
In Part II of this thesis we studied the potential dual impact of having both cancer and 
diabetes on mortality. As only a few previous studies that adjusted for lifestyle factors 
found an increased mortality risk for CRC patients with versus without diabetes, we 
aimed to assess whether lifestyle factors, including BMI, MVPA, smoking, and alcohol 
consumption, explain the increased mortality rates among CRC patients with diabetes 
(Chapter 7). Independent effects of lifestyle factors as well as effects of different lifestyle 
clusters were identified and associated with mortality. Four different lifestyle clusters 
were identified which were labeled as (1) healthy, (2) moderately healthy, (3) overweight 
and (4) smoking. CRC+DM+ patients had a 29% higher mortality risk as compared to 
CRC+DM- patients. After adjustments for BMI, MVPA, smoking and alcohol use, this 
effect was slightly attenuated to non-significance (Hazard ratio (HR)=1.24; 95%CI: 0.98-
1.56), but remained after adjustments for the lifestyle clusters (HR=1.29; 95%CI: 1.02-
1.61). Alcohol use, MVPA and being overweight were all independently associated with 
a decreased mortality risk, while smoking was associated with an increased mortality 
risk. Moreover, the lifestyle cluster with patients who smoke, with low MVPA and low BMI 
had a 3.7 fold increased mortality risk as compared with those with a healthy lifestyle.
Recent literature shows that metformin, a GLD used as first-line treatment among diabetes 
patients, potentially decreases the risk of cancer and possibly improves outcomes among 
patients with both cancer and diabetes. We aimed to assess the effect of GLDs, including 
metformin, sulfonylurea derivatives, insulin and other GLDs, on mortality among breast 
cancer patients from the United Kingdom (UK) and the Netherlands in Chapter 8 and 
Chapter 9, respectively. In Chapter 8, we included women who started using GLDs prior 
to breast cancer as well as women who started using GLDs after breast cancer diagnosis. 
This study showed some evidence of lower breast cancer-specific and all-cause mortality 
for metformin users among breast cancer patients who started GLDs prior to breast 
cancer diagnosis. Results were mainly apparent among patients with long-term (i.e. ≥2 
years) metformin use, with HR=0.47 (95%CI:0.26-0.82) and HR=0.70 (95%CI:0.49-0.99) 
for breast cancer-specific and all-cause mortality, respectively. Among patients who 
started using GLDs after breast cancer diagnosis, cumulative metformin use was also 
associated with lower overall mortality, while sulfonylurea derivative use was associated 
with substantial higher breast cancer-specific and all-cause mortality. As in the UK sample 
no (complete) data on breast cancer stage and other clinical details such as estrogen or 
progesterone receptor status were available, we conducted these analyses also within 
a sample from the Netherlands that included information on stage and receptor status 
(Chapter 9). As relatively little is known on mortality risk among patients who start 
using GLDs after breast cancer diagnosis, only those patients were included. Using time-
dependent Cox regression analyses, this study found a lower mortality among patients 
using metformin (HR=0.47; 95%CI: 0.29-0.74) and a higher mortality among patients 
using insulin (HR=1.85; 95%CI:1.09-3.15) as compared to non-users. However, no clear 
association between cumulative use of any GLD on overall mortality was observed. Thus 
the found effects are likely to result from factors other than GLDs, such as BMI, glycemic 
control, diabetes complications and differences in diabetes severity, as metformin is 
prescribed earlier in the disease course.
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General discussion
As a result of the aging of the population, the prevalence of both cancer and diabetes 
is rapidly increasing1,2. Subsequently, an increasing number of individuals will have both 
cancer and diabetes. The number of cancer patients with diabetes at cancer diagnosis 
in the Netherlands was expected to drastically increase from 5,500 in 2000 to 10.000 in 
20153. Up to now, the dual impact of cancer and diabetes on Patient Reported Outcomes 
(PROs) has rarely been studied. PROs are used as an umbrella term and include a wide 
range of different measurements that reflect patients’ perspectives, and include for 
example Health-Related Quality of Life (HRQoL), perceived symptoms and satisfaction 
with health care.  Moreover, as previous research shows that cancer patients with diabetes 
have a 40% higher mortality risk4, it is important to study which factors contribute to this 
increased mortality. This information may guide future interventions that help to improve 
HRQoL and reduce mortality. Thus, in order to improve outcomes among patients with 
both cancer and diabetes, this thesis aimed to assess the dual impact of cancer and 
diabetes on PROs and mortality.
The dual impact of cancer and diabetes on PROs and mortality
In this thesis we showed that the impact of cancer and diabetes on PROs is largely 
neglected in current literature. The studies that did assess PROs primarily focused 
on HRQoL, while other PROs such as symptoms of pain and fatigue and emotional 
functioning including anxiety and depression were neglected. In our own research, 
we observed that having both cancer and diabetes results in worse HRQoL, more 
neuropathic symptoms and an increased mortality risk as compared to having only 
cancer, only diabetes and/or neither of both diseases. In the following paragraphs we 
will present possible explanations for the worse outcomes found among cancer patients 
with concurrent diabetes.
The influence of cancer stage at diagnosis, treatment and disease progression on 
deteriorated outcomes
Previous research suggests that cancer patients with diabetes present with a higher 
cancer stage at diagnosis5-7, possibly as a result of the underuse of screening8. This was 
mainly found among breast cancer patients5-7 while the evidence was less convincing 
among colorectal cancer patients7,9. However, in our colorectal cancer sample, cancer 
patients with diabetes did not present with a more advanced cancer stage at diagnosis, 
while we did observe deteriorated outcomes among patients with both diseases. A 
more plausible explanation for the deteriorated outcomes among patients with both 
cancer and diabetes may lie within the received cancer treatment. Research showed 
that esophageal, colon, breast and ovary cancer patients with diabetes often received 
less aggressive treatment7. However, in our study described in the present thesis we 
did not find differences in the receipt of chemotherapy, radiotherapy and surgery 
in the six months after cancer diagnosis between cancer patients with and without 
diabetes. We also observed that colorectal cancer patients with diabetes reported more 
neuropathic symptoms, which is in accordance with previous studies that found more 
toxicities related to radiotherapy or chemotherapy among cancer patients with versus 
without diabetes6,10. It is possible, that among cancer patients with diabetes, the doses 
for certain chemotherapeutic agents have been adjusted or that patients were switched 
to a different type of chemotherapeutic agent as a result of these treatment-related 
toxicities. Especially taxanes and platinum derived chemotherapeutic agents such as 
oxaliplatin are known to induce these neuropathic symptoms11. Unfortunately, we had 
no data regarding the type and dose of chemotherapeutic agent used. Thus it remains 
possible that cancer patients with diabetes are less aggressively treated by alterations 
in the dose and type of agents, which might result in an increased risk for cancer 
progression and recurrence. At the same time, the higher prevalence of neuropathic 
symptoms and treatment-related toxicities may have resulted in worse HRQoL. Previous 
research concluded that neuropathic symptoms are common up to 11-years after cancer 
diagnosis and having these symptoms results in worse HRQoL12. Further research should 
assess whether differences in dose and type of chemotherapeutic agents explain the 
deteriorated outcomes (i.e. both PROs and mortality) among cancer patients with 
diabetes as compared to patients without diabetes. And if so, it should be assessed 
whether these alterations in chemotherapeutic schedule outweigh the risk for cancer 
progression and mortality.
The influence of lifestyle on deteriorated outcomes
Cancer and diabetes share several lifestyle-related risk factors including overweight and 
obesity, physical inactivity, poor dietary habits and smoking13. Besides influencing the risk 
of developing both diseases, lifestyle-related risk factors may also impact negatively on 
outcomes among patients with both diseases. Previous studies showed that overweight 
and obesity, physical inactivity, smoking and excessive alcohol consumption are all 
independently associated with worse HRQoL14-20 and increased mortality21-28 among both 
cancer and diabetes patients. In this thesis we observed that lifestyle factors did explain 
the worse HRQoL found among patients with both cancer and diabetes. The lower 
physical functioning and HRQoL and higher levels of fatigue found among colorectal 
cancer patients with diabetes disappeared after adjustments for BMI, MVPA, smoking and 
alcohol use in longitudinal analyses. Thus, in order to improve HRQoL among patients 
with both diseases, lifestyle improvements seem to be crucial, yet further experimental 
research is needed to test this hypothesis.
In contrast, we also showed that the increased mortality rates found among cancer 
patients with diabetes could not be explained by lifestyle factors. Even after adjustments 
for BMI, MVPA, smoking and alcohol use, colorectal cancer patients with diabetes had 
a 29% higher mortality risk as compared to those without diabetes. Thus, the increased 
mortality found among cancer patients with diabetes is not fully explained by lifestyle 
and therefore it is likely that other factors are involved. As previously discussed, the 
increased mortality could be due to clinical factors including the underuse of screening, 
less aggressive cancer treatment, and more treatment-related toxicities among cancer 
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patients with diabetes. Moreover, as previous research shows that cancer patients with 
diabetes perform less diabetes related self-management activities29, cancer patients with 
diabetes may prioritize their cancer care over there diabetes care. In turn, this may lead to 
more diabetes-related complications resulting in worse prognostic outcomes. Although 
differences in mortality between cancer patients with and without diabetes were not 
(fully) explained by lifestyle, individual factors such as being overweight, high MVPA, and 
moderate alcohol use were associated with lower mortality while smoking was associated 
with higher mortality. Thus, regardless of having diabetes, lifestyle improvements might 
reduce mortality among cancer patients.
The effect of glucose lowering drugs on mortality after breast cancer
Currently, the evidence regarding the effects of metformin and other GLDs on mortality 
among breast cancer patients is inconclusive. Some previous studies reported a protective 
effect of metformin on mortality30-32 while others found no effect33-37. Several of these 
studies may have been influenced by different types of bias which are discussed later 
in this chapter. Only one previous study35 used a time-dependent analysis to adjust for 
immortal time bias, included a measure of cumulative exposure and reported results 
for different GLDs similar to the analyses in this thesis. This Canadian study observed 
that metformin and any of the other GLDs was not associated with mortality rates in 
breast cancer patients35. In the study that is described in the present thesis, based on 
a large UK dataset, we observed a protective effect of metformin on mortality, mainly 
among patients who developed diabetes after their cancer diagnosis and among long-
term users of metformin. However, these results were not confirmed in similar analyses 
among a Dutch sample, although this can possibly be explained by a small sample 
size and a possible lack of power. In order to obtain a definite answer regarding the 
potential effects of metformin on mortality among breast cancer patients, there is 
still a need for additional, large and well-designed observational studies. One way to 
achieve this is by combining different data sources. Furthermore, although laboratory 
studies and observational studies show potential beneficial effects on cancer prevention 
and prognosis, the mechanism of action of metformin needs to be further elucidated. 
Currently numerous randomized controlled trials (RCTs) are being conducted among 
breast cancer patients and the majority focus on the efficacy of metformin during cancer 
treatment38. Another ongoing RCT among breast cancer patients without diabetes 
administers daily metformin till 5 years after cancer diagnosis39,40. This study assesses 
the effect of metformin use versus placebo on cancer free survival, of which the results 




The lower PRO scores among persons with both cancer and diabetes may have been 
influenced by selection bias. Even though participants were selected from a population-
based sample and initial response rates in the studies presented in this thesis were 
relatively high (i.e. ranged between 67 and 73%), selection bias could have occurred. 
To explore the representativeness of the data, we compared data on sociodemographic 
and clinical characteristics between respondents and non-respondents. We found that 
in general more males responded and that respondents were younger. Moreover, it is 
possible that non-respondents had more complications at cancer diagnosis, had a poorer 
general health to start with or may have deceased prior to the study as patients were 
selected between 1 and 10 years after cancer diagnosis. Furthermore, our findings may 
also have been biased by attrition bias as a result of loss to follow-up. By comparing 
colorectal cancer patients who completed 1 versus 2 or more questionnaires, we showed 
that, as expected, those who completed 1 questionnaire had a lower educational level, 
engaged less in physical activity and reported worse overall HRQoL and physical 
functioning17. It remains a challenge to maintain high response rates and minimize loss 
to follow-up. A more personal invitational approach, for example via telephone contact, 
could possibly improve response rates in future studies, although these strategies are 
time consuming and more expensive. Moreover, future studies should also focus on 
the reasons for participants drop-out to identify barriers for participation. In addition, 
the difference in disease progression and survival between respondents and non-
respondents should be compared in order to gain more insight into the degree of 
selection bias.
Immortal time bias 
One of the most criticized biases among research on the effect of metformin and other 
GLDs on mortality is immortal time bias41. Several of the previous observational studies 
that found a remarkably decreased mortality, ranging between 34 and 62%, among 
metformin users appear to have been influenced by immortal time bias30,41-44. These 
studies classified metformin users as users from cancer diagnosis onwards and not 
from the time of actual drug initiation. Thus in the period between cancer diagnosis 
and drug initiation, death could not occur; a period of ‘immortal time’ was initiated as 
the patient stayed alive at least until the first drug dispensing. This bias is known to 
result in a higher protective effect than the true drug effect45. A more optimal statistical 
analysis that can avoid immortal time bias is a time-dependent Cox regression analysis 
in which the exposure to the drug remains zero until the first drug dispensing. These 
time-dependent analyses have been applied in this thesis.
Confounding by disease severity
The studies that assessed the effects of different drugs on mortality among diabetes 
patients may have been confounded by disease severity. Currently in the Netherlands, 
metformin is used as a first choice in the treatment of type 2 diabetes46 and is therefore 
used earlier in the disease course than other GLDs. Thus, patients who are treated with 
metformin only, generally have a lower diabetes severity and often a better glycemic 
control. Subsequently these patients may have better outcomes than those who received 
add-on treatments or switched to other GLDs such as insulin. These differences in 
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the allocation of GLDs may be (partly) responsible for the found protective effects of 
metformin in previous studies that used a dichotomous variable for metformin use versus 
non-use30,42,43. We confirmed that confounding by disease severity had occurred in this 
thesis as we observed a lower mortality among metformin users as compared to non-
users, while no effect of cumulative exposure to metformin was observed. This indicates 
that metformin users had more favorable characteristics at baseline as compared to 
users of other GLDs.
To avoid confounding by disease severity it is essential to consider cumulative exposure 
to the drugs as was done in this thesis. The cumulative drug exposure represents the daily 
or monthly drug use and thus we modelled the effect of each additional day or month 
of use on mortality. These analyses were adjusted for the difference between the users 
and non-users of the drugs. Although we included cumulative exposure to the drugs, 
we did not take the dosage of the drugs into account. As the dosage of GLDs can vary 
strongly during the course of disease, this asks for far more complex statistical analyses. 
Moreover, datasets with detailed and accurate information regarding the dosage need 
to be available. However, even after considering cumulative exposure and dosage of 
GLDs in observational studies, residual confounding remains. Therefore ongoing trials 
could provide more insight into the dose-response effect of metformin. The majority of 
ongoing trials on the effect of metformin among cancer patients use conventional doses 
of metformin, while preclinical studies that report a beneficial effect for metformin use 
considerably higher doses47,48. Thus results of these ongoing trials should be awaited to 
see whether conventional doses of metformin are also associated with decreased tumor 
progression and mortality. At the same time several current ongoing trials that test the 
effect of metformin during cancer treatment on tumor response, activity or time to cancer 
progression are studying the maximum tolerable dose of metformin49.
Strengths and limitations of the data sources
Netherlands Cancer Registry
The studies that are described in this thesis are based on different data sources, which 
have several methodological strengths and weaknesses. The majority of studies were 
based on routinely collected data from the Netherlands Cancer Registry (NCR) on all 
newly diagnosed cancer patients in the South of the Netherlands (formerly known as the 
Eindhoven Cancer Registry (ECR)). This area comprises an area of 2.4 million inhabitants 
served by 10 community hospitals50. Detailed clinical data regarding cancer diagnosis, 
stage and primary treatment are available. Since 1995, the ECR registers comorbidity at 
cancer diagnosis51, which is unique as compared to other cancer registries in the world. 
Although data regarding comorbidity including diabetes were collected, no information 
regarding diabetes type, complications, blood glucose levels and diabetes severity were 
available. Moreover, data on systemic primary cancer therapy were available, but we had 
no details on the type of agent, dosage and treatment regimen used. Although we did 
not observe differences in cancer treatment between cancer patients with and without 
diabetes, it is possible that doses were adjusted or treatments were ended early. These 
modifications in dosage and treatment regimen may have influenced the differences 
found in neuropathic symptoms, HRQoL or mortality between cancer patients with and 
without diabetes, as investigated in this thesis.
PROFILES registry
PROs were collected using the Patient Reported Outcomes Following Initial treatment 
and Long-term Evaluation of Survivorship (PROFILES) registry52. For our analyses we 
mainly used longitudinal data from a cohort of colorectal cancer patients diagnosed 
between 2000 and 2009. Thus at the time of the first data collection in 2010, patients 
were between 1 and 10 years after cancer diagnosis. A strength of this dataset is the 
relatively large population-based sample that results in large statistical power. Moreover, 
the data is linked to clinical data from NCR. Furthermore, longitudinal data on HRQoL, 
symptoms, and lifestyle were collected in 2010, 2011 and 2012 which enabled us to 
look at changes over time. In addition, the response rates were relatively high, with a 
73% response rate at the first wave in 2010. This is much higher than the 40% average 
response rate for mailed cross-sectional surveys found in an earlier meta-analysis53. After 
the initial data collection, the response rates dropped to 55% and 49% for the second 
wave in 2011 and third wave in 2012, respectively, with mainly the healthiest patients 
continuing to participate in the study. The invitation letter for the study was sent from 
the hospital by the (ex-) attending specialist of the patient, which may have resulted in 
the high initial response rate. Patients may have developed a good relationship with 
their specialist and may have felt more motivated to participate. Nevertheless, it remains 
a challenge to encourage patients to participate continuously in longitudinal studies. 
Recently our research group investigated whether a monetary incentive can increase 
the response rate (results have not been published yet). In this study, patients who were 
asked to complete a third questionnaire in a longitudinal study received a 10 euro gift 
card which increased the overall response from 66% to 90%. In addition, patients who 
received the monetary incentive responded quicker. Thus sending a monetary incentive 
may outweigh the cost of sending reminders.
However, one of the main limitations of the data used in this thesis is that the collection 
of PROs started shortly or even up to years after cancer diagnosis and treatment, so 
no information on PROs before cancer diagnosis was available. Without a measure 
prior to the cancer treatment it is unknown whether the found deteriorated outcomes 
are a result of the studied predictors, the cancer treatment, or whether they can be 
explained by differences in patient characteristics that existed prior to cancer diagnosis. 
Moreover, cancer patients may have adjusted several lifestyle behaviors shortly after 
cancer diagnosis, they might have improved their dietary habits, quitted smoking and/
or increased their physical activity as has been seen in a previous study54. This could 
have influenced the findings in this thesis. Currently our research group is planning to 
start a new prospective PRO data collection in the fall of 2015 among colorectal cancer 
patients in 4 hospitals in the south of the Netherlands. This study will assess PROs directly 
after cancer diagnosis and prior to cancer treatment which will help to explore changes 
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in PROs and lifestyle behaviors around cancer diagnosis. At the same time the impact 
of cancer treatment on PROs can be evaluated. Another limitation in our data is that 
misclassification regarding diabetes status may have occurred as having diabetes was 
self-reported in the majority of studies presented in this thesis. However, in community 
dwelling elderly self-reports on several chronic diseases were fairly accurate with an 
accordance of 98% between the self-reports and records of the general practitioner for 
diabetes55. Moreover, undiagnosed or untreated diabetes patients may have been missed. 
Misclassification also could have occurred as cancer treatment can result in transient 
diabetes. A previous study among colorectal cancer patients observed that 12% of the 
patients developed diabetes, during or shortly after chemotherapy treatment, of whom 
17% returned to normal blood glucose levels during follow-up56. Finally, no information 
regarding the type of diabetes, complications or severity of diabetes was available.
Data on glucose lowering drugs
In this thesis, data regarding GLD use in the Netherlands were retrieved from the 
out-patient pharmacy database from the PHARMO database network. PHARMO has 
previously been linked to clinical data from the NCR covering a demographic area of 
approximately 1 million inhabitants in the south-east of the Netherlands. For the linkage 
a validated algorithm that used multiple variables for matching, including patients’ 
initials, last name and their most recent zipcode, was used57. The outpatient pharmacy 
database comprises information regarding type of product, date of dispensing, dosage, 
and quantity. The linkage between PHARMO and the NCR provides us with unique 
information, and the linkage is annually updated, resulting in longer follow-up of existing 
cancer patients each year. Although we had detailed information regarding dispensed 
products, we cannot ascertain whether the dispensed products were actually ingested 
by the patients. A previous study compared pharmacy records with a home inventory 
and interview and showed that 85% of the drugs in use based on the pharmacy records 
were also in use at the home inventory58. The misclassification that does occur is likely 
to result in an underestimation of the true intake58. Thus pharmacy records seem to 
be fairly reliable data sources to estimate drug use. Moreover, the sample size for this 
study type was relatively low but currently an expansion of the linkage is pursued by 
means of geographic coverage as well as increasing follow-up time. The expansion of 
this linkage will result in an overlapping area of approximately 4 million inhabitants in 
the Netherlands. Furthermore, as PHARMO is also linked with other databases including 
in-patient pharmacies, general practitioner databases, and clinical laboratory databases, 
this provides unique opportunities for further research.
Implications of the main findings and directions for the future
The research conducted in this thesis provides several insights in the dual impact of 
cancer and diabetes on PROs and mortality. In this section we will discuss the implications 
of our main findings for future research and clinical practice. 
Implications for future research
Intervening on self-management
Due to the aging of the population the number of patients with multiple chronic diseases, 
including cancer and diabetes is rapidly increasing. To maintain good health in the 
long-term, self-management is becoming more important. Self-management can be 
defined as a person’s ability to manage symptoms, treatment, physical and psychosocial 
consequences and lifestyle changes following a chronic disease59. To achieve good self-
management, patients need to be educated and supported on, for example, medication 
use, the prevention, detection and treatment of complications, and personal skills such 
as solving problems and dealing with psychological consequences. Current evidence 
on effective self-management interventions mainly focus on information provision, 
symptom management and improving lifestyle behaviors59. Among cancer as well as 
diabetes patients, self-management interventions have been found to reduce distress, 
improve HRQoL and increase knowledge and self-efficacy60-62. As poor lifestyle behaviors 
are a risk factor for developing cancer as well as diabetes, intervening on lifestyle will 
be discussed in more detail.
Intervening on lifestyle behaviors
In this thesis we showed that cancer patients with diabetes had a poorer lifestyle than 
those without diabetes. These poor lifestyle habits were independently associated with 
worse HRQoL and increased mortality. Moreover, unhealthy lifestyle habits among 
cancer patients have previously been associated with more chronic conditions including 
diabetes63. Therefore, among this group of patients, there is a need for effective lifestyle 
interventions that may improve HRQoL and lower the risk of mortality. Current evidence 
on the effectiveness of lifestyle interventions among cancer patients often focuses on 
only one component, such as enhancing weight loss, increasing physical activity or 
improving dietary quality64. However, according to the results presented in this thesis, 
lifestyle behaviors often cluster together. Thus an intervention focused on multiple 
components is possibly more effective. Among cancer patients, only a few previous 
intervention studies focused on multiple lifestyle components and showed positive 
results. A telephone-based health coaching intervention among colorectal cancer 
patients that focused on physical activity, dietary habits, weight management, smoking 
and alcohol use showed that the intervention resulted in increased physical activity, lower 
BMI, and improved dietary quality at 12 months follow-up as compared to a control 
group that received usual care65. Similar results were found from the FRESH START trial 
that randomly assigned breast and prostate cancer patients to a 10-month program or 
to a control group that received non-tailored general health education66. The program 
aimed to promote fruit and vegetable consumption, reduce fat intake and increase 
physical activity via tailored mailed print materials. Results showed that after 1 year of 
follow-up the intervention group significantly lowered fat intake, increased fruit and 
vegetable consumption and increased physical activity66; these results remained at 2 
years of follow-up67,68. Although the majority of studies among both cancer and diabetes 
patients report short-term effects of lifestyle interventions, recently the results of a 
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large intervention study among diabetes patients with a median follow-up of 10 years 
were presented69. This study randomized over 5000 obese diabetes patients to either 
an intensive lifestyle intervention focused on diet and physical activity or to a diabetes 
education program69. Patients in the intervention lost significantly more weight than the 
control group; differences were largest at 1 year (8.6 versus 0.7% weight loss), directly 
after the intervention, but remained during the next 9 years of follow-up69.
Although the evidence on the effectiveness of previous lifestyle interventions is 
promising, studies that assess sustainable long-term changes remain scarce. Possibly 
these sustainable changes can be reached by interventions that intervene on lifestyle 
but additionally focus on several other aspects of self-management. If patients gain 
more confidence in their own abilities, are able to set goals and learn strategies to deal 
with the consequences of their diseases, patients may adhere better to an intervention 
program and the lifestyle changes may sustain for a longer period of time.
Targeting patients with both cancer and diabetes in interventions
Although the provision of self-management and lifestyle interventions seem to be 
effective among patients with cancer or diabetes only, it is questionable whether these 
interventions are also effective among patients with both cancer and diabetes as in 
previous intervention studies often patients with multiple chronic diseases have been 
excluded70. Patients with multiple chronic diseases are likely to have poor general health, 
lower health literacy and, are older and more often cognitively impaired which may limit 
the effectiveness of self-management interventions70. On the other hand, as their health 
is poor, they may benefit most from these interventions. Thus, future research should 
establish whether self-management interventions among patients with both cancer and 
diabetes can improve self-efficacy, lifestyle behaviors and knowledge. The effectiveness 
of these interventions on improving HRQoL and symptom management in the long run, 
and decreasing the risk of complications and mortality should also be studied.
The need for well-designed observational studies on the effect of GLDs
In this thesis we did not find convincing evidence that GLDs, including metformin, are 
associated with mortality among breast cancer patients. Currently the evidence from 
well-designed studies that account for time-related biases among breast cancer patients 
is scarce. In order to establish the effect of the use of different GLDs on mortality there is 
a need for large well-designed observational studies while the results of ongoing RCTs 
are awaited. We did observe a difference in patient characteristics, with metformin users 
having characteristics that are associated with lower mortality. More research is needed 
to assess which factors explain this prognostic difference. These factors may include 
co-medication, complications, hospitalizations, lifestyle behaviors and glycemic control.
Implications for clinical practice
Both oncologists and primary care physicians will encounter an increasing number of 
patients with (a history of) both cancer and diabetes, and need to become aware that 
these patients have an increased mortality risk and report worse PROs. As lifestyle 
behaviors were independently associated with both HRQoL and mortality, these patients 
should be informed about the consequences of poor lifestyle behaviors and should be 
encouraged to improve their health behavior. However, specialists often have to deal with 
time constraints which is an important barrier for providing this crucial information. A 
possible solution is to increase referrals to rehabilitation programs where patients receive 
help from physiotherapists, dieticians and medical psychologists or health psychologists, 
when necessary. Moreover, during the active cancer treatment phase, treatment regimens 
for both diseases should be considered. Previous research shows that around cancer 
diagnosis patients with co-occurring diabetes seem to prioritize their cancer care over 
their diabetes care which affects blood glucose monitoring activities, exercise and 
the ability to eat and drink29. This may lead to more diabetes-related complications 
and poorer outcomes. Clinical care for patients with both cancer and diabetes is often 
fragmented and usually involves primary care and multiple secondary care specialists. As 
such, there is a need for close collaboration and integrated care to monitor the treatment 
and progression of both diseases. Moreover, primary care physicians need to be involved 
more in the follow-up care of cancer survivors. Primary care physicians will attend to a 
growing group of patients with (a history of) both cancer and diabetes and should be 
educated about self-management strategies and provide the necessary information to 
patients to maintain good health in the long-term.
Concluding remarks
The number of patients with both cancer and diabetes is rapidly increasing. In this 
thesis we showed that this growing group of patients reports worse HRQoL, more 
neuropathic symptoms and have an increased mortality risk as compared to patients 
with cancer only. Currently the factors underlying these worse outcomes are not (fully) 
known. Further research should focus on self-management, including lifestyle behaviors 
as we showed that healthy lifestyle behaviors are associated with better HRQoL and 
decreased mortality. Finally, we did not found convincing evidence for an association 
between GLDs, including metformin, on mortality. More evidence from well-designed 
observational studies is needed and the results of ongoing trials should be awaited. 
The results of this thesis highlight the need to increase awareness among physicians on 
the association between cancer and diabetes and their negative impact on outcomes. 
Endocrinologists, oncologists and primary care physicians should work closely together 
as treatment regimens of both diseases may interfere with each other. Moreover, due 
to aging of the population, primary care physicians may play an increasingly important 
role in providing information and self-management strategies to ensure good health 
outcomes in the long-term for patients with multiple chronic conditions.
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Inleiding
Door de vergrijzing van de bevolking en de verhoogde levensverwachting neemt het 
aantal mensen dat één of meerdere chronische ziekten heeft toe. In Nederland heeft 
ongeveer 34% van de bevolking minstens 1 chronische ziekte en deze prevalentie ligt 
hoger onder ouderen (≥75 jaar) waar 84% minstens 1 chronische ziekte heeft. Zowel 
kanker als diabetes behoren tot de meest voorkomende chronische ziekten en behoren 
daarnaast tot de meest levensbedreigende ziekten wereldwijd. 
Kanker
Kanker is een veel voorkomende ziekte die gekenmerkt wordt door de ongecontroleerde 
deling van lichaamscellen. Iedere dag vinden er miljoenen celdelingen plaats in het 
lichaam en tijdens deze celdelingen kan er schade ontstaan. Normaal gesproken zorgen 
reparatiegenen voor het herstel van deze schade. Wanneer deze genen niet werken 
kan een cel zich ongecontroleerd delen wat kan leiden tot een gezwel die omliggend 
weefsel binnendringt; een kwaadaardige tumor. De meest voorkomende kankersoorten 
zijn huid-, dikkedarm-, borst-, long- en prostaatkanker. In het algemeen wordt kanker 
behandeld met chirurgie, radiotherapie en/of chemotherapie. Dit proefschrift is gericht 
op zowel dikkedarmkanker als borstkanker.
Diabetes
Diabetes, ook wel suikerziekte genoemd, is een chronische ziekte die gekenmerkt wordt 
door een te hoge glucose, of bloedsuiker, spiegel. Bij gezonde mensen zorgt insuline, 
wat gemaakt wordt door de alvleesklier, ervoor dat het overschot aan glucose door de 
lever en spieren wordt opgenomen. Bij diabetes is de glucosespiegel te hoog en ervaart 
men klachten zoals dorst, vermoeidheid, wazig zicht en veel plassen. Op langere termijn 
kunnen er ernstigere gevolgen optreden zoals blindheid, nierfalen of hartproblemen. Er 
worden twee typen diabetes onderscheiden waarvan type 1 diabetes het minst voorkomt 
(in 5-10% van alle gevallen). Type 1 diabetes ontwikkelt zich tijdens de kindertijd en 
hierbij zijn cellen in de alvleesklier beschadigd waardoor er geen insuline gemaakt kan 
worden. Bij het veel frequenter voorkomende type 2 diabetes reageert het lichaam 
niet meer goed op insuline waardoor de bloedglucose waarden te hoog blijven. Type 
2 diabetes ontwikkelt zich vaak op hogere leeftijd en ontstaat vaak door ongezonde 
leefgewoonten zoals weinig fysieke activiteit en ongezonde voeding. Bij type 2 diabetes 
wordt eerst leefstijladvies gegeven om de bloedglucose waarden te controleren. Wanneer 
dit niet werkt wordt er overgeschakeld op medicatie. Sinds 2006 wordt metformine als 
eerste behandeling gegeven en dit kan eventueel aangevuld worden met sulfonylureum 
derivaten, andere glucose verlagende middelen of uiteindelijk het spuiten van insuline.
De relatie tussen kanker en diabetes
Door de vergrijzing van de bevolking, maar ook door de betere detectie en 
behandelingsmethoden neemt zowel het aantal kankerpatiënten als diabetespatiënten 
toe. Doordat beide ziekten vaker voorkomen, komen ze ook steeds vaker samen voor. 
Daarnaast toont eerder onderzoek aan dat diabetes geassocieerd is met een hoger risico 
op het ontwikkelen van verschillende typen kanker. Hierdoor wordt verwacht dat het 
aantal patiënten met zowel kanker als diabetes de komende jaren sterk zal toenemen. 
Uit gegevens van de Nederlandse Kankerregistratie blijkt dat inmiddels bijna 1 op de 5 
oudere kankerpatiënten ook diabetes heeft ten tijde van de diagnose kanker.
Momenteel is het precieze mechanisme dat ten grondslag ligt aan de associatie 
tussen kanker en diabetes nog niet bekend. Mogelijk verklaren de verschillende 
gedeelde risicofactoren voor zowel kanker als diabetes een deel van de associatie. 
Zo zouden bijvoorbeeld een hogere leeftijd en etniciteit een rol kunnen spelen, maar 
ook modificeerbare factoren zoals overgewicht, fysieke inactiviteit, roken, overmatig 
alcoholgebruik en een ongezond voedingspatroon. Daarnaast geeft de huidige literatuur 
ook een aantal mogelijke biologische verklaringen. In een vroeg stadium van diabetes 
gaat de alvleesklier meer insuline produceren om te compenseren voor de slechte reactie 
van het lichaamsweefsel op insuline. Deze hoge insulinewaarden in het bloed zouden 
mogelijk de tumorcelgroei stimuleren.
De duale impact van kanker en diabetes op patiënt gerapporteerde uitkomstmaten 
en overlijden
Voorgaand onderzoek over de associatie tussen kanker en diabetes richt zich vooral 
op harde uitkomstmaten zoals de ontwikkeling van de ziekten en het overlijdensrisico, 
terwijl patiënt gerapporteerde uitkomstmaten nauwelijks onderzocht zijn. Patiënt 
gerapporteerde uitkomstmaten weerspiegelen het perspectief van de patiënt en omvatten 
verschillende uitkomsten zoals kwaliteit van leven, symptomen, en tevredenheid met de 
zorg. Eerder onderzoek naar het effect van kanker en diabetes op patiënt gerapporteerde 
uitkomstmaten, richt zich vooral op kwaliteit van leven en laat zien dat patiënten met 
beide ziekten een slechtere kwaliteit van leven rapporteren. Doordat er weinig onderzoek 
is gedaan, er een beperkte populatie is onderzocht (vooral prostaatkankerpatiënten) en 
er verschillende meetinstrumenten gebruikt zijn, is er meer onderzoek nodig om het 
effect van beide ziekten op patiënt gerapporteerde uitkomsten vast te stellen.
Eerder onderzoek laat zien dat patiënten met kanker en diabetes een 40% hoger 
overlijdensrisico hebben ten opzichte van kankerpatiënten zonder diabetes. En hoewel 
de exacte verklaring van dit verhoogde risico nog onbekend is, zijn er wel een aantal 
mogelijke verklaringen in de literatuur. Zo wordt de kankerdiagnose bij patiënten met 
daarnaast diabetes mogelijk in een later stadium gesteld dan bij patiënten zonder 
diabetes, waardoor de kanker vaak verder gevorderd is. Dit is mogelijk een gevolg van 
een lager gebruik van screening bij diabetespatiënten. Daarnaast zijn er indicaties dat 
kankerpatiënten met diabetes minder agressief behandeld worden voor hun kanker, zij 
krijgen bijvoorbeeld minder vaak chemotherapie en/of radiotherapie. Ook zouden hier 
de slechtere leefgewoonten zoals overgewicht, fysieke inactiviteit, roken, overmatig 
alcoholgebruik en een ongezond voedingspatroon een rol kunnen spelen.
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Glucoseverlagende geneesmiddelen en overleving
In 2005 ontstond grote interesse in de associatie tussen kanker en diabetes nadat er 
een onderzoek werd gepubliceerd waaruit bleek dat metformine, een geneesmiddel 
dat gebruikt wordt voor de behandeling van diabetes, was geassocieerd met een 
lager risico op kanker. Hierna werden vele studies gepubliceerd naar het effect van 
glucoseverlagende middelen op het risico op kanker en op het overlijdensrisico. Omdat 
patiënten met diabetes vaak verschillende soorten geneesmiddelen gelijktijdig of 
afwisselend gebruiken is het erg moeilijk om het effect van glucoseverlagende middelen 
op het overlijdensrisico in kaart te brengen. Vele voorgaande studies hadden dan ook 
methodologische tekortkomingen en vaak werd er geen rekening gehouden met de 
gebruikte dosis.  Daarom is het belangrijk om het effect van glucoseverlagende middelen 
op het overlijdensrisico van kankerpatiënten verder te onderzoeken in studies met een 
goede onderzoeksopzet.
Doel van dit proefschrift
In dit proefschrift wordt de duale impact van kanker en diabetes op patiënt gerapporteerde 
uitkomstmaten en het overlijdensrisico onderzocht. De belangrijkste doelstellingen van 
dit proefschrift zijn als volgt:
 - Evalueren van het effect van kanker en diabetes op patiënt gerapporteerde 
uitkomstmaten zoals kwaliteit van leven en symptomen (Deel I)
 - De impact van kanker en diabetes, en de rol van leefstijlfactoren, op het 
overlijdensrisico onderzoeken (Deel II)
 - Het effect van glucoseverlagende middelen op het overlijdensrisico van 
borstkankerpatiënten onderzoeken (Deel II)
Belangrijkste bevindingen
De impact van kanker en diabetes op patiënt gerapporteerde uitkomsten
In Deel I van dit proefschrift is middels een literatuuroverzicht bekeken wat er tot 
nu toe bekend is over het effect van kanker en diabetes op patiënt gerapporteerde 
uitkomstmaten (Hoofdstuk 2). In eerste instantie leverde de zoekactie 3.553 mogelijke 
studies op, maar na selectie bleken er slechts 10 studies de impact van zowel kanker 
als diabetes op patiënt gerapporteerde uitkomsten te onderzoeken. Het merendeel 
was gericht op kwaliteit van leven, functioneren of symptomen. Patiënten met kanker 
en diabetes rapporteerden voornamelijk een lagere algemene kwaliteit van leven, 
een lager fysiek functioneren en een lager seksueel functioneren ten opzichte van 
patiënten met alleen kanker, alleen diabetes en/of patiënten zonder beide ziekten. 
Omdat er beperkt literatuur over dit onderwerp beschikbaar is, hebben we een aantal 
belangrijke onderwerpen voor vervolgonderzoek aangedragen. Mentale problemen 
komen bijvoorbeeld bij zowel kanker als diabetes patiënten veelvuldig voor en mogelijk 
zijn deze klachten erger bij mensen met beide ziekten. Daarnaast leidt het hebben van 
meerdere chronische ziekten tot beperkingen in het dagelijkse leven. Het is daarom 
belangrijk om aandacht te besteden aan zelfmanagement. Door bijvoorbeeld informatie 
te verzamelen, symptomen te monitoren en actief in gesprek te gaan met de behandelaar 
kunnen patiënten meer grip krijgen op hun ziekten.
Eerder onderzoek laat zien dat het hebben van andere chronische ziekten, ook wel 
comorbiditeiten genoemd, naast kanker geassocieerd is met een lagere kwaliteit van 
leven. In Hoofdstuk 3 bekeken we wat de relatieve impact van deze comorbiditeiten in 
vergelijking met sociaal demografische kenmerken en klinische karakteristieken op de 
kwaliteit van leven van kankerpatiënten is. We vonden dat het hebben van comorbiditeiten 
een grotere invloed op de kwaliteit van leven heeft dan sociaal demografische kenmerken 
waaronder leeftijd en geslacht en klinische kenmerken, waaronder het kanker stadium 
en behandeling. Dit resultaat vonden we voor patiënten met dikkedarmkanker, (non-)
Hodgkin lymfoom en schildklierkanker. We vonden dat vooral hartziekten en rugpijn het 
fysiek functioneren negatief beïnvloedde terwijl depressie voornamelijk een negatieve 
invloed op het mentaal functioneren had.
Het is bekend dat zowel kankerpatiënten als diabetespatiënten een slechtere kwaliteit 
van leven rapporteren dan de gezonde populatie. Daarnaast worden er in beide groepen 
ook veel problemen met het seksueel functioneren gerapporteerd. Het is echter niet 
bekend of patiënten met zowel kanker als diabetes een slechtere kwaliteit van leven en 
seksueel functioneren rapporteren dan mensen met één van beide ziekten. In Hoofdstuk 
4 lieten we zien dat de groep met zowel kanker als diabetes inderdaad de laagste 
kwaliteit van leven en het laagste seksueel functioneren rapporteerde, gevolgd door 
patiënten met alleen kanker en alleen diabetes. De groep zonder kanker en diabetes 
rapporteerde de hoogste kwaliteit van leven. Kanker in vergelijking met diabetes leek 
de sterkste voorspeller van de lagere kwaliteit van leven en seksueel functioneren.
Bij zowel kanker als diabetespatiënten komen vaak neuropathische klachten voor, zoals 
het tintelen van handen en voeten. Bij kankerpatiënten ontstaan deze klachten vaak als 
gevolg van de chemotherapie terwijl bij diabetes beschadigingen van zenuwuiteinden 
ontstaan door de te hoge bloedsuikerspiegel. In Hoofdstuk 5 hebben we bekeken of 
er verschillen zijn in neuropathische klachten tussen kankerpatiënten met en zonder 
diabetes en of dit een mogelijk gevolg is van verschillen in de behandeling met 
chemotherapie. Eerder onderzoek liet zien dat kankerpatiënten met diabetes minder vaak 
chemotherapie krijgen en minder agressief behandeld worden voor hun kanker. Zoals 
verwacht vonden we dat kankerpatiënten met diabetes meer klachten rapporteerden, 
voornamelijk tintelende vingers of handen, tintelende tenen of voeten, doofheid in 
tenen of voeten en erectieproblemen bij mannen. Er werden voornamelijk milde klachten 
gerapporteerd en relatief weinig ernstige klachten. Daarnaast leken deze verschillen niet 
verklaard te kunnen worden door de kankerbehandeling.
In Hoofdstuk 6 onderzochten we of de eerder gevonden verschillen in kwaliteit van 
leven tussen kankerpatiënten met en zonder diabetes verklaard konden worden door 
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leefstijlfactoren, zoals, fysieke inactiviteit, roken en overmatig alcoholgebruik, en 
overgewicht. Dikkedarmkankerpatiënten met diabetes bleken een hogere body mass 
index (BMI) te hebben en minder vaak alcohol te drinken. Er werden geen verschillen in 
fysieke activiteit en rookgedrag gevonden. Verdere analyses lieten zien dat het slechte 
fysieke functioneren, de lagere kwaliteit van leven en de hogere vermoeidheidsklachten 
die patiënten met zowel kanker als diabetes rapporteerden, gedeeltelijk verklaard werden 
door de verschillen in leefstijlfactoren.
De impact van kanker en diabetes op het overlijdensrisico
In Deel II van dit proefschrift hebben we onderzocht wat de duale impact van 
kanker en diabetes op het overlijdensrisico is. In Hoofdstuk 7 hebben we bekeken 
of leefstijlfactoren het verhoogde overlijdensrisico in kankerpatiënten met of zonder 
diabetes kunnen verklaren. In dit hoofdstuk lieten we zien dat leefstijl sterk geassocieerd 
is met het overlijdensrisico: (matig) alcoholgebruik, fysieke activiteit en overgewicht 
waren geassocieerd met een lager overlijdensrisico terwijl roken geassocieerd was met 
een hoger overlijdensrisico. Daarnaast hebben we ook gekeken naar leefstijlclusters 
omdat slechte leefstijlgewoonten vaak samen voorkomen. Hieruit bleek dat patiënten 
die roken, weinig fysiek actief zijn en een laag BMI hebben (ondergewicht), een ruim 
3 keer hoger overlijdensrisico hadden in vergelijking met de mensen met een gezond 
leefstijlpatroon. Na correctie voor deze leefstijlfactoren bleken de patiënten met zowel 
kanker als diabetes nog steeds een hoger overlijdensrisico te hebben dan kankerpatiënten 
zonder diabetes.
In Hoofdstuk 8 en 9 hebben we onderzocht of er een verschil is in het overlijdensrisico 
tussen borstkankerpatiënten met diabetes die verschillende geneesmiddelen voor diabetes 
gebruikten. Dit naar aanleiding van eerder onderzoek waarin metformine mogelijk een 
verlaagd en insuline mogelijk een verhoogd overlijdensrisico met zich mee brengt. In 
Hoofdstuk 8 hebben we gegevens vanuit het Verenigd Koninkrijk gebruikt en vonden we 
dat borstkankerpatiënten die voor langere tijd (>2 jaar) metformine gebruiken mogelijk 
een lager overlijdensrisico hebben. Daarnaast vonden we dat borstkankerpatiënten 
die sulfonylureum derivaten gebruiken mogelijk een hoger overlijdensrisico hebben. 
In een soortgelijke studie waarbij we gebruik hebben gemaakt van Nederlandse data 
vonden we geen overtuigende verschillen in overlijdensrisico tussen de verschillende 
geneesmiddelen (Hoofdstuk 9). In zowel Hoofdstuk 8 als Hoofdstuk 9 hebben we 
gebruik gemaakt van geavanceerde statistische analyses om bias te voorkomen. Dit 
type analyses blijft echter erg gecompliceerd omdat het type geneesmiddel dat een 
diabetespatiënt voorgeschreven krijgt vaak samenhangt met de ernst van de ziekte. Zo 
wordt metformine in een vroeg stadium van de ziekte voorgeschreven en zouden deze 
patiënten daarom dus mogelijk een lager overlijdensrisico hebben.
Concluderende opmerkingen
In dit proefschrift lieten we zien dat de groeiende groep patiënten met zowel kanker als 
diabetes een slechtere kwaliteit van leven en meer neuropathische klachten rapporteert 
en een hoger overlijdensrisico heeft dan kankerpatiënten zonder diabetes. Daarnaast 
vonden we geen overtuigend effect van verschillende geneesmiddelen voor diabetes 
op het overlijdensrisico bij borstkankerpatiënten. Er is echter meer bewijs nodig van 
grote en methodologisch goed opgezette studies om hier een eenduidige conclusie 
over te trekken.
In vervolgonderzoek moet er aandacht zijn voor zelfmanagement. Zelfmanagement 
houdt in dat patiënten leren omgaan met hun chronische ziekten en zich capabel 
voelen om bijvoorbeeld informatie in te winnen over de ziekten, tijdig symptomen of 
complicaties op te merken en daarop actie te ondernemen, maar ook leren omgaan met 
de psychologische consequenties van de ziekten. Daarnaast is het belangrijk om verder 
onderzoek te doen naar de verbetering van leefstijlgewoonten omdat leefstijlfactoren 
een grote invloed hebben op zowel de kwaliteit van leven als het overlijdensrisico van 
patiënten met zowel kanker als diabetes. Vanuit de literatuur zijn er effectieve interventies 
bekend die leefstijlfactoren op de korte termijn verbeteren, maar er is weinig bekend 
over de lange termijn effecten van deze interventies.
Ook in de klinische praktijk moet er aandacht besteed worden aan de groeiende 
groep van patiënten met zowel kanker als diabetes. Er zijn verschillende zorgverleners 
betrokken bij patiënten met kanker en diabetes in zowel de eerste lijn (huisartsen) als 
in de tweede lijn (internisten, chirurgen, en radiotherapeuten). Deze specialisten zullen 
samen moeten werken om bijvoorbeeld de behandeling van beide ziekten op elkaar 
af te stemmen. Daarnaast zal ook de huisarts een steeds belangrijkere rol krijgen in de 
nazorg van patiënten met kanker en diabetes. Zij zouden bijvoorbeeld informatie of 
training kunnen geven over zelfmanagementstrategieën zodat patiënten ook op de 
langere termijn in goede gezondheid verder kunnen leven.
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